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Abstract
Apoptosis of inflammatory cells is a critical event in the resolution of
inflammation, as failure to undergo this form of cell death leads to increased tissue
damage and exacerbation of the inflammatory response. Prolonged survival of the
neutrophilic granulocyte has been implicated in the pathogenesis of many chronic
inflammatory conditions. Many factors are able to influence the rate of apoptosis in
neutrophils. Among these is the signalling molecule, nitric oxide (NO), which
possesses both anti-apoptotic and pro-apoptotic properties in many cell types,
depending on the concentration and flux ofNO, and also the source from which NO
is derived.
Characterisation of the NO-related species generated by four 'NO-donating'
compounds, spermine diazeniumdiolate (SPER/NO), diethylamine diazeniumdiolate
(DEA/NO), 1,2,3,4-oxatriazolium, 5-amino-3- (3,4-dichlorophenyl)-chloride (GEA
3162) and 3-morpholinosydnonime (SIN-1) was carried out. It was demonstrated
that the diazeniumdiolates, SPER/NO and DEA/NO both spontaneously liberated
free NO in aqueous solution at physiological temperature and pH. In contrast, both
GEA 3162 and SIN-1 produced NO and superoxide anion (O2") concomitantly, that
rapidly react to form the powerful oxidant species, peroxynitrite (ONOO"). These
two compounds should therefore be considered ONOO" donors rather than NO
donors.
Apoptosis studies demonstrated the biphasic pro- and anti-apoptotic effects of
pure NO donors, SPER/NO and DEA/NO, and the pro-apoptotic effects of ONOO"
donors, GEA 3162 and SIN-1, in human neutrophils. Low concentrations of the pure
NO donors delayed the rate of neutrophil apoptosis, while high concentrations of all
compounds tested accelerated cell death. Time course analyses of four independent
events of apoptosis revealed that morphological and biochemical parameters of
neutrophil apoptosis may proceed independently of internucleosomal DNA
fragmentation, which has long been considered a key hallmark of apoptosis and is
frequently used as the sole criterion for assessment of this form of cell death.
Treatment with high concentrations of ONOO" donors and, to a lesser extent, with
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the longer-lasting pure NO donor, SPER/NO, induced morphological and cell surface
(CD 16 shedding and phosphatidylserine exposure) changes characteristic of
neutrophil apoptosis, but paradoxically inhibited internucleosomal DNA
fragmentation, as measured by propidium iodide intercalation and gel
electrophoresis. In contrast, treatment with the short-lasting NO donor, DEA/NO,
produced no such inhibition. An oxidation reaction was shown to be responsible for
the suppression of the DNA fragmentation pathway, as the reducing agent,
dithiothreitol, restored DNA fragmentation back to control levels. However, GEA
3162-mediated inhibition of DNA fragmentation did not occur upstream or at the
level of degradation of inhibitor of caspase-activated DNase (ICAD/DFF45), as
Western blotting showed breakdown of this protein was enhanced rather than
inhibited in GEA 3162-treated neutrophils.
Therefore, NO can exert either pro- or anti-apoptotic effects on human
neutrophil apoptosis, depending on its concentration and flux, whereas only pro-
apoptotic effects are achieved with ONOO" donors. Cell death promoted by ONOO"
or SPER/NO is independent of an increase in internucleosomal DNA fragmentation;
this process is inhibited via an oxidative mechanism, but not through inhibition of
ICAD/DFF45 breakdown or upstream mechanisms. Thus, NO and ONOO" are able
to modulate the rate of neutrophil apoptosis, which may have implications for
chronic inflammatory conditions.
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Chapter 1: Introduction
Neutrophil apoptosis is believed to be impaired in chronic inflammatory
conditions, thus delaying resolution of inflammation and increasing tissue injury.
Therefore, promotion of this form of cell death in neutrophils offers potential
therapeutic benefit in a number of conditions. Nitric oxide (NO) and related species,
such as peroxynitrite (ONOO"), have been shown to exert pro-apoptotic effects in
neutrophils, and many other cell types, therefore it is of interest to characterise the
effects of compounds that generate these species on neutrophil apoptosis. This thesis
focuses on a comparison of the effects of a number of different NO and ONOO"
generators on apoptosis in neutrophils obtained from the peripheral blood of healthy
volunteers.
1.1 Nitric Oxide
The free radical, nitric oxide (NO), has been identified as a factor that is a
major factor involved in endothelium-dependent vasorelaxation, first observed by
Furchgott and Zawadski in 1980 (Furchgott and Zawadzki, 1980). Although NO was
first discovered in its capacity as an endogenous regulator of vascular tone (Palmer et
al., 1987), it is now known to be a key mediator in a great number of physiological
and pathophysiological processes (Quinn et al., 1995). NO is formed naturally in the
body from the amino acid L-arginine, by the NO synthase (NOS) family of enzymes,
with L-citrulline being formed in the process (Palmer and Moncada, 1989); Figure
1.1A). Tetrahydrobiopterin and NADPH are required cofactors for NO synthesis
(Tayeh and Marietta, 1989). The NOS isoforms found in endothelial cells (eNOS)
and in neurones (nNOS) are constitutively expressed, with their activity regulated by
the calcium-calmodulin system, but they synthesise only small amounts ofNO (pM -
nM; (Berdeaux, 1993). A third, calcium-independent, isoform located in several cell
types is termed inducible NOS (iNOS), and is stimulated to produce
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Figure 1.1 Synthesis and mechanism of vasodilatory action of nitric oxide. (A) Nitric oxide
(NO) is synthesised from the conversion of the amino acid, L-arginine, to L-citrulline by NO
synthase (NOS) enzymes. NADPH and tetrahydrobiopterin (BH4) are required as cofactors.
(B) Physiological stimuli such as hypoxia, shear stress or stimulation of endothelial
receptors by ligands such as acetylcholine (ACh) or bradykinin causes NO synthesis from
L-arginine via an increase in calcium/calmodulin (Ca2+/CaM) levels. NO diffuses into
vascular smooth muscle cells where it activates soluble guanylate cyclase (sGC), which
catalyses the conversion of GTP to cyclic GMP (cGMP). This causes activation of the
cGMP-dependent protein kinase (PKG), which phosphorylates a number of cellular targets
to cause relaxation of the smooth muscle.
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larger quantities of NO (nM) by a variety of cytokines and other factors (Berdeaux,
1993;Lloyd-Jones and Bloch, 1996).
1.1.1 Biology:
NO has a number of biological effects, although the possibility exists that
some of its properties are mediated in vivo by the formation of other NO-related
species such as dinitrogen trioxide (N2O3) or ONOO" by auto-oxidation or
combination with superoxide anion (O2") respectively. Such reactions limit the
potential for NO itself to be responsible for some of the longer-term biological roles
attributed to NO. The chemistry ofNO with respect to the formation of species that
may have an important role in vivo is discussed below.
The vasodilator effects ofNO have been shown to proceed via the 'classical'
NO-mediated pathway, in which NO from vascular endothelial cells diffuses to and
reacts with the haem group of soluble guanylate cyclase (sGC) within vascular
smooth muscle cells, thereby activating this enzyme (Figure LIB). Activation
occurs through tertiary and quaternary structural changes in sGC on NO binding,
followed by a further relaxation in protein structure (Sharma and Magde, 1999).
This leads to a protein base becoming exposed, which allows the nucleophilic
substitution required for the conversion of GTP to cGMP to occur (Sharma and
Magde, 1999). Vasodilation then occurs via the consequent elevation of cGMP
(Lincoln et al., 1996); this cyclic nucleotide causes relaxation of vascular smooth
muscle principally through the activation of cGMP-dependent protein kinase (PKG),
• • • • '21which acts via several intracellular pathways to decrease the intracellular Ca
• • • • • 2"bconcentration and to decrease the sensitivity of the contractile system to Ca
(Carvajal et al., 2000). PKG phosphorylates a number of cellular targets, including
myosin light chain kinase, ion channels, ion pumps, enzymes and receptors: in
particular PKG phosphorylates and decreases the activity of the receptor for inositol
triphosphate (IP3), which is an important mediator of smooth muscle contraction
(Carvajal et al., 2000). Levels of cGMP are regulated by the activity of
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phosphodiesterases (PDEs), which act to convert cGMP to inactive 5'-GMP
(Carvajal et al., 2000).
Since then, interest has expanded to include the other biological effects of
NO, in particular its protective effects on the cardiovascular system. NO has anti¬
thrombotic effects, having been shown to inhibit platelet aggregation and adhesion to
vascular endothelium (Radomski et al., 1987). In addition, this versatile molecule
inhibits endothelial cell mediated oxidation of low-density lipoprotein (Malo-Ranta
et al., 1994), keeps the vascular endothelium impermeable to leukocytes (Granger
and Kubes, 1996), prevents adhesion of neutrophils and monocytes to the endothelial
wall (Kubes et al., 1991;Kosonen et al., 1999;Niebauer et al., 1999;Gluckman et al.,
2000) and inhibits proliferation of vascular smooth muscle cells (VSMC)
(Mooradian et al., 1995). Moreover, NO inhibits neutrophil function, such as
degranulation, shape change, chemotaxis and O2" release (Moilanen et al.,
1993;Ward et al., 2000;Gluckman et al., 2000).
Within the heart itself, the role ofNO is somewhat controversial. However, it
now appears that NO-mediated effects relating to contractility and heart rate are
biphasic; low concentrations increase both contractility and heart rate, but higher
concentrations have the opposing effect (Casadei and Sears, 2003). At physiological
concentrations, however, it has been proposed that NO exerts predominantly positive
inotropic and chronotropic effects (Casadei and Sears, 2003). Furthermore, NO has
been demonstrated to play a role in the Frank-Starling response to a stretch stimulus
within the heart (Casadei and Sears, 2003).
Alongside release from the endothelial isoform of NOS, NO also acts as a
neurotransmitter that mediates smooth muscle relaxation in the gastrointestinal,
respiratory and urogenital systems (Gibson and Filley, 1997). Additionally, NO
plays several protective roles within the central nervous system, regulating blood
flow in the brain, the coupling of blood flow and metabolism and the neuroendocrine
system, and is involved in the formation of memories and in behaviour (Szabo,
1996), and in the gastrointestinal system, as a mediator of mucosal defence and
repair (Muscara and Wallace, 1999).
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ONOO" possesses several biological characteristics in common with NO; for
example, both species can cause vasorelaxation, although the effects of ONOO" may
be mediated by detoxification by thiols to S-nitrosothiols, which can then elicit
vasodilation through a cGMP-dependent pathway (Ronson et al., 1999). As with
NO, ONOO" from SIN-1 has been shown to have anti-adhesive and antithrombotic
effects in an in vivo model of balloon angioplasty (Provost et al., 1997). Similarly,
inhibition of neutrophil adhesion to endothelium and various cardioprotective effects
of low concentrations of ONOO" during ischaemia-reperfusion has been
demonstrated by several groups. These include protection of contractility and
reduction of infarct size in vivo (although ONOO" usually has a deleterious effect on
contractility in vitro, unless glutathione is also present; (Ronson et al., 1999). In all
these cases, ONOO" may act through a mechanism remarkably similar to NO, again
suggesting that conversion of ONOO" to an S-nitrosothiol or related species may be
responsible for these effects, which are not due to generation of NO itself, as they
could not be blocked by haemoglobin (Ronson et al., 1999). It has been suggested
that ONOO" from SIN-1 is able to activate sGC, but that authentic ONOO" cannot do
so (Trakranrungsie and Will, 2001).
As for NO, the effects of ONOO" appear to be dependent on the
concentration, with low concentrations being protective but high concentrations
deleterious (Ronson et al., 1999). It is tempting to speculate that protective species
may be formed in the presence of low concentrations of ONOO" but that higher
concentrations may overwhelm the protective and detoxifying mechanisms and be
injurious to tissues. However, some similar biological actions ofNO and ONOO" are
believed to proceed through different mechanisms; for example, both species inhibit
mitochondrial respiration, but act at different respiratory complexes and are
differentially regulated (Lizasoain et al., 1996). Additionally, both NO and ONOO"
may induce apoptotic cell death in various cell types, with a large number of
potential mechanisms being proposed.
Taken together, these studies demonstrate that NO is a highly relevant
molecule in cardiovascular and inflammatory cell biology, and there is the potential
for its effects to be manipulated therapeutically.
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1.1.2 Chemistry:
The chemistry of NO is complex, as NO is a free radical and therefore able to
rapidly combine with other molecules to form reactive nitrogen oxide species
(RNOS), particularly at high fluxes of NO, which may have indirect biological
effects of their own. The issue is further complicated by the fact that NO and its by¬
products may have opposing effects, having either antioxidant or pro-oxidant
properties, depending on the species; therefore NO and NO-related species may have
a profound impact on the redox status of a cell (Espey et al., 2000).
NO is a highly diffusible and lipophilic molecule and as such has no need for
membrane receptors; rather, this molecule simply permeates cell membranes in order
to stimulate intracellular biological effects (Lincoln et al., 1996). NO may bind
directly to haem groups of proteins (forming a nitrosyl-haem complex) to regulate
their activity, for example activation of sGC proceeds through this mechanism
(Craven and DeRubertis, 1978). However, in vivo, NO is extremely short-lived, as it
may be auto-oxidised to N2O3 by O2 in the gaseous or aqueous phases, via formation
ofNO2 as an intermediate (Espey et al., 2000); Fig 1.2). N2O3 is a hugely important
mediator of cGMP-independent effects in NO biology, as it appears to be the central
species involved in S-nitrosation reactions. It is able to donate a nitrosonium ion
(NO+) to reduced cysteines, forming S-nitrosothiols (RSNO), which may regulate
protein functions and possibly act as an important storage form ofNO (Stamler et al.,
1992). The breakdown of S-nitrosothiols or nitrosyl-metal complexes leads to the
formation of nitroxyl (NO") which may itself have damaging oxidative effects
including the formation of double strand DNA breaks (Espey et al., 2000).
Another critical reaction ofNO in biological systems is that with O2" to form
ONOO" (Figure 1.2); this reaction is particularly prevalent in inflammatory cells,
which produce O2" as part of the respiratory burst that occurs on activation. ONOO"
is a powerful oxidising species that may be responsible for the cytotoxicity ofNO in
many cell types. ONOO" is able to cause DNA strand breaks and lipid peroxidation,
nitrate tyrosine residues and oxidise reduced cysteine residues, forming either S-
nitrosothiols or disulphide bridges in proteins (Kuo and Kocis, 2002;Virag et al.,
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2003). Such modifications can alter the protein activity, resulting in profound
biological effects. It is thought that some of the damaging effects of ONOO" are
mediated through the hydroxyl radical (OH"), which is formed as an intermediate of
ONOOH conversion to NO3", or through interaction of O2" with Fe3+ (Espey et al.,
2000;Virag et al., 2003). N2O3 can also be formed from ONOO", through interaction
with H+ to form ONOOH, followed by reaction with NO (Espey et al., 2000),
possibly explaining why many of the effects of NO are also obtained with ONOO"
donors (Figure 1.2).
In summary, NO may act as an antioxidant by scavenging potentially harmful
ROS to convert them to less damaging RNOS, or by forming relatively stable
nitrosyl-haem complexes which reduces the potential for formation of strong
oxidants through reaction of H2O2 with transition metals. It may also have oxidant
properties through generation of oxidative species such as ONOO" and NO" (Espey et
al., 2000). Although these species are themselves oxidants, NO can further react
with many RNOS such as NO" to convert them to less harmful molecules (Espey et
al., 2000). The relative abundance of NO and other molecules with which NO can
interact in a given environment determines the anti- or pro-oxidant status of this
molecule.
1.1.3 NO Donors:
The traditional NO donors currently in clinical use for the treatment of
cardiovascular disease each have limitations that make them far from ideal, such as
tolerance or toxic by-products. As a consequence, the search is ongoing for novel
compounds that retain biological activity, but are free of inadequacies. This section
outlines the mechanisms ofNO generation by existing drugs and describes novel NO
donors that may have potential therapeutic benefits.
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1.1.3.1 Traditional NO donors:
The most frequently used NO donor drugs are the organic nitrates, which are
esters of nitric acid and mono- or polyhydric alcohols (Feelisch, 1991). The best-
known compound in this class is glyceryl trinitrate (GTN), which is still in use today
- mainly in angina and acute heart failure, but occasionally in myocardial infarction
or severe ischaemia (Megson, 2000). Organic nitrates exert selective vasodilatory
effects on the veins through the release ofNO and subsequent stimulation of soluble
sGC and increased cGMP, leading to decreased venous return and reduced cardiac
workload. Although the mechanism of NO release remains controversial, it is
thought that both enzymatic and non-enzymatic processes may contribute to a
complex multistep reaction mechanism. Initially, it was believed that NO is released
by reaction of the nitrate with endogenous thiols, forming S-nitrosothiols, which
decompose to release NO (Feelisch, 1991). However, it is now doubted whether
thiols are sufficiently powerful reducing agents to cause decomposition in this way.
Ascorbic acid and NADPH have been proposed as potential alternative reducing
agents for this process (Kishnani and Fung, 1996). Considerable evidence has been
accumulated for the involvement of at least three enzymes; glutathione-S-transferase,
cytochrome P450 and a 200kDa microsomal enzyme in vascular smooth muscle cells
in the release ofNO (Kishnani and Fung, 1996), and a further enzyme, mitochondrial
aldehyde dehydrogenase, has recently been demonstrated to have a role in NO
generation from GTN (Chen et al., 2002). Whether NO generation from the organic
nitrates occurs by enzymatic or non-enzymatic means, or a combination of both,
remains to be determined. The major problem encountered with long-term use of
organic nitrates is that of tolerance. Depletion of tissue thiols, increased oxidative
stress or activation of opposing (e.g. sympathetic nerves, endothelin, renin-
angiotensin) systems have all been suggested as possible explanations for this
phenomenon (Megson, 2000).
Sodium nitroprusside (SNP), used to treat acute hypertension, is also beset by
difficulties in clinical use, as it can only be administered intravenously. In addition,
potentially toxic cyanide can be generated as a by-product of NO release from SNP
with long-term therapy (Megson, 2000). The vasodilator effects of SNP are believed
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to be mediated at least partially by NO and sGC activation (Feelisch, 1991).
Although initially believed to decompose spontaneously in aqueous solution
(Feelisch, 1991), release of NO from SNP is now thought to occur via membrane-
bound proteins (Kowaluk et al., 1992) and possibly also enzymatic processes
(Kishnani and Fung, 1996).
Sydnonimines are heterocyclic NO donor drugs, which are known to cause
biological effects such as vasodilation and inhibition of platelet aggregation,
primarily through activation of sGC (Feelisch et al., 1989), although activation of K+
channels has also been implicated (Mistry and Garland, 1998). Sydnonimines are
occasionally used in stable angina, coronary vasospasm and heart failure, and their
beneficial effects in cardiovascular disease are likely to include actions other than
vasodilation, including inhibition of platelet activation and VSMC proliferation, and
protection of LDL against oxidation. They may also help to protect against
reperfusion injury following ischaemia (Megson, 2000).
1.1.3.2 Novel NO donors:
The search for improved cardiovascular drugs has resulted in the
development of several groups of compounds that have the ability to generate NO by
a variety ofmechanisms. It is hoped that these drugs may be free of the inadequacies
associated with the drugs currently in clinical use, and may even show additional
beneficial actions on the cardiovascular system.
One such group of compounds is the diazeniumdiolates - nucleophile/NO
adducts - also referred to as NONOates. These contain two molecules of NO
attached to a nucleophilic molecule through a nitrogen atom (Maragos et al., 1991).
NO is released predictably and spontaneously in aqueous solution, with no enzyme
or thiol requirement, to activate sGC (Keefer et al., 1996). Overall, these compounds
are useful research tools due to their wide range of rates ofNO release, their stability
as solids and their predictable generation of NO. Furthermore, a transdermal
delivery system has been developed for these compounds (Smith and Simmons,
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1998), thus giving them further potential for therapeutic use, as they could easily be
self-administered by the patient.
Mesoionic 3-aryl substituted oxatriazole-5-imine derivatives such as GEA
3162 and GEA 3175 are able to induce neutrophil apoptosis, inhibit neutrophil
function, suppress tumour cell proliferation, and have bronchodilatory, antibacterial,
vasodilator, antiplatelet, fibrinolytic and LDL oxidation inhibitory activities (Ward et
al., 2000;Kankaanranta et al., 1996).
GEA 3162 decomposes spontaneously in physiological solution, although
reducing agents may contribute to this process in vivo (Megson, 2000). Many of the
biological actions of liberated NO are mediated at least partially through sGC,
although a role for opening of large conductance K+ channels has also been proposed
(Vaali et al., 1998). Release ofNO from GEA 3175 but not GEA 3162 is increased
in the presence of human plasma, suggesting that decomposition of this compound
may be accelerated by enzymatic degradation, perhaps degradation of the
sulphonamide moiety, or by thiols, before it is able to release NO (Kankaanranta et
al, 1996).
These compounds could be particularly beneficial in the respiratory system,
due to the combined effects on bronchi and inflammatory cells. They may be
preferred to existing drugs as no tolerance has been observed and O2" is thought not
to be generated alongside NO (Megson, 2000), although it has been suggested that
this group of compounds has the ability to donate ONOO" (Kankaanranta et al.,
1996).
The mechanism of NO release by some NO donors such as nitrates, nitrites
and furoxans has been suggested to involve the intermediate formation of S-
nitrosothiols, chemically RS-N=0 (Feelisch, 1991). Some of these have now been
synthesised in order to study their effects and potential therapeutic benefits. These
compounds form stable red or green solids, solutions of which decompose on
exposure to heat or light, (Feelisch, 1991;Megson, 2000).
NO is generated nonenzymatically in vitro by homolytic cleavage of the S-N
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bond, the rate of which is increased by heat, light, oxygen and alkaline pH (Feelisch,
1991). However, in vivo other processes such as transnitrosation of tissue thiols,
interaction with ascorbate or O2", or enzymatic degradation by Cu/Zn superoxide
dismutase, glutathione-S-transferase, glutathione peroxidase, cell-surface protein
disulphide isomerase and xanthine oxidase may contribute to NO release (Megson,
2000). Disulphide and thiyl radicals are formed as a result of the liberation of NO
(Feelisch, 1991;Williams, 1996), which may have biological effects of their own, and
transnitrosation of proteins may affect enzyme activity, which in turn may regulate
cell function (Feelisch, 1991;Megson, 2000).
The rate of S-nitrosothiol decomposition varies from ms to h, depending on
the identity and chemical nature of the bulk of the molecule (R; (Megson, 2000), and
the ability to stimulate sGC increases with decreasing stability (Feelisch, 1991).
However, the decomposition of S-nitrosothiols can be somewhat unpredictable, due
to NO release being catalysed by trace amounts of Cu(I) (Dicks and Williams, 1996),
the concentration of which can vary between laboratories, and even experiments.
Particular interest has been focused on the endogenous S-nitrosoglutathione
(GSNO), as it is relatively stable in solution and its degradation produces non-toxic
by-products. This compound has been shown to have great potential for therapeutic
use, as its effects include arterial vasodilation and inhibition of platelet aggregation
and embolisation (Megson, 2000). Endogenous NO may be stored within cells as
GSNO, or in plasma as S-nitroso-albumin, therefore these are useful compounds to
study, particularly S-nitrosoalbumin because the generation of NO from this thiol
complex follows more predictable kinetics than that from the commonly-used
synthetic compound S-nitroso-acetyl-penicillamine (SNAP;(Gluckman et al., 2000).
One method of reducing sensitivity to catalytic effects of copper is to change
the molecular structure so that Cu+ is no longer able to catalyse decomposition. Such
compounds include RIG200 (SNAP coupled to acetylated glucosamine) and SNVP,
which is formed by lengthening the acetyl side chain of SNAP. These have
prolonged vasodilator activity, suggesting that they may be retained in blood vessel
walls from where they can decompose slowly to produce a sustained biological effect
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(Megson et al., 1997). It is hoped that S-nitrosothiols, especially RIG200, may be
used to target delivery of the drug to regions of endothelial damage, as their
lipophilic nature allows absorption into the endothelium-denuded vessel wall from
where prolonged NO release can occur (Megson et al., 1997).
A further group of NO-donating compounds, which may have therapeutic
potential in inflammatory conditions, are the NO-conjugated non-steroidal anti¬
inflammatory drugs (NO-NSAIDs), several of which have recently been synthesised,
including NO-aspirin and nitroparacetamol (Keeble and Moore, 2002). These drugs
have an improved pharmacological profile versus traditional NSAIDs because they
retain the anti-inflammatory and anti-pyretic properties of the parent compounds but
greatly attenuate the gastro-intestinal irritation observed as a side-effect of traditional
NSAIDs (Fiorucci et al., 2003;Keeble and Moore, 2002). Thus, this group of
compounds represents a highly exciting prospect for the clinical treatment of
inflammation.
Additionally, NO moieties have been conjugated to steroids such as
prednisolone. Steroids are widely-used anti-inflammatory agents, but are associated
with side effects such as osteoporosis. However, it has been shown that addition of
NO to prednisolone reduces such side effects by reducing the activity of osteoclast
cells, which are involved in bone resorption (Perretti et al., 2003). Such compounds
have been shown to have increased anti-inflammatory activity (Paul-Clark et al.,
2000) and are effective in in vivo models of inflammation (Paul-Clark et al.,
2002;Paul-Clark et al., 2000). These novel NO donors also represent a potential
novel anti-inflammatory therapy.
1.2 Inflammation:
Inflammation is a physiological response to cellular injury or infection, which
is characterised by redness, oedema, heat, leukocytic infiltration and pain. Its
purpose is to destroy or sequester the infectious agent and injured tissue. There are
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two main types of leukocytes involved in inflammatory responses in the body;
granulocytes, which can be subdivided into neutrophils, eosinophils and basophils,
and mononuclear cells including monocytes/macrophages and lymphocytes. These
leukocytes arise from a common myeloid precursor, and exposure to different growth
factors causes differentiation into the distinct classes of white blood cell.
1.2.1 The Inflammatory Response:
The neutrophilic granulocyte plays a critical role in the host defence against
bacterial and fungal infection, whereas eosinophils are primarily involved in parasitic
infection and allergic reactions. The neutrophil differentiates from the myeloid
precursor cell under the influence of colony-stimulating factors such as granulocyte-
macrophage colony-stimulating factor (GM-CSF) and, in particular, granulocyte
colony-stimulating factor (G-CSF(Metcalf and Nicola, 1983). It is packed with pre¬
formed granules, of which 4 distinct types have been identified, containing a battery
of molecules designed to eliminate infectious agents (Witko-Sarsat et al., 2000). The
vast majority of microbicidal molecules are contained within azurophilic granules,
alongside various proteases to digest extracellular matrix and intracellular proteins,
therefore these granules are regarded as critical in combatting infection and injury
(Witko-Sarsat et al., 2000).
The neutrophil is the first leukocyte to migrate into the inflammatory site in
response to chemoattractant molecules released from invading microorganisms, host
tissue or dying cells (Rossi and Haslett, 1998). For example, activated cells release
pro-inflammatory mediators such as IL-8 and LTB4, whereas invading
microorganisms secrete fMLP and LPS, and plasma factors such as C5a also
contribute to the inflammatory process (Rossi and Haslett, 1998).
Interactions between selectins and integrins (|31 or p2 integrins) on the
neutrophil and cell adhesion molecules (CAMs, e.g ICAM-1, ICAM-2 and ICAM-3)
and selectins (E-selectin, P-selectin) on endothelial cells allow the neutrophil to
adhere loosely to, then 'roll' along, the endothelium. If the leukocyte is activated by
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chemoattractants (e.g. PAF, IL-8, fMLP, C5a), cytokines, growth factors (TNFa,
GM-CSF) or bacterial products such as LPS, it adheres more firmly and spreads.
The neutrophil then passes between endothelial cells through modified tight
junctions (diapedesis), and moves into the site of inflammation down a number of
chemoattractant gradients (Witko-Sarsat et al., 2000). Once there, it exerts its
antimicrobial and cytotoxic effects by various mechanisms. The neutrophil releases
its stores of granules, which are packed with microbicidal proteins, collagenase,
gelatinase, proteases and plasma proteins into the extracellular medium. These
molecules kill the organism, but tissue damage can also occur as a result of their
action. Reactive oxygen species (ROS) are produced by NADPH oxidase in the cell
membrane, which kill micro-organisms, but can also damage normal tissue if
produced inappropriately.
Although it is well established that macrophages are able to generate iNOS-
derived NO on stimulation with inflammatory mediators such as LPS and IFN-y
(Brune et al., 1997), there remains some controversy over the ability of human
neutrophils to generate NO in a similar manner (Armstrong, 2001). Some studies
have reported NO generation in neutrophils (Wright et al., 1989;Schmidt et al.,
1989;Carreras et al., 1996). However, others have observed no NO release from
neutrophils (McBride and Brown, 1997). In other cases, NO release has been
enhanced in the presence of SOD (Carreras et al., 1994) and has been detectable in
patients with chronic granulomatous disease (CGD) in which O2" production is
impaired (Condino-neto et al., 1993). This suggests that NO is produced alongside
O2" in human neutrophils, thus generating ONOO" (Carreras et al., 1994), and that
unmasking ofNO by removal of O2" allows detection ofNO, and may explain why in
some studies, NO has not been detected in human neutrophils.
The cell also generates and secretes pro-inflammatory cytokines, which
recruit further inflammatory cells (neutrophils and monocytes) to the site (Witko-
Sarsat et al., 2000). The neutrophil also acts as a phagocyte, ingesting and
destroying the target micro-organisms and cell debris through Fey receptors and
complement receptors (Witko-Sarsat et al., 2000). This process is thought to induce
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the neutrophil to undergo programmed cell death or apoptosis, as described below,
and it becomes unable to respond to external stimuli, causing downregulation of
chemotaxis, phagocytosis and degranulation (Hart et al., 2000). Specific molecules,
including carbohydrates, thrombospondin-binding molecules and phosphatidylserine,
on the surface of the apoptotic neutrophil allow monocyte-derived macrophages to
recognise and phagocytose the apoptotic cells via a non-inflammatory mechanism,
thus resolving the inflammation (Rossi and Haslett, 1998).
1.2.2 Role of NO in Inflammation:
As previously described, constitutively-generated NO from eNOS has a
number of anti-inflammatory actions that protect the cardiovascular system from
formation of inflammatory foci. Anti-thrombotic effects are thought to be due in
part to cGMP-mediated inhibition of P-selectin expression on the surface of the
platelets (Granger and Kubes, 1996). However, recent studies have demonstrated
that cGMP-independent mechanisms may also play their part (Sogo et al., 2000). It
has been shown that the prolonged effects ofNO on inhibition of platelet aggregation
may be due to the formation of S-nitrosothiols, through reaction with plasma proteins
such as albumin in the presence of low molecular weight thiols, allowing prolonged
exposure of the platelets to NO (Crane et al., 2002).
Endothelial cell-mediated oxidation of low density lipoprotein can be
inhibited by GEA 3162; although the precise mechanism was not elucidated, the
authors proposed elevation of cGMP, inhibition of 15-lipoxygenase, free radical
scavenging or iron chelation as potential mechanisms (Malo-Ranta et al., 1994). Of
further interest for the prevention of atherogenesis, vascular smooth muscle cell
(VSMC) proliferation may be inhibited by NO, with the most profound response
obtained with NO donors that release NO at a slow rate (Mooradian et al., 1995).
Once again, sGC stimulation was suggested as a potential mechanism, alongside
inhibition of ribonucleotide reductase (thus preventing DNA synthesis), inhibition of
respiration, and effects on cytokines and growth factors influencing cell growth
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(Mooradian et al., 1995).
NO has been demonstrated to produce a profound inhibition of neutrophil
functions. Leukocyte adhesion and emigration through vascular endothelium was
increased in the presence of inhibitors of NO synthesis through the neutrophil
adhesion molecule, CD11/CD18, demonstrating that endogenous NO possesses anti-
neutrophil properties via effects on adhesion molecules (Kubes et al., 1991).
Treatment of human neutrophils with exogenous NO/ONOO" donors, SIN-1 or GEA
3162, caused an inhibition of the chemotactic response and shape change in these
cells, potentially through modification of cytoskeletal components (Ward et al.,
2000). Additionally, neutrophil degranulation was inhibited in response to the
2+
ONOO" donor, SIN-1, however this was reported to be due to inhibition of Ca
elevation by a metabolite rather than ONOO" itself (Kankaanranta et al., 1997). In
further studies, a number ofNO or ONOO" donors were shown to inhibit neutrophil
functions such as leukotriene B4 (LTB4) production, degranulation, chemotaxis and
O2" release, with elevation of cGMP proposed as a potential mechanism (Moilanen et
al., 1993). In monocytes and macrophages, NO caused a cGMP-independent
inhibition of the oxidative burst through activation of PPAR-y and subsequent
downregulation of the p47 phagocyte oxidase (von Knethen and Brune, 2002).
However, the effects of NO are not exclusively protective and beneficial in
inflammation; excessive production of NO from iNOS in activated inflammatory
cells has been implicated in the pathogenesis of a number of diseases. For example,
in septic shock, iNOS-derived NO is produced from both inflammatory cells and
other cell types in the cardiovascular system in response to LPS from invading
bacteria, which contributes to systemic hypotension and cardiac failure (Brady and
Poole-Wilson, 1993). There are many conditions in which NO plays a dichotomous
role, whereby endogenous low levels of NO serve to protect the tissue or organ in
question, but overproduction ofNO contributes to the pathogenesis of the condition.
Such conditions include gastrointestinal conditions (sepsis, inflammatory bowel
syndrome, ulceration; (Kubes and McCafferty, 2000;Muscara and Wallace, 1999),
CNS disorders (stroke, seizures, acute and chronic inflammatory and
neurodegenerative disorders;(Szabo, 1996), asthma and cystic fibrosis (Robbins et
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al., 2000), chronic pulmonary hypertension (Hampl and Herget, 2000), interstitial
lung disease (Suga et al., 1998), chronic fatigue syndrome, multiple chemical
sensitivity and posttraumatic stress disorder (Pall and Satterle, 2001) and surgical
infection and sepsis (Johnson and Billiar, 1998). In addition, overproduction of NO
is implicated in a whole range of myocardial defects, such as ischaemia-reperfusion
injury, left ventricular hypertrophy, heart failure, transplant vasculopathy and
rejection and myocarditis (Shah and MacCarthy, 2000), despite the protective effects
of low-dose NO on cardiovascular function described above. In almost all cases, the
injurious species has been proposed to be ONOO" formed from the combination of
excessive NO with O2".
It is therefore clear that within many systems, NO may act as a protective or
injurious molecule, whereby physiological production of NO has beneficial
physiological effects but excessive production may lead to the formation of cytotoxic
molecules that damage tissue and may ultimately contribute to the pathogenesis of
many disease states.
Levels of NO may be manipulated in several ways; a number of NOS
inhibitors are available, some of which are non-selective for the NOS isoform.
However, more specific inhibitors are being developed, for example,
aminoguanidine, L-NIL and 1400W have all been reported to be relatively specific
for the inducible form ofNOS, iNOS, although they may still have inhibitory effects
on the other isoforms ofNOS (Alderton et al., 2001). Other NOS inhibitors, such as
L-NMMA and L-NAME are non-selective, affecting the activity of all isoforms of
NOS (Alderton et al., 2001). In contrast, NO levels may be increased through the
use of NO donors (see Chapter 1.1.3), or the effects of NO may be potentiated
through PDE inhibitors such as sildenafil, which inhibit breakdown of cGMP
(Pauvert et al., 2003). Such modifications ofNO levels may have important effects
on the inflammatory process in vivo, as discussed in Chapter 1.5.
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1.3 Apoptosis
Apoptosis is a controlled, physiological form of cell death, first named in
1972 (Kerr et al., 1972), although the process had been described in histological
studies for some years previously (Kerr, 2002). A large number of pro- and anti-
apoptotic factors exist within cells, and it is the net balance between them that
determines whether or not a cell undergoes apoptosis. In contrast to necrosis, the cell
is required to expend energy to undergo this form of cell death, but the process of
apoptosis is ultimately beneficial to the organism as a whole, because the cell
membrane integrity is maintained, thus preventing the release of cellular contents
and elicitation of an inflammatory response (Wyllie, 1997). Phagocytes then
recognise cells that have undergone apoptosis and clear them from the site.
1.3.1 Characteristics and Pathways ofApoptotic Cell Death:
Apoptosis is characterised by a number of morphological and biochemical
changes, executed in a sequential and highly regulated manner. The most striking
and definitive events of apoptotic cell death are the membrane 'blebbing' in which
the cell surface appears to 'boil', division of the cell into a number of 'apoptotic
bodies', and condensation and ultimate fragmentation of the nuclear material
(Wyllie, 1997;Zimmermann et al., 2001). Various cell surface changes, including
the exposure of phosphatidylserine on the outer cell surface allow recognition and
engulfment by phagocytes (Hoffmann et al., 2001). The central effectors of the
apoptotic pathway are the caspase family of cysteine proteases, which cleave
proteins at aspartic acid residues (Thornberry, 1997;Kidd, 1998). A number of these
enzymes have been discovered in humans, and they exist as inactive procaspases in
non-apoptotic cells, but become activated on proteolytic cleavage following initiation
of apoptosis (Wyllie, 1997). Target proteins include those involved in homeostasis
and repair, such as PARP and PKC-5, which allows DNA degradation and ensures
that apoptosis is an irreversible process, downstream effectors such as protein
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STRESS PATHWAY DEATH RECEPTOR PATHWAY
APOPTOSIS
Figure 1.3 Schematic representation of the two main pathways of apoptosis, the stress or
mitochondrial pathway and the death receptor pathway. The stress pathway involves
translocation of pro-apoptotic Bcl-2 family proteins to the mitochondria, release of pro-
apoptotic factors, apoptosome formation and activation of caspase 9 and effector caspases,
3, 6 and 7. Engagement of death receptors (e.g. Fas) causes receptor trimerisation, DISC
formation and activation of caspase 8 followed by activation of effector caspases, which are
responsible for proteolysis of a large number of target proteins, leading to apoptotic cell
death.
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kinases, and structural proteins (e.g. actin, fodrin, lamin), cleavage of which allows
disassembly of the cytoskeleton and nucleus, and therefore cell shrinkage and
nuclear condensation (Thornberry, 1997;Kidd, 1998).
Two principal pathways exist for the initiation of the apoptotic cascade
(Figure 1.3). Firstly, engagement of death receptors such as TNF-R1 or Fas with
their appropriate ligands induces receptor trimerisation and formation of the death
initiating signalling complex (DISC) through interaction of the receptors with
adapter proteins (e.g. TRADD, FADD) via specific 'death domain' amino acid
sequences (Wyllie, 1997;Kidd, 1998). This complex can then recruit procaspase 8
and generate the active apoptosis initiator, caspase 8, through proteolytic cleavage,
although c-FLIP acts as a competitive inhibitor of procaspase 8 binding to the DISC
and therefore has anti-apoptotic effects (Zimmermann et al., 2001).
Once active, caspase 8 can cleave procaspases 3, 6 and 7 to their respective
active effector caspases, which are responsible for the vast majority of proteolytic
cleavage in the apoptotic process (Zimmermann et al., 2001). In addition, in some
cell types (e.g. Type 2 Fas cells), caspase 8 may also initiate the mitochondrial
pathway described below, by promoting translocation of the truncated form of Bid
(tBid) to the mitochondria (Scaffidi et al., 1998;Zimmermann et al., 2001).
Inflammatory cells express Fas and TNF-R1, on the cell surface. TNF-R1 is
unusual in that it mediates both pro- and anti-apoptotic signals in neutrophils
(Murray et al., 1997). Caspase activation and consequent induction of apoptosis may
occur through adaptor proteins such as FADD. However, the TNFa signal can also
recruit an alternative cell survival pathway via TRAF, to activate NF-kB (Kidd,
1998;Barkett and Gilmore, 1999). The ultimate downstream effect of receptor
engagement (apoptosis or proliferation) depends on the adaptor proteins recruited to
the receptor complex; those such as FADD that contain a death effector domain
(DED) allow caspase recruitment and subsequent apoptotic signalling, whereas those
such as TRAF that have no such domain instead signal down the proliferative
pathway (Kidd, 1998).
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The second pathway is the mitochondrial pathway, which is recruited
primarily in response to cellular injury or stress. Examples of stresses that initiate
the mitochondrial apoptotic pathway include DNA damage, damage to cell
membranes or mitochondria, cytotoxic T lymphocyte killing and viruses (Wyllie,
1997).
A large number of pro- and anti-apoptotic Bcl-2 family proteins regulate this
pathway; anti-apoptotic family members, such as Bcl-2, Bc1-xl and A1 tend to be
located on the outer mitochondrial membrane and block the release of pro-apoptotic
factors stored within mitochondria. Pro-apoptotic members (Bax, Bak, Bid) are
more likely to be cytosolic (Zimmermann et al., 2001). Phosphorylation of some
members of the Bcl-2 family is able to regulate their activity. For example, in its
active (unphosphorylated) state, Bad binds to anti-apoptotic Bcl-2 family members
that usually bind to and sequester pro-apoptotic Bax. Binding of these anti-apoptotic
proteins by Bad allows Bax to homodimerise, translocate to the mitochondria and
induce cytochrome c release. However, phosphorylation of Bad makes it unable to
bind anti-apoptotic Bcl-2 family members so they are free to heterodimerise with
Bax and prevent its pro-apoptotic activity (Franklin and McCubrey, 2000).
Upon initiation of apoptosis, the pro-apoptotic proteins may undergo a
conformational change and translocate to the mitochondria, where the mitochondrial
transmembrane potential is lost and further pro-apoptotic proteins are released,
including cytochrome c, which combines with cytosolic apoptotic protease activating
factor-1 (Apaf-1) and procaspase 9 to form an 'apoptosome' (Wyllie,
1997;Zimmermann et al., 2001). Cleavage of Apaf-1-bound procaspase 9 then
releases active caspase 9, which subsequently cleaves procaspase 3, the principal
effector protease in apoptosis (Zimmermann et al., 2001).
Other pro-apoptotic proteins, SMAC/Diablo and Omi/HtrA2, are also
released from the mitochondria alongside cytochrome c, and inhibit the actions of
endogenous 'inhibitor of apoptosis' proteins (IAPs), thus releasing the intrinsic brake
on apoptosis provided by IAPs (Zimmermann et al., 2001 ;Los et al., 2003). The IAP
family of proteins includes XIAP, ML-IAP, cIAP-1 and cIAP-2, and can directly
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interfere with caspase activity via binding to caspases of both mitochondrial and
death receptor apoptotic pathways (Los et al., 2003). SMAC/Diablo and Omi/HtrA2
are able to bind to and inhibit the function of these IAP's, thus allowing caspase
activity (Los et al., 2003).
1.3.2 Neutrophil Apoptosis:
Failure of inflammatory cells to undergo apoptosis, or failure of the
phagocytic removal of apoptotic cells leads to exacerbation of inflammation, as
neutrophils undergo primary or secondary necrosis, whereby their pro-inflammatory
and histotoxic granule contents are released into the surrounding tissue (Haslett,
1992); Figure 1.4). In vivo, neutrophil apoptosis occurs within 8-20 h in circulating
cells as part of the rapid turnover of these cells (Akgul et al., 2001). In an
inflammatory site, however, inflammatory mediators prolong the lifespan of
neutrophils, although the neutrophil is programmed to die once it has performed its
biological functions, such as killing and phagocytosis of bacteria, in response to
cytokine withdrawal (Fortenberry et al., 1999). Phagocytosis-induced cell death
proceeds through the involvement of the P2 integrin, Mac-1, and requires the
generation of reactive oxygen species by the neutrophil. Caspases 8 and 3 become
activated during this process, but the activation of caspase 9 via the mitochondrial
pathway is not observed (Zhang et al., 2003a). However, inflammatory mediators
such as GM-CSF and G-CSF promote activation of opposing survival pathways
(Blaylock et al., 1998), with GM-CSF acting through MAPK/ERK, which may delay
neutrophil apoptosis following phagocytosis (Zhang et al., 2003a) and is responsible
for the accumulation of neutrophils seen in several inflammatory conditions (Ward et
al., 2000).
A large number of stimuli that are likely to be present at inflammatory sites,
such as LPS, fMLP, PAF, LTB4, C5a, inflammatory cytokines, hypoxia and
oxidative stress, inhibit neutrophil apoptosis (Ward et al., 1999b). It has been shown
that some of these stimuli exert their effects by influencing NF-kB activation (Pahl,
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1999). Under normal conditions, NF-kB is kept sequestered in the cytoplasm by
inhibitory IkB proteins such as IkBoc (Barkett and Gilmore, 1999). An activating
stimulus causes phosphorylation of IkB by IkB kinase (IKK), making IkB
susceptible to proteolytic degradation, leaving NF- kB free to translocate to the
nucleus and bind to DNA. There, it induces transcription of target genes that
promote cell survival in most cell types (Barkett and Gilmore, 1999). The cell
survival effects of NFkB are largely due to upregulation of anti-apoptotic genes.
These include the Bcl-2-like genes Al/Bfll, Bc1-xl and Nrl3, plus the adaptor
proteins TRAF-1 and TRAF-2, and the inhibitors of apoptosis proteins H-IAP1 and
H-IAP2 (Pahl, 1999). It has been suggested that A1 inhibits release of cytochrome c
from mitochondria, and may also inhibit caspase-3 activation, while the adaptor
proteins and IAPs may block activation of caspase-8 (Barkett and Gilmore, 1999).
Another way in which NF-kB can promote cell survival is by affecting transcription
of genes that regulate the cell cycle, thus making the cell more or less sensitive to
apoptotic stimuli. Genes encoding certain transcription factors, such as c-Myb, c-
Myc and c-Rel fall into this category (Pahl, 1999). C-myc may achieve its anti-
apoptotic effects by induction of survival factors, by repression of death-inducing
genes, or by a combination of these two mechanisms (Thompson, 1998). In addition,
NF-kB may alter the free levels of cellular proteins, such as the transcriptional co-
activator proteins CBP/p300, through direct protein-protein interactions. These
proteins are able to bind to various cell signalling proteins such as nuclear receptors,
p53 and Rel-A, (Barkett and Gilmore, 1999). Thus, several cell signalling pathways
may be affected in ways that would alter the sensitivity of the cell to pro-apoptotic
stimuli.
Neutrophils undergo constitutive apoptosis in culture, however the
mechanisms by which cell death proceeds remain to be fully elucidated.
Engagement of the Fas death receptor (Liles et al., 1996) has been proposed as a
potential mechanism for spontaneous neutrophil apoptosis, although this is
controversial (Simon, 2003). Activation of p38 MAPK has also been reported to be
involved (Aoshiba et al., 1999). Virtually the only certainty surrounding constitutive
apoptosis is the involvement of caspases, with caspases 1, 3, 8 and 9 all being
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reported to become activated during this process (Khwaja and Tatton, 1999;Simon,
2003), although caspase-independent spontaneous neutrophil apoptosis has been
reported (Harter et al., 2001). Such results suggest that both death receptor and
mitochondrial pathways are responsible for apoptosis. Downstream of caspase
activation, PKC becomes activated by proteolysis (Khwaja and Tatton, 1999), which
allows increased reactive oxygen species generation through NADPH oxidase which
may also play a role (Kasahara et al., 1997;Simon, 2003). Additionally, proteolytic
activity of calpains and the proteasome contribute to constitutive apoptosis
(Knepper-Nicolai et al., 1998), including cleavage of the inhibitor of apoptosis
protein, XIAP (Kobayashi et al., 2002), and actin (Brown et al., 1997) by calpains.
It is clear that pro- and anti-apoptotic members of the bcl-2 family of proteins
play a role in regulating the rate of spontaneous neutrophil apoptosis. Translocation
of Bax into the mitochondria during neutrophil apoptosis has been observed, thus
activating the mitochondrial apoptotic pathway and causing caspase 3 activation
(Maianski et al., 2002). Truncation and translocation of Bid has also been observed
(Simon, 2003). The role of Bak remains controversial; this molecule has been
detected in neutrophils (Pryde et al., 2000;Moulding et al., 2001), but levels
remained unchanged in the presence of factors that modulate the rate of neutrophil
apoptosis (Bazzoni et al., 1999). Expression of anti-apoptotic bcl-2 has been
reported to occur in neutrophils and to be upregulated by LPS (Hsieh et al., 1997).
However other groups have found that bcl-2 is absent from mature neutrophils and
that Al represents the major anti-apoptotic member of the bcl-2 family in
neutrophils, and is upregulated by GM-CSF and LPS (Chuang et al., 1998).
Moulding et al reported that protein levels of pro-apoptotic Bad, Bax, Bak and Bik
remain constant during culture and that anti-apoptotic Bc1-xl protein was
undetectable despite the presence ofmRNA. They proposed that relatively unstable
anti-apoptotic proteins, such as Mcl-1 and Al, are rapidly broken down, unmasking
the effects of the more stable pro-apoptotic proteins named above (Moulding et al.,
2001). Thus, it is believed that Mcl-1 and Al are likely responsible for the
regulation of neutrophil apoptosis.
Neutrophil apoptosis can be modulated during in vitro culture, with many
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agents able to either delay or enhance the rate of apoptosis in these cells; the net
balance of pro- and anti-apoptotic signals determines their longevity. Corticosteroids
have opposing effects in the different inflammatory cell types, as they induce
apoptosis in eosinophils but inhibit neutrophil apoptosis (Haslett, 1997;Meagher et
al., 1996). Interestingly, the effects of glucocorticoids are mimicked by agents that
2+ . . 2-|-
increase the intracellular calcium concentration ([Ca ]i), in that an increase in [Ca ]i
delays neutrophil apoptosis but promotes eosinophil apoptosis (Cousin et al.,
1997;Ward et al., 1999b). Moreover, the proinflammatory cytokine TNF-a induces
neutrophil apoptosis (Ward et al., 1999a), but has no such pro-apoptotic effect in
eosinophils unless NF-kB activation is blocked, unmasking the pro-apoptotis effects
of TNF-a (Fujihara et al., 2002).
On the other hand, the bacterial product lipopolysaccharide (LPS) and agents
that increase the intracellular concentration of cAMP (e.g. db-cAMP, prostaglandins)
delay both neutrophil and eosinophil apoptosis (Ward et al., 1999b), as do IL-3 and
GM-CSF. Protein synthesis inhibitors such as actinomycin D and cycloheximide
have the ability to induce apoptosis in neutrophils (Ward et al., 1999b). Other
potential mechanisms that may regulate apoptosis in granulocytes include oxidative
damage caused by ONOO", which is generated when NO and O2" combine (Blaylock
et al., 1998;Dimmeler and Zeiher, 1997;Ward et al., 2000), direct DNA damage
(Dimmeler and Zeiher, 1997), S-nitrosylation of cysteines of enzymes involved in
the regulation of apoptosis (Melino et al., 1997) or inhibition of mitochondrial
respiration at the level of cytochrome c oxidase (Melino et al., 1997).
1.3.3 Nitric Oxide and Apoptosis:
NO is rapidly being recognised as an important regulatory molecule in
apoptosis in many cell types, and a large number of studies have demonstrated
effects of either endogenously-produced or exogenously-supplied NO on apoptosis.
Chapter 1: Introduction 27
Regulation ofNeutrophil Apoptosis by NO and ONOO"
1.3.3.1 General Effects of NO on Apoptosis:
This ubiquitous signalling molecule can regulate the rate of apoptosis, or
programmed cell death, in many cell types, including human inflammatory cells.
Whether or not cells undergo apoptosis depends on the net balance of a large number
of pro- versus anti-apoptotic factors. Studies have revealed that NO has both pro-
and anti-apoptotic properties, depending largely on the concentration and flux ofNO,
and the cell type under scrutiny (Nicotera et al., 1997;Kim et al., 1999). It has been
proposed that low concentrations of NO, derived from constitutively active
endothelial and neuronal isoforms ofNO synthase (eNOS and nNOS), usually have a
protective effect on cells whereas higher concentrations derived from the inducible
isoform (iNOS) are more likely to drive cell death (Nicotera et al., 1997). The
current line of thinking is that NO has the ability to either induce or inhibit apoptosis,
depending on its concentration, the cell type, the redox state of the cell and the cell's
own defence mechanisms (Nicotera et al., 1997).
Induction of apoptosis has been observed in VSMC (Pollman et al., 1996),
macrophages (Wang et al., 1999), neutrophils (Ward et al., 2000), cardiomyocytes
(Kawaguchi et al., 1997) and neurons (Nicotera et al., 1997). These effects are
generally believed to be cGMP-independent, and may be due to the action of ONOO"
(Wang et al., 1999;Ward et al., 2000), S-nitrosylation of proteins (Nicotera et al.,
1997), the MAPK and Jun kinase (JNK) pathways (Nicotera et al., 1997) or
upregulation of p53, which in turn affects the apoptotic caspase enzymes (Nicotera et
al., 1997). In contrast, other studies have shown NO to inhibit endothelial cell,
lymphocyte and hepatocyte apoptosis (Wang et al., 1999;Nicotera et al., 1997). This
protective effect may be due to elevated cGMP or increased antioxidant levels
(Nicotera et al., 1997).
In stark contrast to cells undergoing necrosis, apoptotic inflammatory cells
fail to release their pro-inflammatory and histotoxic contents (Haslett, 1997).
Furthermore, their clearance by professional phagocytes such as macrophages occurs
via a non-phlogistic mechanism, which additionally aids the resolution of the
inflammatory response (Meagher et al., 1992). Thus, apoptosis is generally regarded
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to be non-inflammatory and is crucial for the successful resolution of inflammation.
Chronic inflammatory conditions are frequently characterised by an apparent
failure of myelocytic inflammatory cells to respond to apoptotic stimuli, or of
phagocytes to remove apoptotic cells. Persistence of these cells leads to damage of
the surrounding tissue and exacerbation of inflammation, as cells ultimately undergo
either primary or secondary (following failed clearance of apoptotic cells) forms of
the extremely pro-inflammatory necrosis (Haslett, 1997;Ward et al., 1999b); Figure
1.4).
Manipulation of the rate of apoptosis in critical inflammatory effector cells
such as neutrophils, eosinophils, monocytes and macrophages, could therefore be of
therapeutic benefit (Ward et al., 1999b). NO is capable of inducing inflammatory
cell apoptosis and, given its other anti-inflammatory properties, manipulation of NO
concentrations is a particularly promising candidate to alter leukocyte function and
rates of apoptosis in inflammatory conditions.
1.3.3.2 NO and Neutrophil Apoptosis
In recent years, it has become clear that NO also has the ability to induce
apoptosis in neutrophils. Wong et al. demonstrated that the oxatriazole-5-imine
derivative, GEA 3162, and SIN-1 increased the rate of apoptosis in human
neutrophils (Wong et al., 1997). Simultaneously, Brennan et al. found increased
markers of DNA fragmentation treated with high (8-32 mM) concentrations of SNP
in these cells (Brennan et al., 1996). However, this effect may have been due to
respiratory inhibition by cyanide derived from the liberation of NO from such high
concentrations of this compound.
Since then, a number of groups have validated these findings through the use
of several different sources of NO. NO gas (20 and 50 ppm) reduces cell viability
and augments DNA fragmentation over 2 or 24 h of culture, an effect that is
particularly pronounced in the presence of 80% O2 (Fortenberry et al., 1998).
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Whether this cell death comprises apoptosis or merely necrosis, however, remains
unclear. An induction of neutrophil apoptosis has also been observed using both
traditional NO donors such as SNP (Singhal et al., 1999) and different sources ofNO
such as GSNO (0.5-5 mM; (Fortenberry et al., 1999).
Blaylock et al. (1998) reported that GEA 3162 (10 pM) increased neutrophil
apoptosis as assessed by Annexin V binding to exposed phosphatidylserine (PS) at 4
and 8 h, but not at 16 h. On the other hand, the ONOO" donor, SIN-1 (1 mM),
showed no significant increase in PS exposure compared to control cells, although
there was a small enhancement of annexin V binding at 4 h (Blaylock et al., 1998).
The effects of these two compounds were also studied by Ward et al., who
demonstrated that concentrations of 10-100 pM GEA 3162 and 0.3-3 mM SIN-1
enhanced caspase dependent morphological neutrophil apoptosis at 6 and 20 h, and
30-100 mM GEA 3162 increased annexin V binding at 6 h (Ward et al., 2000). In
contrast to Blaylock's study, however, the increase in morphological apoptosis by 10
pM GEA 3162 was not significant at 6 h, whereas Blaylock observed significant
differences at just 4 h. The principal methodological difference between the two
studies is in the culture conditions. It has previously been demonstrated that the
micro-environment, including cell density and concentration of plasma proteins, has
a critical effect on the rate of neutrophil apoptosis in vitro (Hannah et al., 1998). It
must therefore be emphasised that the choice of culture conditions may subtly alter
the effects of NO on neutrophils, and experimental design should receive careful
consideration.
1.4 Mechanisms of Action of NO
The mechanisms through which NO is able to both promote and delay
inflammatory cell apoptosis still remain to be fully elucidated. However, it is
generally believed that low concentrations tend to be anti-apoptotic, acting through a























































































































Regulation ofNeutrophil Apoptosis by NO and ONOO"
rise in cGMP or S-nitrosation of caspase enzymes. On the other hand, high
concentrations ofNO are generally more toxic, inducing either apoptosis or necrosis,
with most reports suggesting that such actions occur independently of the sGC
signalling pathway (see below and Figure 1.5).
Another possibility is that NO may indirectly interfere with alternative
pathways that regulate inflammatory cell survival. For example, glucocorticoids
(GCs) promote eosinophil apoptosis but inhibit neutrophil death (Meagher et al.,
1996;Ward et al., 1999b). It has been shown that NO can inhibit GC receptor (GR)
binding through S-nitrosation (Galigniana et al., 1999), and therefore could attenuate
both the pro- and anti-apoptotic effects of glucocorticoids on inflammatory cells.
1.4.1 Anti-apoptotic mechanisms:
The pathway by which NO inhibits apoptosis in neutrophils has not yet been
investigated. However, it is known that NO induces a rise in cGMP in neutrophils
through activation of sGC (Moilanen et al., 1993;Kosonen et al., 1999). Given that
the cell permeable analogues of cAMP (db-cAMP) and cGMP (db-cGMP), can delay
constitutive neutrophil apoptosis (Ward et al., 2000), and that a rise in cGMP has
been postulated to at least partially account for NO-mediated inhibition of apoptosis
in other cell types (Li and Billiar, 1999;Kolb, 2000), it is possible that an increase in
one or other of these cyclic nucleotides mediates the inhibition of apoptosis in
neutrophils exposed to low concentrations ofNO.
A role for cyclic nucleotide (cGMP or cAMP) signalling has also been
proposed in NO-mediated inhibition of both constitutive and Fas-triggered eosinophil
apoptosis. Beauvais et al observed that NO could only reduce eosinophil apoptosis
when compounds that form nitrosyl-haem in their liberation ofNO were used, which
was mimicked by the permeable cGMP analogue db-cGMP and reduced by the sGC
inhibitor LY-83583 (Beauvais et al., 1995). Pure NO donors alone, in contrast,
failed to increase eosinophil survival, although inhibition of apoptosis could be seen
if hematin was added alongside a pure NO donor to artificially create a nitrosyl-heme
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complex (Beauvais and Joly, 1999).
It has been suggested that such inhibition occurs through activation of sGC
by the nitrosyl-haem complex (Beauvais and Joly, 1999), which has been shown to
occur in vitro using purified sGC (Edwards el al., 1981), but as yet there is no
evidence to suggest that this may occur in intact cells in vivo. However, the
mechanism is not fully understood: the issue is complicated by the fact that haem
groups are known to scavenge NO, and therefore might be expected to inhibit NO-
mediated effects.
Inhibition of Fas-mediated apoptosis was reproduced by both db-cGMP and
db-cAMP, and potentiated by the PDE inhibitor, IBMX (Hebestreit et al., 1998),
again suggesting a role for cyclic nucleotides. This group localised the site of Fas
receptor death pathway blockade to downstream of SMase activation and ceramide
generation but upstream or around the level of JNK activation. So et al showed
inhibition of the stress protein JNK2 by NO in vitro via S-nitrosation (So et al.,
1998).
Secondly, the transcription factor NF-kB is known to regulate neutrophil
apoptosis as its inhibition leads to increased apoptosis (Ward et al., 1999a). Agents
such as LPS have been shown to delay apoptosis in this cell type through stimulation
of NF-kB and subsequent caspase-1 dependent activation of IL-1(3 (Watson et al.,
1998). It has been demonstrated in several cell types that activation ofNF-kB leads
to the transcriptional upregulation of survival factors such as the immediate early
gene, IEX-1L, inhibitor of apoptosis proteins (IAPs), and members of the anti-
apoptotic Bcl-2 gene family, including Mcl-1, Al/Bfll, Bc1-xl and Nrl3, potentially
explaining the survival effects of NO which, at low concentrations, induces NF-kB
activation in macrophage cell lines (von Knethen et al., 1999b;Connelly et al., 2001)
and in human peripheral blood mononuclear cells (Fowler, III et al., 1999).
Activation of NF-kB may occur through a cGMP-dependent mechanism
(Kalra et al., 2000) and NO has been demonstrated to modulate the expression of
several proteins affecting the activity of Bcl-2 family members through sGC
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activation. A cGMP-dependent mechanism has been proposed to account for the
NO-induced downregulation of BNIP3, a dominant pro-apoptotic Bcl-2 family
member in hepatocytes (Zamora et al., 2001). Levels of MAPK phosphatase-3
(MKP-3) mRNA, which causes degradation of Bcl-2 via ERK1/2 dephosphorylation,
were seen to be decreased by NO, thus protecting Bcl-2 levels and promoting
survival of endothelial cells (Rossig et al., 2000), although the role of Bcl-2 in
neutrophils is questionable, as described above. The pro-apoptotic adaptor protein,
p66shc, is also downregulated by NO via sGC activation (Andoh et al., 2000).
Furthermore, survival genes such as Bcl-2 and Bc1-xl have been shown to be
upregulated in the presence of NO in endothelial cells (Delikouras et al., 2001) and
human neuroblastoma cells (Andoh et al., 2000), therefore it seems possible that
there is a role for NF-KB-mediated transcriptional regulation in the anti-apoptotic
effects ofNO in inflammatory cells.
Contrasting studies in macrophage cell lines (Brune et al., 1997;Vouldoukis
et al., 2000;Boggs et al., 1998) suggest that the redox status of the cell may partially
determine the effects of NO. An inhibitory effect of endogenous NO on J774 cell
apoptosis can be unmasked when O2 is scavenged (Vouldoukis et al., 2000), and
overexpression of SOD also protects RAW 264.7 cells against apoptosis induced by
endogenous or exogenously-supplied NO (Brockhaus and Brune, 1999). These
studies suggest a role for ONOO" in mediating NO-induced apoptosis.
Conflicting evidence suggests that RAW 264.7 cells that overproduce O2" are
resistant to NO-mediated apoptosis (Brune et al., 1997), and von Knethen et al
observed that O2" activates NF-kB, thus mediating survival in these cells (von
Knethen et al., 1999c). Furthermore, Brockhaus et al found that ONOO" had no role
in NO-evoked apoptosis, despite the protective effect of SOD in RAW 264.7 cells
(Brockhaus and Brune, 1999).
Others have found that such protection is observed when cellular thiols are
depleted in RAW 264.7 cells (Boggs et al., 1998). It has been reported that
endogenous antioxidant levels (Rosenberg et al., 1999), or the balance between
oxidative and nitrosative stress (Espey et al., 2000), can determine the cellular
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response to NO. It has been proposed that in low thiol concentrations, NO actually
protects against cell death, whereas it induces death in cells with normal thiol levels
(Rosenberg et al., 1999). Exogenous glutathione has also been shown to enhance
neutrophil apoptosis and increase H2O2 levels, possibly leading to hydroxyl radical-
mediated damage (Adrie et al., 2000).
In the absence of large quantities of scavenger thiols such as glutathione, but
in the presence of oxygen, it is possible that NO S-nitrosates critical effector
molecules of apoptosis such as caspases, thus preventing their activation and having
an inhibitory effect on the proteolytic cascade. It has been shown by several groups
that NO can inhibit a number of apoptotic proteins (Melino et al., 1997) including
caspase 3 (the protease responsible for the initiation of intemucleosomal DNA
fragmentation) (Mohr et ah, 1997;Zech et al., 1999;Li et al., 1997;Rossig et al.,
1999;Kim et al., 1998;Kim et al., 1997), caspase 8 (Dimmeler et al., 1997;Dimmeler
et al., 1998;Li et al., 1997), caspase 9 (Torok et al., 2002), caspase 1 (Dimmeler et
al., 1997;Dimmeler et al., 1998) and caspases 2, 3, 4, 6 and 7 (Li et al., 1997)
activation via S-nitrosation. Inhibition of caspase 3 has been reported to involve two
distinct mechanisms in hepatocytes - direct protein S-nitrosation, and another
mechanism, which has not yet been elucidated, but is dependent upon cGMP (Kim et
al., 1997). Therefore, the cGMP-dependent anti-apoptotic effects of NO in
inflammatory cells may be mediated through an inhibitory effect on caspases.
1.4.2 Pro-apoptotic mechanisms:
Studies have shown that apoptosis in neutrophils and macrophages proceeds
via activation of caspase protease enzymes (Ward et al., 2000;Williams et al.,
1997;Knepper-Nicolai et al., 1998), part of the classical apoptotic effector cascade.
However, the upstream mechanisms by which exposure to NO causes these enzymes
to become activated has not been clarified, although several theories have been
suggested.
ONOO" is considered to be one of the most likely candidates for the increased
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apoptosis of inflammatory cells observed with higher concentrations of NO,
particularly in the case of neutrophils (Ward et al., 2000;Fortenberry et al.,
1998;Blaylock et al., 1998), which generate large quantities of O2" that rapidly
combines with NO to form ONOO". Compounds that generate ONOO", such as SIN-
1, may promote neutrophil apoptosis similar to that evoked by NO (Ward et al.,
2000), and primary human monocytes also undergo apoptosis in response to ONOO"
by a mechanism that involves mitochondrial membrane depolarisation, release of
cytochrome c and caspase activation (Adrie et al., 2000); see Figure 1.5). ONOO"
has been shown to reversibly or irreversibly inhibit a number of mitochondrial
respiratory complexes as well as inducing mitochondrial swelling, depolarisation,
calcium release and permeability transition (Clementi et al., 1998;Brown and
Borutaite, 2001).
Macrophage apoptosis can also be induced by exposure to ONOO", via
oxidative stress, which can be reduced by antioxidants such as ascorbic acid
(Sandoval et al., 1997b) or phytolens (Sandoval et al., 1997a). Induction of
apoptosis by NO in elicited murine macrophages or RAW 264.7 cells has also been
attributed to formation of ONOO" within mitochondria, as nitrotyrosine residues
were detected in cytochrome c (Hortelano et al., 1999). ONOO" and metabolites of
NO (e.g. N2O3), can cause direct DNA damage or inhibit DNA repair enzymes
(Wink et al., 1996), leading to an increase in the tumour suppressor protein p53,
which has been shown to accumulate in NO-treated macrophages and may be the
factor responsible for driving them towards apoptosis (Brune et al., 1997;von
Knethen et al., 1999a;Messmer et al., 1994;Messmer and Brune, 1996b). The p53
protein promotes apoptosis through upregulation of the apoptotic proteins Bax and
cyclin-dependent kinase p21 and downregulation of the anti-apoptotic protein Bcl-2
(Kolb, 2000); Figure 2). However, Gotoh et al measured no increase of p53 in NO-
mediated apoptosis in RAW 264.7 cells stimulated with LPS/IFN-y (Gotoh et al.,
2002). Instead, this group proposed a role for the endoplasmic reticulum stress
pathway involving the transcription factors ATF6 and CHOP leading to cytochrome
c release (Figure 1.5). Also, studies in murine macrophages (Brockhaus and Brune,
1999) suggest little or no involvement for ONOO" in NO-induced apoptosis in this
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cell type.
As previously described, the activation status of the survival factor, NF-kB,
has been shown to play a role in regulation of the induction of inflammatory cell
apoptosis (Ward et al., 1999a). It has been demonstrated that high concentrations of
NO can inhibit NF-kB activation in macrophage cell lines (Connelly et al., 2001) and
human macrophages (Raychaudhuri et al., 1999), monocytes (Welters et al., 2000)
and neutrophils (Welters et al., 2000;Fortenberry et al., 2001). NO may inhibit NF-
kB DNA binding through S-nitrosation of the p50 subunit of the transcription factor,
as has been demonstrated in isolated NF-kB protein (Matthews et al., 1996) and in
human respiratory cells and murine macrophages (Marshall and Stamler, 2001).
Alternatively, transcriptional induction and stabilisation of the inhibitory molecule I-
kB, that keeps NF-kB sequestered in the cytoplasm, may account for the inhibition
of NF-kB activity (Peng et al., 1995). Furthermore, it has been reported that NO
inhibits NF-kB activation in rat vascular smooth muscle cells via a cGMP-
independent inhibition of the phosphorylation and proteasomal degradation of I-kB
(Katsuyama et al., 1998), and inhibition of the proteasome by NO has additionally
been demonstrated by Glockzin et al in macrophages (Glockzin et al., 1999). The
result of such inhibition would be downregulation of survival factors under the
control of this transcription factor, such as the anti-apoptotic Bcl-2 family members.
Indeed, this has been observed by a number of studies, as exogenous NO
downregulates Bcl-2 but upregulates the pro-apoptotic protein, Bax, in neurons
(Tamatani et al., 1998;Matsuzaki et al., 1999) and upregulates Bad and Bax but
downregulates Bcl-2 in human colon adenocarcinoma cells (Ho et al., 1999).
In non-small cell lung cancer cells, it has been shown that NF-kB inhibition
leads to apoptosis by increasing mitochondrial permeability, thus allowing release of
cytochrome c and subsequent caspase activation (Jones et al., 2002). This concurs
with findings by Borutaite et al, who demonstrated increased mitochondrial
permeability and cytochrome c release from isolated rat mitochondria, and increased
caspase activation in J774 cells treated with S-nitrosothiols (SNAP, GSNO) but not
NONOates (DETA/NO), which activate caspases through an as yet unidentified
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alternative mechanism (Borutaite et al., 2000). As S-nitrosothiols readily
transnitrosate endogenous cysteine residues, this supports the concept of S-
nitrosation of the NF-kB p50 subunit as the mechanism of inhibition.
In addition, the biphasic effects of NO on NF-kB activation reported by
Connelly et al are mirrored by its effects on the open probability of the mitochondrial
permeability transition pore (MPTP). Low concentrations ofNO donors (GEA 3162,
SNAP, SIN-1; 1-20 pM) delayed or had no effect on MPTP opening, while at higher
concentrations (20-100 pM), opening was enhanced (Piantadosi et al., 2002). In this
study GEA 3162 was found to be particularly effective at inducing MPTP opening
compared to the other two NO donors, and this drug induces neutrophil apoptosis at
lower concentrations than NONOates or SIN-1 (Ward et al., 2000), as described in
Chapter 4. Enhanced MPTP opening on exposure to NO was also reported by
Hortelano et al (Hortelano et al., 1997). Therefore there is growing evidence to
suggest that the pro-apoptotic effects ofNO in inflammatory cells may be mediated,
at least in part, through inhibition ofNF-kB.
Albina et al proposed metabolic inhibition as a potential mechanism, as
glucose starvation and inhibition of glycolysis or the TCA cycle all pushed
macrophages into apoptosis (Albina et al., 1993). On the other hand, inhibition of
the electron transport chain of respiration had no effect (Albina et al., 1993), and
Messmer et al showed no reduction in NAD+ or ATP levels in NO-induced apoptosis
(Messmer and Brune, 1996a), suggesting that NO does not act through respiratory
inhibition.
In contrast, others have reported that NO inhibits mitochondrial respiration
through two distinct pathways (Clementi et al., 1998;Brown and Borutaite, 2001).
Reversible inhibition of cytochrome oxidase was seen with low concentrations of
NO, whereas higher concentrations caused an inhibition of alternative respiratory
chain complexes (Brown and Borutaite, 2001). Inhibition of complex IV was
reversible, whereas inhibition of complex I was irreversible (Clementi et al., 1998).
Of course, the mechanisms described above may not be mutually exclusive. For
example, respiratory inhibition by NO may enhance the production of reactive
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oxygen species by mitochondria, leading to the formation of ONOO" and providing a
ONOO'-mediated pathway for NO-induced cytotoxicity (Brown and Borutaite,
2001).
1.5 In Vivo Effects of NO and its Therapeutic Potential
Delayed apoptosis of activated granulocytes has been reported to occur in a
number of inflammatory conditions in humans or animal models (Haslett,
1997;Simon, 1999), including rheumatoid arthritis (Ottonello et al., 2002), acute
pancreatitis (O'Neill et al., 2000), bacterial pneumonia (Droemann et al., 2000),
inflammatory bowel disease (Brannigan et al., 2000), asthma (Turlej et al.,
2001;Woolley et al., 1996;Kankaanranta et al., 2000) and following surgery
(Matsuda et ah, 2001;Chello et al., 2002). Failure of these cells to undergo
programmed cell death and to be cleared by phagocytes allows persistent and
inappropriate inflammation to occur, as activated granulocytes release a number of
pro-inflammatory mediators, which may contribute significantly to the aetiology of
the disease. Therefore, the induction of apoptosis in these cells is a potential target
for therapeutic intervention, by removal of the inflammatory effector cells, thereby
minimising tissue damage and oedema.
Although iNOS has been implicated in the pathogenesis of certain
inflammatory diseases, such as arthritis, SLE and irritable bowel syndrome (Clancy
and Abramson, 1995), a number of studies have demonstrated a protective effect of
NO against several conditions characterised by inflammation, such as
glomerulonephritis (Heeringa et al., 2000), acute hepatic necrosis (Billiar et al.,
1990), arthritis (Veihelmann et al., 2001;McCartney-Francis et al., 2001),
endotoxemia (Billiar et al., 1990) and acute lung injury (Liu et al., 2001) in vivo
(Clancy and Abramson, 1995). Most studies attribute these effects to the wide range
of general anti-inflammatory properties of NO, as reviewed by Granger and Kubes
(Granger and Kubes, 1996). Of particular interest, however, is the increasing
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evidence that the protection afforded against inflammation and immunity by NO may
be mediated in part through the induction of inflammatory cell apoptosis. As for
apoptosis induction in vitro, the concentration of NO in the local environment
(Ormerod et al., 1999;Ross and Reske-Kunz, 2001), the timing of administration
(Okuda et al., 1998;Xu et al., 2001) or the route of administration, and perhaps
therefore the NOS isoform targeted (Paul-Clark et al., 2001) appears to be critical.
Studies have suggested that lower doses of NO may be detrimental but that higher
doses may attenuate the inflammatory response, with some authors proposing a role
for the cytotoxic effects of NO on myeloid inflammatory cells (Okuda et al.,
1997;Wang et al., 1999;Niebauer et al., 1999;Ross and Reske-Kunz, 2001).
NO appears to be particularly effective in autoimmune conditions, such as
experimental allergic encephalomyelitis (EAE), which serves as a model for human
multiple sclerosis (Bogdan, 1998). In this model, several studies have reported that
iNOS-deficient rats or mice that were immunised directly with MBP developed
exacerbated disease, although results obtained following immunisation with MBP-
specific T cells often contradict these findings (Bogdan, 1998). One proposed
mechanism for the protective effect of iNOS-derived NO is induction of apoptosis in
macrophages or T cells (Puerta et al., 2000;Xu et al., 2001).
Other autoimmune disease models in which NO has been reported to be
protective are the rat model of autoimmune interstitial nephritis and experimental
autoimmune uveitis, as inhibition ofNOS caused exacerbated injury in both models,
although again other studies have produced conflicting results (Bogdan, 1998).
Therefore, NO may be protective in a number of autoimmune conditions, although
further research will be required to fully understand the apparent contradictory
effects ofNO.
A beneficial protective effect of NO has also been shown in the elicitation
phase of contact hypersensitivity, as prolonged inflammatory reactions were
observed in iNOS knockout mice (Ross and Reske-Kunz, 2001). Again, it has been
suggested that this effect may be partly due to the induction of apoptosis in
infiltrating cells. In a human model similar to sunburn and psoriasis, Ormerod et al
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described a cytotoxic effect of high concentrations of topically-administered NO to
immunocompetent cells, which was not seen with low concentrations (Ormerod et
al., 1999). Aminoguanidine, an inhibitor of iNOS, prevented the impairment of renal
vascular bed responses and reduced urine nitrate levels and apoptotic mononuclear
cells in a rat model of experimental nephropathy (Ozen et al., 2001). However,
although inflammatory apoptosis might be expected to be beneficial, the effect of this
form of cell death on prognosis was not studied within the late, sclerotic phase of the
disease during this study. In the same model, Rangan et al discovered that NOS
inhibitors exacerbated progression of the disease (Rangan et al., 2001), and
tubulointerstitial injury was also found to be increased in the presence of NOS
inhibitors in a model of thrombotic microangiopathy (Shao et al., 2001).
Two in vivo studies were published in 1999, investigating the effects of NO
on macrophage apoptosis in cardiovascular disease of cholesterol-fed rabbits.
Niebauer et al demonstrated that provision of L-arginine (the substrate for NOS) in
drinking water could reduce the formation of inflammatory lesions following balloon
angioplasty (Niebauer et al., 1999), while Wang et al showed that it decreased
existing atherosclerotic lesions, by inducing macrophage apoptosis (Wang et al.,
1999).
Thus, there is a significant body of evidence to suggest that supplementation
of NO may be beneficial in certain inflammatory diseases and that the induction of
apoptosis in infiltrating cells may have a role in mediating this protection. However,
these issues remain controversial, with much conflicting evidence. It is clear that
provision ofNO may not be suitable for the treatment of all inflammatory conditions,
and indeed may only be appropriate at certain stages of disease progression or
disease provoked by a particular mechanism. Much further work is required to
clarify these issues.
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1.6 Summary
NO has a biphasic effect on apoptosis in many cell types, in which low
concentrations delay but higher concentrations enhance this form of cell death, a
pattern that has recently been confirmed in neutrophils. This correlates with the
dichotomous action of NO on the activity of caspase enzymes responsible for the
execution of apoptosis in vitro. Inhibition of caspases by S-nitrosation is a direct
consequence of exposure to low concentrations of NO or, more likely, its oxidation
products (e.g. N2O3). On the other hand, activation of these enzymes observed
during pro-apoptotic actions of higher concentrations represents a downstream event
following initial effects on DNA or mitochondria, and can therefore be considered an
indirect effect of NO. Although the mechanism of inhibition has not yet been
investigated, it is likely that cGMP production, NF-kB activation and subsequent
expression of survival proteins, or S-nitrosation of apoptotic proteins will play a role.
It has been demonstrated that exogenous NO can induce apoptosis in
monocytes, monocyte-derived macrophages, neutrophils and eosinophils. In
addition, endogenous NO from iNOS also promotes apoptosis in macrophages.
There still remains some controversy over the mechanism by which this molecule
causes this form of cell death in these cells, although it involves activation of caspase
proteases, and most agree that this occurs through a cGMP-independent pathway.
Moreover, mitochondria appear to play a key role in the initiation of apoptosis by
NO through release of cytochrome c, resulting in caspase activation.
It is clear that ONOO" derived from SIN-1 or other agents has the ability to
promote apoptosis in its own right, but its role in mediating NO-induced apoptosis
remains controversial. Some groups have reported that NO-evoked cytotoxicity is
likely to be effected through ONOO" formation, while studies by others have
indicated little or no role for ONOO". Modulation of the activation status of the
transcription factor NF-kB has also been proposed to account for NO-induced
apoptosis in neutrophils and macrophages, and there is an increasing body of
evidence to support this theory. On the other hand, DNA damage (by N2O3 or
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ONOO") has also been shown, leading to an accumulation of pro-apoptotic p53.
Differences may exist in the mechanisms by which NO causes apoptosis in
different cell types that could potentially be exploited to target a particular
inflammatory cell type in certain conditions. Despite the uncertainties and
controversies surrounding the regulation of inflammatory cell apoptosis by NO, it is
clear that the class and concentration of NO-donating compound used and the cell
type are critical determinants of the response. Major differences between different
classes of NO donors and opposing effects with low and high concentrations of
certain NO donors are observed. Thus, the amount and rate of NO release and the
redox status of the target cell appear to be key factors in the cellular response to NO
exposure, and certain NO donors appear to be more effective than others at
promoting inflammatory cell apoptosis.
It is also important to realise that the concentration of NO donor used may
not necessarily reflect the concentration of NO to which the cells are exposed.
Equivalent concentrations of different NO donors may liberate NO to different
extents or at different rates, or may produce different reactive nitrogen species, such
as ONOO". Culture conditions may also affect NO levels; for example plasma
proteins such as albumin are able to scavenge NO through the formation of S-
nitrosothiols (Stamler et al., 1992;Butler and Rhodes, 1997;Ramachandran et al.,
2001). Therefore, the concentration of free NO in the vicinity of the cells at any
given time may vary from compound to compound, and the NO concentration in the
system needs to be measured in order to directly compare different NO donors.
Further studies are required to fully elucidate the initiation of apoptosis by NO, in
order to identify potential targets for the treatment of human inflammatory conditions
and to evaluate the sources ofNO that provide greatest therapeutic potential.
Chapter 1: Introduction 43
Regulation ofNeutrophil Apoptosis by NO and ONOO"
1.7 Aims of Thesis
The aims of this thesis were to characterise the effects of several distinct
compounds that release 'pure' NO or a combination of NO and O2" on neutrophil
apoptosis in vitro. The intention was to study a number of independent events of
apoptosis to determine the temporal relationship between them and to evaluate
whether different compounds affected them differently. The aim was to ascertain
whether NO or ONOO" is more effective at regulating neutrophil apoptosis, and
whether a rapid burst of high concentrations of NO has different effects than
prolonged release of lower concentrations. In addition, the mechanisms of action of
these compounds were to be studied and compared.
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Chapter 2: Materials and Methods
2.1 Isolation of Human Neutrophils
Human neutrophils were isolated from the blood of healthy volunteers as
previously described (Haslett et al., 1985;Ward et al., 2000). Venous blood (36 ml)
was removed into 50 ml polypropylene tubes containing 4 ml of sterile 3.8% sodium
citrate solution to prevent coagulation, and mixed by gentle inversion. This was
followed by centrifugation at 350g for 20 min at room temperature with the
deceleration rate set to zero, which separated the blood into two fractions; a
leukocyte- and erythrocyte-rich lower layer and a platelet-rich plasma upper layer.
The platelet-rich plasma was aspirated from the tubes without disturbing the lower
fraction, and aliquots of 10 ml transferred to sterile glass tubes in order to prepare
autologous serum by addition of 220 pi 1M CaCl2 (final concentration 20 pM)
followed by incubation at 37°C to initiate platelet aggregation.
Erythrocytes were sedimented from the remaining cellular fraction by
addition of 2.5 ml of 6% T500 dextran solution (pre-warmed to 37°C) per 10 ml
haematocrit, followed by adjustment of the volume to 50 ml using pre-warmed 0.9%
saline solution. Cells were allowed to sediment for no longer than 30 min at room
temperature. The leukocyte-rich upper layer was then carefully removed into 50 ml
polypropylene tubes, the volume was made up to 50 ml with saline, and tubes were
centrifuged at 350g for 6 min at room temperature. Following this, the supernatant
was decanted and the cell pellet resuspended in 2.5 ml of 55% isotonic Percoll
(prepared as a 9:1 (v:v) ratio of Percoll: 1 Ox PBS without Ca2+/Mg2+) in lx PBS
2_j_ o-pwithout Ca /Mg . Discontinuous gradients were prepared by overlaying 2.5 ml of
68% isotonic Percoll onto 2.5 ml of 81% isotonic Percoll in a 15 ml Falcon tube,
then layering the resuspended cells in 55% Percoll as the upper layer of the gradient.
Gradients were then centrifuged at 720g for 20 min at room temperature with the
deceleration rate set to zero in order to separate the subpopulations of leukocytes.
Granulocytic leukocytes were harvested from the 81:68% interface of the gradient
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Figure 2.1 Schematic representation of the isolation of granulocytes and preparation of
autologous serum from the peripheral blood of healthy volunteers.
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and washed twice in lx PBS without Ca /Mg (centrifuged at 220g, 6 min, room
temperature). Granulocyte bands that were heavily contaminated with erythrocytes
were discarded, as haemoglobin is able to scavenge NO and may affect the results of
experiments using NO donors.
2.2 Assessment of Neutrophil Yield, Purity and Viability
Neutrophil yield was assessed using a haemocytometer. A single drop of
9+ 9+
granulocytes suspended in 50 ml PBS without Ca /Mg was added to the
haemocytometer and the number of neutrophils in 25 squares was counted by light
microscopy, and cell activation, in the form of shape change, was assessed at the
same time, with activated neutrophil preparations being discarded. This number
represented the neutrophil count in 0.1 pi PBS, and was therefore multiplied by
10,000 to obtain the number of neutrophils present in 1 ml. In order to obtain the
total neutrophil yield from the preparation, this number was then multiplied by the
number of ml PBS in which the cells were suspended (usually 50 ml). The typical
neutrophil yield was 250 x 106 neutrophils from 160 ml whole blood, although it
varied considerably between donors.
The neutrophil isolation procedure is unable to separate neutrophils from
basophils and eosinophils, therefore the percentage contamination by other types of
granulocyte was assessed by cytocentrifugation. A volume of 100 pi of isolated
9+ 9+
granulocytes was removed, diluted using PBS without Ca /Mg if required and
cytocentrifuged (300 rpm, 3 min). The resulting slide was fixed in methanol (100%,
1 min) and stained using Diff-Quik physiological stain (1 min each in pink and blue
dyes), then observed by oil immersion light microscopy. The percentage of
contaminating basophils and eosinophils was measured by counting 500 cells at
random. Basophils were rarely seen, and eosinophils usually represented only a
small percentage of the total cell count. Preparations containing > 5% basophils or
eosinophils were discarded. Figure 2.2 shows the different morphologies and
staining of neutrophils and eosinophils from cytospun freshly-isolated leukocytes.
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Figure 2.2 Fresh neutrophils and contaminating eosinophil from the peripheral blood of a
healthy volunteer.
Mononuclear cell contamination was assessed by flow cytometry. A small
aliquot of isolated granulocytes in PBS without Ca2+/Mg2+ was removed and further
• • 9_i_ 9+
diluted with PBS without Ca /Mg . The suspension was then run by flow
cytometry and a dot plot generated on the basis of side scatter (x-axis, representing
cell granularity) and forward scatter (y-axis, representing cell size). Using these
parameters, cells can be distinguished on the dot plot, and the percentage of cells that
falls into each subset of leukocyte can be measured; neutrophils are more granular
than either monocytes or lymphocytes and therefore form a distinct population when
assessed by flow cytometry (Figure 2.3). A representative flow cytometry profile
showing distinct leukocyte populations and neutrophil cell purity is shown in Figure
2.1. Typically, ~98% of the isolated cells were neutrophils, and contamination levels
of> 5% by mononuclear cells led to the granulocyte preparation being discarded.








Figure 2.3 Typical flow cytometry profile showing purity of isolated human neutrophils.
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Neutrophil viability was assessed by Trypan Blue exclusion. Viable cells
have the ability to exclude the vital dye, Trypan Blue. Isolated granulocytes (10 pi)
were placed on a haemocytometer and 40 pi Trypan Blue added. Microscopic
examination then allowed the determination of the percentage of cells that excluded
the dye. Only granulocyte preparations that exhibited > 99% viability were used.
2.3 Cell Culture
2.3.1 Neutrophil Culture
Harvested neutrophils were routinely resuspended at 5 x 106 cells/ml in
Iscove's Modified Dulbecco's Medium (IMDM) supplemented with penicillin (100
U/ml) and streptomycin (100 U/ml), plus 10% (v:v) autologous serum. Cells were
cultured in flat-bottomed 96-well Falcon Flexiwell plates at 37 °C in a humidified
5% CO2 atmosphere. Extensive studies, such as recovery experiments and shape
change asays, carried out previously in the laboratory have demonstrated a lack of
neutrophil adherence to these polypropylene plates and lack of cell activation.
Neutrophils (135 pi; final cell density 4.5 x 106 cells/ml, i.e. approximately
675,000 cells/well) were added to 15 pi of PBS (controls) or the NO/ONOO" donors,
GEA 3162 (0.1 pM - 100 pM), SPER/NO (0.1 pM - 1 mM), DEA/NO (0.1 pM - 1
mM) or SIN-1 (1 mM - 3 mM), and cultured for between 1 and 20 h. In certain
experiments, neutrophils were preincubated for 10 min with pharmacological agents
such as the reducing agent, dithiothreitol (DTT 123; 100 - 300 pM),
dihydrorhodamine 123 (DHR 123; 1 pM) or the protein kinase C inhibitor, Ro 31-
8220 (1 pM). In other experiments, where neutrophils were to be incubated with two
or more reagents (e.g. NO/ONOO" donors and superoxide dismutase; SOD), cells
were resuspended at 10 x 106 cells/ml and 75 pi of cells were plated out with 15 pi of
each reagent and volumes made up to 150 pi with PBS.
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2.3.2 3G8 Hybridoma
The hybridoma, 3G8, raised against the leukocytic cell surface Fey receptor
III (CD16) was grown and maintained in CL350 concentrator flasks. The cell line
was initially grown up in 75 ml cell culture flasks before being seeded into CL350
flasks (8 x 106 cells per flask). The nutrient compartment membrane was dampened
with 10 ml 'nutrient medium'; Dulbecco's Modified Eagle's Medium (DMEM)
supplemented with L-glutamine, penicillin (100 U/ml), streptamycin (100 U/ml) and
1% foetal calf serum (FCS). After splitting, cells were resuspended in 5 ml of
'complete medium' (as nutrient medium except containing 10% FCS) and seeded
into the cell compartment. A further 340 ml of nutrient medium was then added to
the nutrient compartment, then cells were cultured for 7 days. To harvest cell
supernatant containing the anti-CD 16 antibody, liquid was aspirated from the
nutrient compartment of the flask then the cell compartment liquid was removed
using a pipette and transferred to a 15 ml Falcon tube. Cells were centrifuged (220g,
6 min) and supernatant transferred to a separate tube. The cell pellet was
resuspended in 10 ml of complete medium and a 5 ml volume was seeded back into
the flask as before. Cell supernatant was harvested every 3 days. In order to assess
the binding activity of antibodies, supernatant was added to 100,000 freshly-isolated
neutrophils in the CD 16 assay described below. Supernatant aliquots that produced
high fluorescence were pooled and used in subsequent experiments at a 1:10 dilution
in PBS without Ca2+/Mg2+.
2.4 Assessment of Apoptosis
Apoptosis was measured according to a number of different criteria thought
to represent apoptotic cell death in neutrophils: morphological changes, shedding of
cell surface CD 16, annexin V binding and DNA fragmentation.
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2.4.1 Morphological changes
Viable neutrophils have a characteristic nuclear morphology, with distinctive
multilobed nuclei. During apoptosis, cells become shrunken and the chromatin
condenses and rounds up and stains more darkly than in viable cells; these alterations
are clearly visible by oil immersion microscopy, as shown in Figure 2.4 (Ward et al.,
2000).
Figure 2.4 Photograph (x100 objective) demonstrating altered morphology of apoptotic vs.
viable neutrophils. Viable neutrophils have multilobed nuclei whereas apoptotic cells have
characteristic darkly stained rounded and condensed nuclei following staining with DiffQuik™
solution. Typical neutrophil diameter is 8-12 pm.
Following incubation, 100 pi of recovered cells were cyto-centrifuged in
duplicate, fixed in 100% methanol and stained using Diff-Quik™ physiological stain,
then observed by oil-immersion light microscopy (xlOO objective) to determine the
proportion of darkly-stained cells with condensed nuclei. At least 500 cells per slide
were counted, with the observer blinded to the experimental conditions by
numbering the slides rather than labelling the conditions and counting them in a
random order.
In order to verify that the effects of the diazeniumdiolate compounds on
neutrophil apoptosis were caused by NO generation rather than being an effect of the
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parent amines that remain after decomposition of the diazeniumdiolates, a control
experiment was carried out to examine the effects of spermine tetrahydrochloride and
diethylamine hydrochloride on morphological apoptosis compared to control
(spontaneous) apoptosis over 20 hours. Concentrations of 0.1 pM and 1 mM of these
compounds were tested, as these concentrations correlated with the lowest and
highest concentrations of the diazeniumdiolates that were to be used in the
concentration-response studies. Figure 2.5 shows the lack of effect of spermine or
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Figure 2.5 Control experiment to determine the effects of spermine and diethylamine on
neutrophil apoptosis. Neutrophils (4.5 x 106/ml) were incubated for 20 hours in the presence
of PBS (control), spermine tetrahydrochloride (0.1 pM or 1 mM) or diethylamine hydrochloride
(0.1 pM or 1 mM), then apoptosis was assessed by morphology.
2.4.2 Shedding of cell surface CD 16
CD16 is the Fc-y receptor III glycoprotein antigen present on the surface of
granulocytes. During the apoptotic process in neutrophils, CD 16 is shed from the
cell surface (Dransfield et al., 1994;Homburg et al, 1995). This change can be
exploited using flow cytometry to determine the percentage of cells undergoing
apoptosis within a given population (Dransfield et al., 1994). Antibody binding in
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Figure 2.6 Flow diagram of assessment of apoptosis by CD16 shedding
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general is not altered as neutrophils undergo apoptosis, as demonstrated by the use of
an isotype control antibody during the development of the CD 16 shedding assay
(Dransfield et al., 1994).
Neutrophils (60pl of recovered cells) were transferred to a U-bottomed 96-
well Flexiwell plate and centrifuged (200g, 2 min). Following resuspension of the
cells by gentle vortexing, 50 pi of a 1:10 dilution of the 3G8 hybridoma supernatant
containing monoclonal Ab against CD16 was added. Following incubation (4°C, 30
min), the cells were washed 3x in PBS without Ca2+/Mg2+, before addition of 50 pi
of a FITC-conjugated goat anti-mouse secondary antibody (1:40 dilution). Cells
were incubated (4°C, 30 min) before being washed 3x as before, resuspended and
analysed by flow cytometry using an EPICS XL2 (FL1), with CD16 'low' expressing
cells representing the apoptotic population (see Chapter 4 for t ypical p rofiles). A
schematic representation of the protocol is shown in Figure 2.6.
2.4.3 Annexin V binding
Annexin V is a phospholipid-binding protein with a high affinity for
phosphatidylserine (PS). In viable cells, PS has an asymmetric distribution, being
retained on the inner cell surface. During apoptosis, this asymmetry is lost, and PS
becomes exposed on the outer surface of the cell, thus allowing annexin V binding,
which can be measured using flow cytometry (Homburg et al., 1995).
Fluorescein isothiocyanate (FITC)-conjugated annexin V (5 pi), was added to
15 ml of annexin V binding buffer (Hanks Balanced Salt Solution plus 2.5 ml of 1 M
CaC^; final concentration 5 pM). Following incubation, 20 pi of recovered
neutrophils were transferred to a FACS tube and 180 pi of the annexin V binding
solution was added. Cells were incubated on ice for 10 min before flow cytometric
analysis using an EPICS XL2 (FL1), with annexin V positive cells representing the
apoptotic population. A schematic representation of the protocol is shown in Figure
2.7.
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Figure 2.7 Flow diagram of assessment of apoptosis by Annexin V binding
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Figure 2.8 Control annexin V binding experiment. Neutrophils (4.5 x 106 cells/ml) were
incubated for 20 h with PBS (control), gliotoxin (0.1 pg/ml) or db-cAMP (0.2 mM). Apoptosis
levels were then assessed by annexin V binding. Horizontal lines represent the apoptotic
population of neutrophils, and numbers in brackets show the levels of apoptosis detected by
this method.
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In order to verify that the annexin V assay is able to detect changes in the rate of
neutrophil apoptosis, control experiments were carried out using the known inhibitor
of neutrophil apoptosis, db-cAMP, and known inducer of apoptosis, gliotoxin.
Neutrophils (4.5 x 106 cells/ml) were incubated for 20 hours with PBS (control),
gliotoxin (0.1 pg/ml) or db-cAMP (0.2 mM), then apoptosis was assessed by
Annexin V binding. Figure 2.8 shows that the annexin V assay was able to detect
acceleration of neutrophil apoptosis by gliotoxin and delayed apoptosis mediated by
db-cAMP.
2.4.4 Internucleosomal DNA fragmentation
Internucleosomal DNA fragmentation is considered to be a characteristic
feature of apoptotic cell death. During apoptosis, DNA is cleaved by CAD/DFF40
into specific-sized fragments. This process can be assessed by measuring the DNA
content o f c ells o r b y running DNA gels t o 1 ook for t he c haracteristic 'laddering'
pattern ofDNA from apoptotic cells (Wyllie, 1997).
2.4.4.1 Propidium Iodide Staining
The fluorescent molecule, propidium iodide (PI), intercalates into DNA and
can be used to measure the amount of DNA in a given cell. This can be used to
assess internucleosomal DNA fragmentation in apoptotic cells.
Neutrophils (lOOpl of recovered cells) were transferred to a U-bottomed 96-
well Flexiwell plate and centrifuged (200g, 2 min). Following resuspension of the
cells by gentle vortexing, 100 pi of 70% ethanol was added to fix and permeabilise
the cells. Cells were then incubated on ice for 10 min before being washed 3x with
PBS without Ca2+/Mg2+. 50 pi ofRNase A (0.5 mg/ml) then 50 pi of PI (0.1 mg/ml)
were then added to the cells, which were wrapped in foil at room temperature for 25
min before analysis by flow cytometry using an EPICS XL2 (FL3) to determine the
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Figure 2.9 Flow diagram of assessment of apoptosis by PI intercalation
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percentage of cells with hypodiploid DNA content. The permeabilisation of cells in
all conditions was shown to be effective by Trypan Blue staining and also by the lack
of a flow cytometry peak at the far left side of the histogram on analysis (coinciding
with unlabelled cells), which would have represented gated cells exhibiting no PI
staining at all (see Chapter 4 for representative flow cytometry histograms). A
schematic representation of the protocol is shown in Figure 2.8.
2.4.4.2 DNA Gel Electrophoresis
Internucleosomal DNA fragmentation during apoptosis generates pieces of
DNA that produce a distinctive 'laddered' appearance when separated by gel
electrophoresis (Wyllie, 1997).
Neutrophils (5 x 106 cells per sample) were incubated for 8 or 20 h in the
presence of PBS, NO/ONOO" donors, the known inducer of neutrophil apoptosis,
gliotoxin, and the known neutrophil apoptosis inhibitor, db-cAMP. Cells were then
harvested and centrifuged (14,000 rpm, 10s) and pellets resuspended in 50 pi of PBS
without Ca2+/Mg2+. 500 pi of 7M guanidine hydrochloride was added to each
sample to lyse the cells, then DNA was extracted using a Wizard Miniprep kit
according to the manufacturer's instructions.
Miniprep Columns were dampened by addition of 50 pi of Column Wash
Solution (90 mM NaCl, 9 mM Tris-Cl pH 7.4, 2.25 mM EDTA, 55% ethanol) then
lysed cells were added to the columns. Columns were centrifuged at 14,000rpm for
1 min at room temperature, then the flowthrough was poured off and 750 pi of Wash
Solution was added before centrifugation as before. After discarding flowthrough,
250 pi of Wash Solution was added before centrifugation at 14,000 rpm for 2 min.
Spin Columns were then transferred to a fresh, sterile 2 ml Eppendorf tube and 50 pi
of TE + RNase A added (10 mM Tris-Cl pH 8.0, 1 mM EDTA, 50 pg/ml RNase).
The Eppendorf tubes were then centrifuged at 14,000 rpm for 1 min at room
temperature to elute the DNA. DNA samples (23 pi DNA plus 7 pi loading buffer)
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were then run on a 2% Sea Kem agarose gel containing 1 pi of ethidium bromide
stock solution (500 pg/ml), in TBE (10 mM Trisma base, 10 mM boric acid, 1 mM
EDTA) for 1 h at 100V and DNA was viewed under uv light.
2.5 Electrochemical Detection of NO Generation
An NO electrode (Iso-NO II, World Precision Instruments) was calibrated
daily in pH 4 buffer at 37 °C using concentrations of 1 x 10~7 M - 3.2 x 10"6 M
DEA/NO. This yielded free NO in the range 2 x 10"7 M - 6.4 x 10"6 M, as there are
two molecules of NO per molecule of DEA/NO. NO release was measured in
milliVolts (mV) by the electrode; plotting logio mV vs logio [NO] gave a straight line
of equation, y = mi + c, from which subsequent NO release could be calculated (see
Figure 3.2).
GEA 3162 (100 pM), SIN-1 (100 pM), DEA/NO (1 pM) or SPER/NO (1
pM) were then added to stirred, pre-warmed PBS (2 ml) in order to detect free NO
liberated from these compounds. NO generation was measured for 20 min, then the
electrode was rinsed in distilled H2O before insertion into fresh PBS and addition of
the next NO donor.
In order to investigate the masking effect of O2" on detection of NO from
these compounds, these experiments were repeated in the presence of 50 U/ml Cu/Zn
superoxide dismutase (SOD). Again, NO liberation was measured for 20 min before
rinsing of the electrode and insertion into fresh prewarmed PBS containing 50 U/ml
SOD (Lizasoain et al., 1996).
2.6 Dihydrorhodamine 123 Studies
Dihydrorhodamine 123 (DHR 123) is a dye which is oxidised to its
fluorescent form, rhodamine 123 by various reactive oxygen species, including
ONOO, O2, H2O2 and HOC1, but not by NO (Crow, 1997). This compound can
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therefore be used to discriminate between agents that release NO only and those that
generate NO and O2" simultaneously.
2.6.1 Direct Measurement of ROS generation from NO/ONOO' Donors
A volume of 100 pi of PBS, the neutrophil activating agent, phorbol 12-
myristate 13-acetate (PMA; final concentration 10 nM), SIN-1 (1 mM), GEA 3162
(100 pM) or DEA/NO (1 mM) was added to 900 pi PBS in 2 ml Eppendorf tubes.
DE1R 123 was added to each tube to a final concentration of 1 pM. Tubes were
incubated for 60 min (37°C, 5% CO2), then 450 pi was transferred to a 0.5 ml
cuvette, excited at 480 nm and the fluorescence emitted at 500 nm was read using a
spectrofluorimeter (Perkin Elmer, UK).
2.6.2 Measurement of ROS in Neutrophils
Further DHR 123 studies were carried out in the presence of neutrophils in
order to determine whether ONOO" may be generated by the interaction of drug-
derived NO with O2" from neutrophils, or whether ONOO" is derived from the drug
itself. This was determined by using the protein kinase C inhibitor, Ro-31-8220
(Dieter and Fitzke, 1991). Neutrophil generation of reactive oxygen species such as
O2" proceeds through activation of protein kinase C (Wilson et al., 1986). Therefore,
if DHR 123 is activated by ONOO" produced from combination of NO with
neutrophil-derived O2", oxidation of DHR 123 should be inhibited in the presence of
Ro-31-8220. On the other hand, fluorescence should be unchanged in the presence
of Ro-31-8220 if the compound itself generates ONOO".
Isolated cells were resuspended in IMDM at a density of 5 x 106 cells/ml and
DHR 123 was added to a final concentration of 1 pM. Neutrophils (135 pi) were
added to a 15 pi volume of PBS, PMA (final concentration 10 nM), SIN-1 (1 mM),
GEA 3162 (100 pM) or DEA/NO (1 mM) in a flat-bottomed 96-well plate in the
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absence or presence of the protein kinase C inhibitor, Ro-31-8220 (1 pM).
Following incubation (37°C, 5% CO2) for 45 min or 2 h, samples were removed and
assessed by flow cytometry (FL2) using an EPICS XL2 (Coulter Electronics, Luton,
UK).
2.7 Western Blotting
Western blotting was carried out to investigate the breakdown of
ICAD/DFF45 in neutrophils undergoing apoptosis. This breakdown allows
CAD/DFF40 to translocate to the nucleus and cause internucleosomal DNA
fragmentation.
2.7.1 Preparation of Whole Cell Neutrophil Lysates
Isolated neutrophils (5 x 106 cells/sample) were incubated in 24-well plates
for 8 h in the presence of PBS, NO/ONOO" donors or the known inducer of
apoptosis, gliotoxin (0.1 pg/ml; (Ward et al., 2000). Whole cell neutrophil lysates
were then made from these cells and also from freshly isolated neutrophils as a
negative control for ICAD/DFF45 breakdown.
A number of protease inhibitors (7 mM AEBSF, 3 pM aprotinin, 0.42 mM
leupeptin, 30 pM pepstatin A, 20 mM sodium orthovanadate, 10 mM benzamidine,
40 mM levamisole and 6 mM P-glycerophosphate) were added to 0.5 ml of whole
cell lysis buffer (Sigma Protease Cocktail, 1:50 dilution in TBS) and the volume
made up to 1 ml with TBS. These extremely high concentrations of protease
inhibitors are required in the preparation of neutrophil lysates because neutrophils
contain large amounts of protease enzymes that may cleave proteins on extraction if
incompletely inhibited. Rigorous titration of protease inhibitor concentrations
required for the preparation of neutrophil whole cell lysates has previously been
carried out in the laboratory to minimise the risk of protein cleavage during the
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extraction process. This was done by applying neutrophil lysates prepared in the
presence of varying concentrations of protease inhibitors to Jurkat T cell lysates and
blotting to determine the breakdown of I-kB. The concentrations of inhibitors that
caused no I-kB breakdown in Jurkat lysates were considered adequate to completely
inhibit neutrophil proteases and were used for subsequent lysate preparation.
Non-adherent apoptotic neutrophils were aspirated from the plate and
transferred to 2 ml Eppendorf tubes. A volume of 50 pi of the protease inhibitor
cocktail described above was added to each well and the well was gently scraped to
harvest any adherent cells. This procedure was carried out on ice to minimise the
activity of any protease liberated, alongside the presence of protease inhibitors. Cells
were centrifuged (14,000 rpm, 10s) and supernatant removed, then cells were washed
in PBS. Cells were resuspended in 100 pi of the protease inhibitor cocktail before
addition of 10 pi of NP-40 to each sample and incubation for 10 min on ice.
Eppendorf tubes were centrifuged (15,000 rpm, 20 min, 4°C) then supernatant
removed and added to 50 pi of sample buffer (30% glycerol; 10% (3-
mercaptoethanol; 8% SDS; 0.25 M Tris HC1 pH 6.8%, 0.02% bromophenol blue)
prewarmed to 95°C. Lysates were then boiled at 95°C for 5 min before being stored
at -20°C as 45 pi aliquots.
2.7.2 Western Blotting
Protein separation in previously prepared neutrophil lysates was carried out
by SDS-PAGE. Lysates (40 pi) were loaded onto a 9% acrylamide gel (0.375 M
Tris-ElCl pH 8.8) and electrophoresed at 100 V through the stacking gel (0.125 M
Tris-HCl pH 6.8, 9% acrylamide) and at 150 V through the separating gel for
approximately 1 h, using a running buffer of 25 mM Tris, 192 mM glycine pH 8.3
and 0.1% SDS. Proteins were then transferred onto nitrocellulose membranes at 80
V for 1 h using a transfer buffer of 20% methanol, 250 mM Tris and 1.92 M glycine
pH 8.3. Non-specific binding sites were blocked by incubation of nitrocellulose
membranes in 5% casein solution in TBS 0.1% Tween-20 on a shaker for 1 h at room
Chapter 2: Materials and Methods 63
Regulation ofNeutrophil Apoptosis by NO and ONOO
temperature. Membranes were then washed 3x 3 min using TBS 0.1% Tween-20
before addition of primary antibody (ICAD/DFF45 mouse monoclonal antibody,
1:500 dilution in TBS 0.1% Tween-20) and incubation overnight at 4°C on a shaker.
Following 3x 3 min washes with TBS 0.1% Tween-20, the secondary antibody (goat
anti-mouse IgG-HRP) was added at a dilution of 1:1250 in TBS 0.1% Tween-20 and
left for 1 h on a shaker at room temperature. Membranes were washed 3x3 min in
TBS 0.1% Tween-20 before addition of ECL Plus electrochemiluminescence
solution for 5 min, then exposed to film for 2 min before developing. Equal protein
loading to the gels was assessed by Ponceau staining and always showed equal
loading.
In order to determine appropriate antibody concentrations to use, whole cell
neutrophil lysates were blotted using 1:500 and 1:1000 dilutions of the primary
antibody against ICAD/DFF45 and with 1:1250 and 1:2500 dilutions of secondary
antibody (goat anti-mouse HRP). The film was exposed for 1 and 2 min to
determine the optimal exposure time. The optimal conditions for this antibody were
found to be a 1:500 primary antibody dilution with a 1:1250 dilution of the
secondary antibody, which detected the long (45 kDa) and short (40 kDa) splice
variants of ICAD/DFF45, with a 2 min exposure time, as shown in Figure 2.10.
Figure 2.10 Control Western blot for the ICAD/DFF45 antibody. Whole cell neutrophil lysates
were blotted using primary antibody at a 1:500 dilution and secondary antibody at 1:1250, and
the film was exposed for 2 minutes.
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2.8 Statistical Analysis
Results are plotted as mean ± S.E.M. Data were analysed for statistical
significance by one-way ANOVA with either Student-Newman-Keuls (to compare
each group with all others e.g. concentration in the concentration-response studies) or
Dunnett's (to compare every group to control, e.g. gliotoxin in the absence or
presence of DTT) post-hoc test. Where there were two variables, such as
concentration and time in the time-course studies, two-way ANOVA with Bonferroni
post-hoc test was used, and where two points were being compared, a two-tailed
paired t test was used. Values of p < 0.05 were considered to be statistically
significant.
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2.9 Materials
Alexis Biochemicals (Nottingham, UK): Diethylamine Diazeniumdiolate
(DEA/NO); GEA 3162; Spermine Diazeniumdiolate (SPER/NO)
Amersham Pharmacia Biotech, UK Ltd (Buckinghamshire, UK): Hybond C
nitrocellulose membrane
Baxter Healthcare (Glasgow, UK): Diff-Quik physiological stain
Becton Dickinson (Oxford, UK): Cell culture plastic
Bender MedSystems (Vienna, Austria): FITC-labelled recombinant human
Annexin V
BioVision: ICAD/DFF45 mouse monoclonal antibody
Flowgen (Ashby-de-la-Zouch): Sea Kem agarose
Gibco Life Technologies (Paisley, UK): Iscoves Modified Dulbecco's Medium
(IMDM); L-Glutamine; Penicillin (50 U/ml); Streptomycin (50 U/ml); Trypsin
EDTA
Pharmacia (Milton Keynes, UK): Dextran; Percoll
Promega (Southampton, UK): Wizard® Plus SV Minipreps DNA Purification
System
Sigma (Poole, UK): 3-morpholinosydnonimine hydrochloride (SIN-1);
Dithiothreitol (DTT); Dulbecco's Phosphate Buffered Saline (PBS) without
Ca2+/Mg2+, sterile, endotoxin free pH 7.4; DMEM; Ethidium Bromide; Kodak
Biomax Film; Propidium Iodide
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Chapter 3: Characterisation of NO and ONOO' generation
from NO donors
3.2 Introduction
A wide variety of NO donor compounds are available either for clinical use
or as experimental tools. Each class of NO donors has unique chemical properties
and differing mechanisms of NO generation, with some compounds liberating NO
spontaneously and others requiring complex enzymatic degradation or the presence
of intracellular thiols (Megson, 2000). Such differences may be exploited to
examine the mechanisms through which biological effects are mediated; for example,
compounds that spontaneously release free NO can be compared with S-
nitrosothiols, that might also cause biological effects through transnitrosation.
NO generation from sydnonimines can be mediated by both enzymatic and
nonenzymatic processes. For example, the prodrug molsidomine is metabolised in
the liver to form SIN-1 (Figure 3.ID). This is then converted by hydrolysis to the
active metabolite SIN-1A, from which NO is liberated without need for thiols or
other cofactors. The rate of release is strongly influenced by pH, oxygen and light,
and is non-linear due to the hydrolytic step required to generate SIN-1A (Feelisch et
al., 1989). In the presence of O2, however, O2" is formed concomitantly with NO,
which rapidly combine NO to form cytotoxic ONOO" (Feelisch et al., 1989). Thus,
these drugs are limited in their clinical potential, as oxidative damage is believed to
be involved in early disease processes, such as atherogenesis (Bult, 1996).
Diazeniumdiolates contain two molecules of NO attached to a nucleophilic
molecule through a nitrogen atom (Figure 3.1), which may be contained within a
primary or secondary amine, polyamine, oxide or sulphite (Maragos et al., 1991).
NO is released predictably and spontaneously by first-order kinetics in aqueous
solution, with no enzyme or thiol requirement, to activate sGC (Keefer et al., 1996).
Each dizeniumdiolate molecule is capable of liberating up to 2 molecules of NO.
The exact amount of NO generated, and the rate at which it is released depends on
the nature of the nucleophile molecule, the pH and temperature - the rate of release
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rises with increasing acidity and temperature (Maragos et al., 1991).
The half-lives of decomposition of the diazeniumdiolates range from 1 min to
1 day at physiological pH at 37°C (Keefer et al., 1996). For example, diethylamine
diazeniumdiolate (DEA/NO) has the NO linked to diethylamine (Figure 3.1A), and
can be used to provide a rapid, brief spike ofNO, as the half-life of this compound is
just 2 min. Decomposition of DEA/NO liberates 1.5 molecules ofNO per molecule
of drug, but may also produce the potent carcinogen N-nitrosodiethylamine as a by¬
product (Keefer et al., 1996). At the other end of the scale, the half-life of DETA
diazeniumdiolate (DETA/NO) has been measured as 20 h, and this compound
releases 2 molecules ofNO from each molecule of drug. Intermediate to these two is
spermine diazeniumdiolate (SPER/NO; Figure 3.IB), the half-life of which is
generally believed to be ~ 40 min, although published values range from 10 to 90
min (Keefer et al., 1996). It has been reported to release 1.9 molecules of NO per
mole of drug, although this may be an overestimate, as measurements were made at
pH 2, which ought to increase the amount ofNO generated (Maragos et al., 1991).
Mesoionic 3-aryl substituted oxatriazole-5-imine derivatives such as GEA
3162 and GEA 3175 are another class of NO donors. GEA 3162 (Figure 3.1C)
decomposes spontaneously in physiological solution, although reducing agents may
contribute to this process in vivo (Megson, 2000). Release of NO from GEA 3175
but not GEA 3162 is increased in the presence of human plasma, suggesting that
decomposition of this compound may be accelerated by enzymatic degradation,
perhaps degradation of the sulphonamide moiety, or by thiols, before it is able to
release NO (Kankaanranta et al., 1996). They may be preferred to existing drugs as
no tolerance has been observed and O2" is not thought to be generated alongside NO
(Megson, 2000), although it has been suggested that this group of compounds has the
ability to donate ONOO" (Kankaanranta et al., 1996).
Early investigations using various techniques, including NO-haemoglobin
formation, ozone chemiluminescence, nitro blue tetrazolium reduction and
nitrotyrosine formation suggested that the species generated from GEA 3162 is free
NO and that no O2" is liberated alongside NO, therefore this compound was regarded
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Figure 3.1 Structures of NO and ONOO" donors. Chemical structures of (A)
diethylamine diazeniumdiolate (DEA/NO) (B) spermine diazeniumdiolate
(SPER/NO) (C) 1,2,3,4-oxatriazolium, 5-amino-3-(3,4-dichorophenyl)-chloride
(GEA 3162) and (D) 3-morpholinosydnonimine (SIN-1)
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as a pure NO donor (Kankaanranta et al., 1996; Holm et al., 1998). In contrast,
recent work using an NO electrode has demonstrated concomitant release ofNO and
O2" from this compound, making GEA 3162 a ONOO" donor (Schmidt et al., 2001).
The aim of these investigations was to use an NO electrode and
spectrofluorimetric and flow cytometric techniques to characterise the rate and extent
of release ofNO or ONOO" from four compounds, DEA/NO, SPER/NO, SIN-1 and
GEA 3162 (Figure 3.1), for future biological studies in this thesis. In particular, it
was intended to resolve the controversy surrounding GEA 3162 with regard to the
NO-related species liberated from this compound.
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3.2 Results
3..1 Measurement of release of NO from NO and ONOO' donors
Different NO-donating compounds have different rates of liberation of NO,
which may influence the biological effects of these compounds. In order to
characterise the amount and rate of NO generated by NO donors which were to be
investigated in apoptosis studies, an NO-specific electrode was used. Following
calibration of the electrode using DEA/NO in pH 4 phosphate buffer (Figure 3.2),
NO donors were added to pre-warmed PBS buffer into which an electrode was
inserted, and left for 20 min or until the level of NO being generated returned to
baseline.
The diazeniumdiolate, DEA/NO, is known to be a fast-releasing NO donor
that liberates NO spontaneously at physiological temperature and pH. Figure 3.3
shows a typical NO electrode trace obtained with DEA/NO in PBS over 20 min.
Addition of this compound to a final concentration of 1 pM caused a rapid and
predictable increase in the level of NO within the solution, reaching a maximal
concentration of 1.42 ± 0.14 pM after approximately 3 min (Figure 3.4). As
expected, levels of NO quickly fell to baseline levels; NO release was undetectable
after approximately 15 min.
SPER/NO is another diazeniumdiolate compound, but the nature of the
nucleophile (spermine) to which the NO is attached means that NO is released more
slowly from this compound than from DEA/NO. A typical NO electrode trace for
SPER/NO in PBS over 20 min is shown in Figure 3.3. These studies showed that 1
pM of SPER/NO (which would release ~ 2 pM of NO in total) spontaneously
generated a maximum concentration of 0.64 ±0.15 pM free NO over a 20 min
period and that the release of NO was slower than that observed from DEA/NO
(Figure 3.4). NO generation from SPER/NO reached a maximum after
approximately 20 min, then slowly declined back to baseline until the signal was
abolished after approximately 200 min (Figure 3.5).
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Figure 3.2 Typical NO electrode trace and calibration curve. (A) Diethylamine
diazeniumdiolate (DEA/NO; 100 nM - 3.2 pM) was added cumulatively to pH4 buffer
into which an NO electrode was immersed, yielding NO in the range 200 nM - 6.4
pM. (B) Resulting NO generation was measured in mV and plotted as a calibration
curve.
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In contrast to the diazeniumdiolates, neither SIN-1 nor GEA 3162 (100 p,M)
generated any detectable levels ofNO in solution; representative traces are shown in
Figure 3.3. Concentrations ofNO detected from the four compounds in PBS over a
20 min period are shown in Figure 3.4.
However, in the presence of SOD (50 U/ml), free NO was detectable from
both SIN-1 and GEA 3162. Typical electrode traces obtained with 50 U/ml SOD
over 20 min are shown in Figure 3.6. NO release from GEA 3162 increased steadily
in the presence of SOD over the 20 min period of measurement, and reached a
maximum level of 2.71 ± 0.18 pM by 20 min (Figure 3.7). Release ofNO from SIN-
1 occurred to a lesser extent than that from GEA 3162 in the presence of SOD, with a
maximum concentration of 1.41 ± 0.09 pM NO achieved after 20 min (Figure 3.7).
Preincubation with SOD (50 U/ml) had little effect on the amount of NO
released from DEA/NO or SPER/NO (Figure 3.7). The profdes of NO release from
both DEA/NO and SPER/NO are similar in the absence (Figure 3.3) and presence
(Figure 3.6) of SOD. NO from DEA/NO reached a peak concentration of 1.1 ± 0.06
pM NO after just 3-4 min in the presence of SOD, while that from SPER/NO
reached 0.88 ± 0.03 pM NO after 20 min. Although the height of the peak obtained
with DEA/NO in the presence of SOD was very similar to that seen without SOD
(Figure 3.6), it appears that addition of SOD to the buffer may prolong the duration
ofNO release, as the level ofNO does not return fully to baseline (Figure 3.7).
In order to verify that the signals achieved from these compounds in the
absence or presence of SOD were authentic NO, the known scavenger of NO,
oxyhaemoglobin (Hb; 25 pM) was added to the cuvette. In all cases, the electrode
signal was quenched by the addition of Hb, demonstrating that the signal was caused
by NO release from these compounds (Figure 3.8).
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Figure 3.3 Spontaneous release of NO from DEA/NO and SPER/NO, but not GEA
3162 or SIN-1, in PBS. Typical electrode traces for spontaneous NO release from NO
and ONOO" donors are shown. Diethylamine diazeniumdiolate (DEA/NO; 1 pM),
spermine diazeniumdiolate (SPER/NO; 1 pM), 1,2,3,4-oxatriazolium, 5-amino-3-(3,4-
dichorophenyl)-chloride (GEA 3162; 100 pM) or 3-morpholinosydnonimine (SIN-1; 100
pM) were added to PBS buffer into which an NO electrode was immersed, and NO
generation was measured for 20 minutes. Arrows represent addition of NO/ONOO"
donor.
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Figure 3.4 Amount and rate of NO released from NO and ONOO- donors in PBS over
a 20-min period. Diethylamine diazeniumdiolate (DEA/NO; 1 pM), spermine
diazeniumdiolate (SPER/NO; 1 pM), 1,2,3,4-oxatriazolium, 5-amino-3-(3,4-
dichorophenyl)-chloride (GEA3162; 100 pM) or 3-morpholinosydnonimine (SIN-1; 100
pM) were added to PBS buffer into which an NO electrode was immersed, and the
concentration of NO generated was measured for 20 minutes. Results represent
mean ± SEM from n = 3 experiments
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Figure 3.5 Decomposition of SPER/NO in PBS. NO electrode trace showing NO release from
SPER/NO (1 pM) over a 215 min period. Spermine diazeniumdiolate (SPER/NO; 1 pM), was
added to PBS buffer into which an NO electrode was immersed, and NO generation was
measured until NO levels returned to baseline. Arrows represent addition of SPER/NO
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Figure 3.6 Unmasking of free NO from ONOO" donors by SOD. Typical electrode
traces are shown for NO release from NO and ONOO" donors, in the presence of SOD
(50 U/ml). Diethylamine diazeniumdiolate (DEA/NO; 1 pM), spermine diazeniumdiolate
(SPER/NO; 1 pM), 1,2,3,4-0xatriazolium, 5-amino-3-(3,4-dichorophenyl)-chloride (GEA
3162; 100 pM) or 3-morpholinosydnonimine (SIN-1; 100 pM) were added to PBS buffer
preincubated with SOD (50 U/ml) for 10 min, and NO generation was measured for 20
min. Arrows represent addition of NO/ONOO" donor.
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Figure 3.7 Extent and rate of free NO release from NO and ONOO" donors in the
absence and presence of SOD. Diethylamine diazeniumdiolate (DEA/NO; 1 pM),
spermine diazeniumdiolate (SPER/NO; 1 pM), 1,2,3,4-oxatriazolium, 5-amino-3-
(3,4-dichorophenyl)-chloride (GEA 3162; 100 pM) or 3-morpholinosydnonimine
(SIN-1; 100 pM) were added to PBS buffer or PBS buffer preincubated with SOD
(50 U/ml) for 10 min, and NO generation was measured for 20 min. Results
represent mean ± SEM from n = 3 experiments
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Figure 3.8 Quenching of NO signal by oxyhaemoglobin. Diethylamine diazeniumdiolate
(DEA/NO; 1 pM) or spermine diazeniumdiolate (SPER/NO; 1 pM) were added to PBS
buffer, and 1,2,3,4-oxatriazolium, 5-amino-3-(3,4-dichorophenyl)-chloride (GEA 3162;
100 pM) or 3-morpholinosydnonimine (SIN-1; 100 pM) were added to PBS buffer
preincubated with 50 U/ml SOD. NO generation was measured, then oxyhaemoglobin
(Hb, 25 pM) was added to the cuvette to demonstrate that the signal generated was NO
(indicated by arrows).
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3.2 Spectrofluorimetric detection of reactive nitrogen species liberated by
NO/ON00" donors
Dihydrorhodamine 123 (DHR 123) is a dye that can be oxidised to
fluorescent rhodamine 123 by a number of reactive oxygen and nitrogen species,
including O2", ONOO", hydrogen peroxide (H2O2) and hypochlorous acid (H0C1).
However, free NO is unable to cause such oxidation. DHR 123 was therefore used
as a tool to discriminate between compounds that liberate pure NO and those that
generate ONOO". NO/ONOO" donors were incubated with DHR 123 for 1 h at 37°C
then fluorescence was measured using a spectrofluorimeter.
These studies showed that fluorescence was low (22.8 ± 4.7 units) in control
samples, which comprised DHR 123 in PBS (Figure 3.9). In contrast, in the
presence of either 1 mM SIN-1 or 100 pM GEA 3162, fluorescence was high (803.2
± 73.8 units and 756.7 ± 100.0 units respectively; p < 0.05, one-way ANOVA with
Dunnett's post-hoc test), indicating a high level of conversion of DHR 123 to
rhodamine 123 by oxidative species distinct from NO.
However, in the presence of the pure NO donor, DEA/NO (1 mM),
fluorescence was slightly increased from control (52.5 ± 8.6 units), but this did not
reach statistical significance (p > 0.05, one-way ANOVA with Dunnett's post-hoc
test). None of the NO donors exhibited any autofluorescence in the absence of DHR
123 (all < 1 unit of fluorescence), thereby excluding autofluorescence as a possibility
for the differences seen with these compounds.
3.2.3 Flow cytometric detection of reactive nitrogen species liberated by
NO/ONOO' donors
The DHR 123 experiments were repeated in the presence of neutrophils (5 x
106 cells/ml) in order to determine whether a pure NO donor such as DEA/NO can
form ONOO" through combination of drug-derived NO with neutrophil-derived O2",
through which its biological effects may be mediated.
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Figure 3.9 Spectrofluorimetric detection of the generation of oxidative species from
NO or ONOO" donors. Diethylamine diazeniumdiolate (DEA/NO; 1 mM), 1,2,3,4-
oxatriazolium, 5-amino-3-(3,4-dichorophenyl)-chloride (GEA 3162; 100 pM) or 3-
morpholinosydnonimine (SIN-1; 1 mM) were incubated with DHR 123 for 1 hour
before analysis of fluorescence levels using a spectrofluorimeter. Results represent
mean ± SEM from n = 3 experiments and asterisks represent significant (p < 0.05,
one-way ANOVA with Dunnett's post-hoc test) difference from control (PBS).
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Figure 3.10 Oxidation of DHR 123 to rhodamine 123 by NO and ONOO" donors in the
presence of neutrophils, and contribution of cell-derived oxidants. PBS, the neutrophil
activating agent PMA (10 nM), 3-morpholinosydnonimine (SIN-1; 100 pM), 1,2,3,4-
oxatriazolium, 5-amino-3-(3,4-dichorophenyl)-chloride (GEA 3162; 100 pM) or
diethylamine diazeniumdiolate (DEA/NO; 1 mM), were incubated with neutrophils in the
presence of DHR 123 (1 pM) for 45 min before analysis of mean fluorescence levels
using a flow cytometer. (A) Typical flow cytometry profiles showing fluorescence in
treated cells (blue peaks) vs. control cells (transparent peaks) after 45 min (B) Graph of
fluorescence in untreated and treated cells and effects of the PKC inhibitor, Ro 31-8220
(1 pM). Results represent mean ± SEM from n = 6 experiments. Analysis by two-way
ANOVA with Bonferroni post-hoc test showed a significant (p < 0.05) difference between
groups, and asterisks represent significant (p < 0.05) difference from control without Ro
31-8220. Hashes represent significant (p < 0.05) difference between fluorescence
observed in the absence or presence of Ro 31-8220 for a given condition.
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Figure 3.11 Oxidation of DHR 123 to rhodamine 123 by NO and ONOO" donors in the
presence of neutrophils, and contribution of cell-derived oxidants. PBS, the neutrophil
activating agent PMA (10 nM), 3-morpholinosydnonimine (SIN-1; 100 pM), 1,2,3,4-
oxatriazolium, 5-amino-3-(3,4-dichorophenyl)-chloride (GEA 3162; 100 pM) or
diethylamine diazeniumdiolate (DEA/NO; 1 mM), were incubated with neutrophils in the
presence of DHR 123 (1 pM) for 120 min before analysis of mean fluorescence levels
using a flow cytometer. (A) Typical flow cytometry profiles showing fluorescence in
treated cells (blue peaks) vs. control cells (transparent peaks) after 120 min (B) Graph
of fluorescence in untreated and treated cells and effects of the PKC inhibitor, Ro 31-
8220 (1 pM). Results represent mean ± SEM from n = 6 experiments. Analysis by two-
way ANOVA with Bonferroni post-hoc test showed a significant (p < 0.05) difference
between groups, and asterisks represent significant (p < 0.05) difference from control
without Ro 31-8220. Hashes represent significant (p < 0.05) difference between
fluorescence observed in the absence or presence of Ro 31-8220 for a given condition.
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Neutrophils (5 x 106 cells/ml) were incubated in the presence of DHR and
NO/ONOO" donors for 45 min before assessment by flow cytometry, in the absence
and presence of the protein kinase C (PKC) inhibitor, Ro 31-8220 (1 pM).
Generation of ROS from neutrophils is PKC-dependent, therefore use of Ro 31-8220
eliminates any fluorescence caused by cell-derived ROS, and oxidation of DHR 123
can be mediated only by drug-derived oxidant species. In this case, it would be
expected that if SIN-1 and GEA 3162 are both ONOO" generators, the presence of
Ro 31-8220 would have little effect on the amount of fluorescence seen in
neutrophils treated with these compounds, only abolishing the oxidative burst-
derived fluorescence. On the other hand, if fluorescence observed with DEA/NO
represents ONOO" formed as a result of combination of NO from DEA/NO and
neutrophil-generated O2", fluorescence should be drastically reduced in the presence
of Ro 31-8220.
Representative flow cytometry histograms for a 45-min incubation period
with DHR 123 in the presence of NO/ONOO" donors are shown in Figure 3.10A.
Analysis of the mean fluorescence generated showed a significant (p < 0.05)
difference between groups, therefore a further analysis by Bonferroni post-hoc test
was carried out to reveal which groups differed from control (Figure 3.10B).
Fluorescence from control (PBS-treated) cells was reduced by the presence of
Ro 31-8220 (1.4 ± 0.4 units vs 2.7 ± 0.6 units control) after 45 min, and this effect
was more pronounced in cells treated with the powerful PKC activator, PMA (1.5 ±
0.4 vs 3.8 ± 0.8 control units, p < 0.05, 2-way ANOVA with Bonferroni post-hoc
test). Fluorescence was observed to be significantly different (p < 0.05) from control
in cells treated with either SIN-1 (5.4 ± 1.4 vs. 2.7 ± 0.6 log units) or GEA 3162 (5.0
± 2.0 vs. 2.7 ± 0.6 units). However, in contrast to control and PMA-treated cells,
fluorescence was not attenuated by Ro 31-8220; with SIN-1 in the presence of Ro
31-8220, fluorescence was 4.5 ± 1.3 units, and with GEA 3162 plus Ro 31-8220, it
was 4.1 ± 1.4 units (p < 0.05 from control, two-way ANOVA with Bonferroni post-
hoc test).
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In DEA/NO-treated cells, fluorescence was not increased from control;
indeed it was slightly decreased in the presence of DEA/NO (1.5 ± 0.5 units vs 2.7 ±
0.6 units control; p > 0.05 from control, two-way ANOVA with Bonferroni post-hoc
test). Furthermore, the presence of Ro 31-8220 had no effect on the level of
fluorescence in DEA/NO-treated cells (1.4 ± 0.4 vs 1.5 ± 0.5 units; p > 0.05 from
control, two-way ANOVA with Bonferroni post-hoc test).
Typical flow cytometry traces obtained following 2 h incubation are shown in
Figure 3.11A. Analysis of the data by two-way ANOVA showed a significant
difference (p < 0.05) between treatments, therefore a Bonferroni post-hoc test was
carried out to determine where these differences occurred. A significant increase in
fluorescence was seen with PMA (9.4 ±3.1 units) and SIN-1 (10.7 ± 2.9 units)
compared to control (5.0 ±1.2 units; p < 0.05, two-way ANOVA with Bonferroni
post-hoc test).
The trends of the results followed much the same pattern as for 45 min
(Figure 3.1 IB), with fluorescence in control (2.1 ± 0.3 vs 5.0 ± 1.2 units) and PMA-
treated (2.1 ± 0.4 vs 9.4 ± 3.1 units, p < 0.05, two-way ANOVA with Bonferroni
post-hoc test) cells being abrogated by Ro 31-8220 (p > 0.05 vs. control, two-way
ANOVA with Bonferroni post-hoc test), but not that seen in the presence of SIN-1
(8.9 ± 2.2 vs 10.7 ± 2.9 units, p < 0.05 vs. control, two-way ANOVA with
Bonferroni post-hoc test). GEA 3162-treated cells showed no significant increase in
the level of fluorescence compared to control (5.0 ± 1.0 vs.5.0 ± 1.2 units; p > 0.05,
two-way ANOVA with Bonferroni post-hoc test). However, in contrast to control
cells, the presence of Ro 31-8220 did not decrease the fluorescence observed in these
cells (4.5 ± 0.9 vs 5.0 ± 1.0 units).
3.2.4 Effect of whole serum and human serum albumin on oxidation of DHR
123 by NO/ONOO' donors in human neutrophils
Different levels of DHR 123 oxidation were seen with neutrophils incubated
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in the presence of autologous serum compared to those seen in the absence of serum
in the same set of cells in concurrently-run experiments; typical flow cytometry
histograms are shown in Figure 3.12A. Two-way ANOVA showed no significant
differences between treatment groups (p > 0.05) in the presence of serum.
Preliminary studies showed that serum reduced the extent of fluorescence
achieved, with control fluorescence of 1.9 ± 0.5 units after 2 h compared to 5.0 ± 1.2
units achieved in the absence of serum, and Ro 31-8220 failed to reduce the
fluorescence (1.7 ± 0.3 vs 1.9 ± 0.5 units). PMA again increased fluorescence (8.6 ±
6.6 vs 1.9 ± 0.5 units), although not to the same extent as in medium alone, and this
did not reach statistical significance due to the high variability of fluorescence
achieved between experiments. This appears to be due to variability between donors
of the responsiveness to PMA in the presence of serum, as increased fluorescence in
response to PMA was observed in some replicates of the experiment but not others.
Again, increased fluorescence in the presence of 1 mM SIN-1 or 100 pM
GEA 3162 could not be reduced back to control levels by Ro 31-8220. Fluorescence
generated by SIN-1 was 6.6 ± 2.4 units in the presence of Ro 31-8220 compared to
6.5 ± 2.0 units with SIN-1 alone, and GEA 3162 gave a fluorescence of 6.4 ± 1.3
units with Ro 31-8220 vs. 7.4 ± 1.6 units without the PKC inhibitor.
In contrast, results obtained with 1 mM DEA/NO conflicted with those seen
in the absence of serum for experiments carried out on the same set of cells on the
same day. In the presence of serum, fluorescence obtained with DEA/NO was
increased compared to control (5.4 ± 0.5 vs 1.9 ± 0.5 units), and was brought back
down towards control levels (3.1 ± 0.4 units) by Ro 31-8220. Although two-way
ANOVA showed no significant differences between groups, two-tailed paired t test
of fluorescence obtained with DEA/NO versus that seen in control cells showed a
significant increase in fluorescence by DEA/NO (p < 0.05). This is in contrast with
data obtained in the absence of serum at 2 h, in which no significant difference was
detectable between the two groups (p > 0.05, two-tailed paired t test). Although two-
way ANOVA showed no significant differences in these preliminary studies, there
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Figure 3.12 Effect of autologous serum on oxidation of DHR 123 to rhodamine
123 by NO and ONOO donors in the presence of neutrophils, and contribution of
cell-derived oxidants. PBS, the neutrophil activating agent PMA (10 nM), 3-
morpholinosydnonimine (SIN-1; 1 mM), 1,2,3,4-oxatriazolium, 5-amino-3-(3,4-
dichorophenyl)-chloride (GEA 3162; 100 pM) or diethylamine diazeniumdiolate
(DEA/NO; 1 mM), were incubated with neutrophils in 10% autologous serum in
the presence of DHR 123 (1 pM) for 120 min before analysis of mean
fluorescence levels using a flow cytometer. (A) Typical flow cytometry profiles
showing fluorescence in treated cells (blue peaks) vs. control cells (transparent
peaks) after 120 min (B) Graph of fluorescence in untreated and treated cells and
effects of the PKC inhibitor, Ro 31-8220 (1 pM). Results represent mean ± SEM
from n = 3 experiments. Data did not reach statistical significance.
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was a clear trend towards increased fluorescence with DEA/NO in the presence of
serum, and further replications would be expected to show a significant difference.
In order to further investigate the differential effects obtained with DEA/NO
in the absence and presence of serum, studies were carried out to determine the role
of DEA/NO-mediated modification of plasma albumin. Neutrophils (4.5 x 106
cells/ml) were incubated for 2 h in the absence and presence of serum (10%) and in
the absence and presence of PMA (10 nM) and DEA/NO (1 mM). Neutrophils were
also incubated in culture medium supplemented with human serum albumin (HSA;
0.4 % w/v) in the absence and presence ofPMA or DEA/NO.
These studies also showed suppression ofDHR 123 oxidation by the presence
of serum in control cells (1.8 ± 0.7 units vs 2.4 ± 0.6 units in the absence of serum),
although this failed to reach statistical significance, and the attenuation of oxidative
burst stimulated by PMA (2.6 ± 0.8 units vs 4.2 ± 0.8 units in the absence of serum;
p < 0.05, one-way ANOVA with Student-Newman-Keuls post-hoc test).
Furthermore, the reduction in fluorescence from control by DEA/NO in culture
medium alone, but increased fluorescence in the presence of serum was also
observed. However, these results did not reach statistical significance, although a
clear trend was observed in each replication of the experiment. DEA/NO-induced
fluorescence was 1.6 ± 0.5 units vs 2.4 ± 0.6 units control in medium alone, but was
2.5 ± 1.0 vs 1.8 ± 0.7 units control with serum.
Supplementation of culture medium with albumin, a major serum protein,
mimicked the effects of whole human serum, producing an inhibition (albeit not
statistically significant) of spontaneous ROS generation (1.8 ± 1.0 units vs 2.4 ± 0.6
units in the absence of HSA; Figure 3.13B). In the presence of both DEA/NO and
HSA, fluorescence increased to higher than control levels; 3.3 ± 0.8 units
fluorescence was seen with DEA/NO and HSA compared to 1.8 ± 1.0 units in HSA-
supplemented medium alone (p < 0.05, one-way ANOVA with Student-Newman-
Keuls post-hoc test). This increased fluorescence observed with DEA/NO was also
significantly different from that seen with DEA/NO in IMDM in the absence ofHSA
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Figure 3.13 Contribution of human serum albumin (HSA) to autologous serum
(AS)-mediated inhibition of ROS generation by neutrophils and reversal of inhibition
by DEA/NO. PBS, the neutrophil activating agent PMA (10 nM) or diethylamine
diazeniumdiolate (DEA/NO; 1 mM), were incubated with neutrophils in Iscove's
MDM (IMDM) alone, or supplemented with 10 % AS or 0.4 % HSA in the presence
of DHR 123 (1 fiM) for 120 min before analysis of mean fluorescence levels using a
flow cytometer. (A) Typical flow cytometry profiles showing fluorescence in PMA-
treated cells (blue peaks) and DEA/NO-treated cells (red peaks) vs. control cells
(white peaks) after 120 min (B) Graph of fluorescence in untreated and treated cells
in IMDM, IMDM + 10% AS or IMDM + 0.4% HSA. Results represent mean ± SEM
from n = 3 experiments. Asterisks represent significant (p < 0.05) difference from
control (untreated) cells under the same culture conditions and hashes represent
differences between the same treatment under different conditions by one-way
ANOVA with Student-Newman-Keuls post-hoc test.
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(3.3 ± 0.8 vs. 1.6 ± 0.5 units, p < 0.05, one-way ANOVA with Student-Newman-
Keuls post-hoc test). Furthermore, the presence of HSA caused PMA-induced
fluorescence to be significantly higher than that seen in control (p < 0.05, one- way
ANOVA with Student-Newman-Keuls post-hoc test).
3.2 Discussion
Preliminary characterisation of the extent and rate of liberation of NO from
various compounds is very important, as it has been shown that the rate of NO
release can have profound implications for the biological effects of NO donors or
their mechanisms of action. For example, high-flux diazeniumdiolates such as
MAMA/NO inhibit cholesterol peroxidation through a chain prevention mechanism,
whereas slower-releasing compounds such as PAPA/NO and SPER/NO act at the
level of downstream radicals (Korytowski et al., 2000). Furthermore, it has been
shown that the rate of NO release from diazeniumdiolates influences the efficacy of
inhibition of vascular smooth muscle cell proliferation; diazeniumdiolate compounds
with short half lives (DEA/NO and PAPA/NO) were unable to inhibit proliferation,
whereas longer-lasting diazeniumdiolate compounds (SPER/NO, DPTA/NO and
DETA/NO) were effective, with efficacy of inhibition being positively correlated
with the half life ofNO release (Mooradian et al., 1995). Furthermore, the extent of
inhibition of platelet aggregation by diazeniumdiolates also correlated with the
amount ofNO delivered (Raulli, 1998) and induction of apoptosis in neuronal PC 12
cells was only observed with NO donors of intermediate duration (NOR2 and NOR3)
but not those of short (NOR1) or long (NOR4) duration (Yamamoto et al., 2000).
Studies using an NO electrode showed that free NO was liberated
spontaneously from the diazeniumdiolate compounds (1 pM). Thus, with DEA/NO
at this concentration, all NO is released from this compound after 15 min, whereas
SPER/NO takes approximately 200 min to fully liberate its attached NO. The
maximal concentration of NO achieved with 1 pM DEA/NO was 1.42 ± 0.14 pM,
whereas only 0.64 ±0.15 pM was achievable from 1 pM SPER/NO over 20 min,
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indicating that local concentrations ofNO from DEA/NO in future apoptosis studies
are likely to be higher than those using SPER/NO. These compounds can therefore
be used to distinguish between effects of a short burst of high concentrations ofNO
(from DEA/NO) and more sustained release of lower concentrations of NO (from
SPER/NO).
It is also crucial to know the nature of the NO-related species derived from
so-called 'NO donors' as NO-related species may exert differential biological effects
or similar effects to NO that are mediated through different mechanisms. For
example, both NO and ONOO" from SIN-1 cause vasodilation in isolated blood
vessels through elevation of cGMP, although ONOO" itself may cause vasodilation
via a cGMP-independent mechanism (Trakranrungsie and Will, 2001). Furthermore,
both NO and ONOO" decrease LTB4 release from neutrophils via cGMP (Ney et al.,
1990). However, it has been reported that NO inhibits the oxidative burst in
neutrophils, especially at low oxygen tensions (Iha et al., 1996), but that ONOO"
enhances ROS generation in response to neutrophil activating agents such as PMA
(Iha et al., 1996; Bednar et al., 1996). Although both species inhibit respiration, they
do so through different mechanisms (Lizasoain et al., 1996).
In contrast to diazeniumdiolates, liberation of free NO from either SIN-1 or
GEA 3162 was not detected by the NO electrode. Absence of an NO signal from
these compounds was due to scavenging of free NO by O2" produced alongside NO
(forming ONOO") as free NO could be unmasked by the presence of SOD, which
converts O2" to H2O2 and therefore protects free NO from scavenging. These studies
were carried out with only one concentration of SOD (50 U/ml). However, further
studies by our group showed that for both GEA 3162 and SIN-1, the amount ofNO
unmasked followed a non-linear relationship with the concentration of SOD, with the
NO concentration detected levelling off with higher concentrations of SOD. This
suggests that the capacity for SOD to protect NO from O2" scavenging becomes
saturated.
The reaction kinetics for the dismutation of O2" by SOD is considerably
slower than the reaction of NO with O2" for a 1:1 ratio of NO and O2" generation
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(Huie and Padmaja, 1993). Such kinetics suggest that, although a certain proportion
of ONOO" generation is blocked by the presence of SOD, this scavenging would be
incomplete and some ONOO" could still be generated by ONOO" donors, therefore
the NO levels detectable using the NO electrode would not necessarily represent the
same concentrations of ONOO" achievable with these compounds. GEA 3162 and
SIN-1 are therefore both ONOO" generators rather than donors of pure NO.
Although this has long been known for SIN-1, it is a novel finding for GEA 3162.
However, given the striking structural similarity between these two compounds (Fig
3.1) along with previous reports of the potential for GEA 3162 to generate ONOO"
(Kankaanranta et al., 1996), it is not a surprising finding. The findings from these
studies agree with those previously published for SIN-1 regarding the detection of
free NO following O2" dismutation by SOD (Lizasoain et al., 1996). However, they
are at odds with published reports on the nature of the species generated by GEA
3162.
Previous studies using a number of different techniques but, importantly, not
NO electrode studies have found that GEA 3162 generated NO in the absence of O2"
release, making GEA 3162 a pure NO donor rather than a ONOO" donor
(Kankaanranta et al., 1996; Holm et al., 1998). However, more recent evidence has
suggested that GEA 3162 may indeed co-generate NO and O2" (Schmidt et al., 2001).
In order to clarify this issue, these two compounds, DEA/NO or PBS were
incubated in the presence ofDHR 123 to distinguish between those that liberate pure
NO and those that generate ONOO". Such studies are founded on the premise that
DHR 123 can be oxidised to fluorescent rhodamine 123 by certain reactive oxygen
species, but not by pure NO, therefore fluorescence should only be increased from
control in the presence of ONOO" generating compounds and not in the presence of
compounds that liberate pure NO. These studies concurred with the NO electrode
findings, as both SIN-1 and GEA 3162 increased fluorescence, but no significant
increase in fluorescence was obtained with the known pure NO generator, DEA/NO.
However, it is still conceivable that biological actions of DEA/NO in
neutrophils are mediated through the generation of ONOO". DEA/NO is known to
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liberate free NO in aqueous solution, and activated neutrophils are known to produce
O2" as part of the oxidative burst following activation of these cells. Therefore, the
potential exists for these species to combine to generate ONOO". In order to test this
possibility, the DHR 123 experiments were also carried out in the presence of
neutrophils, to determine if exposure of neutrophils to DEA/NO results in ONOO"
being generated from combination of drug-derived NO and cell-derived O2". This
was done using the protein kinase C inhibitor, Ro 31-8220 (Dieter and Fitzke, 1991),
to inhibit endogenously produced oxidants, so any remaining fluorescence observed
in the presence of Ro 31-8220 must be oxidants generated from the drugs
themselves. Using this method, it should be able to determine what component of
DHR 123 oxidation in the presence of NO or ONOO" donors results from the
oxidative burst from neutrophils. In this case, compounds that liberate ONOO"
would generate a high fluorescence which would not be significantly reduced by
inhibition of the neutrophil oxidative burst. In contrast, pure NO donors would only
generate high fluorescence if the NO reacts with neutrophil-generated O2" to form
ONOO", and this would be inhibitable by Ro 31-8220.
In the absence of serum, results correlated with those obtained using the NO
electrode. GEA 3162 and SIN-1 were ONOO" generators, as the high levels of DHR
123 oxidation induced by these compounds were only slightly reduced by Ro 31-
8220. The observed small reduction most likely represented the minor contribution
of spontaneous ROS generation by neutrophils to oxidation of DHR 123. This
demonstrates that the major oxidant species responsible for the generation of
fluorescence is derived from the compounds themselves, and therefore this rules out
these compounds as pure NO donors, as free NO by itself is incapable of oxidising
DHR 123 to rhodamine 123, as previous studies have shown (Crow, 1997). These
studies also confirmed the absence of oxidant production from DEA/NO, as
fluorescence was not significantly increased compared to control. Indeed, there was
a small reduction in DHR 123 oxidation by DEA/NO, suggesting an inhibitory effect
of DEA/NO on ROS generation by neutrophils. This concurs with a number of
studies that have proposed inhibitory actions of NO on neutrophil functions,
including chemotaxis, degranulation, shape change and oxidative burst (Moilanen et
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al., 1993; Ward et al., 2000; Gluckman et al., 2000). A number of studies have
demonstrated an inhibitory effect of NO on the neutrophil respiratory burst in vitro
(Clancy et al., 1992; Forslund and Sundqvist, 1995; Iha et al., 1996) and in vivo
(Gessler et al., 1996; Bloomfield et al., 1997) and others have found an inhibitory
action of ONOO" (Clements et al., 2003). However, other studies have shown
increased oxidative burst in response to ONOO" (Iha et al., 1996; Bednar et al.,
1996), and others have demonstrated no effect of NO on ROS generation in an in
vivo model of acute pulmonary inflammation (Kermarrec et al., 1998).
Addition of 10% autologous serum to these experiments led to suppression of
ROS generation by neutrophils in most experimental conditions versus matched
experiments in the absence of serum. Although this effect was not found to be
statistically significant over the three replications of the experiment, there was a
consistent trend observed each time, and suggests that this may be a real effect that
would be significant on further investigation. Control fluorescence was reduced
compared to that seen in the absence of serum when neutrophils were incubated with
DHR 123 for 2 h. This represents suppression of endogenous activation of the
oxidative burst in the presence of serum, as Ro 31-8220 was unable to further reduce
the extent ofDHR 123 oxidation.
Additionally, the extent of stimulation of the oxidative burst by the neutrophil
activating agent, PMA, was severely attenuated by the presence of serum with some,
but not all, donors. This suggests that a factor (or factors) in serum protects
neutrophils from becoming activated. As in culture medium alone, GEA 3162 and
SIN-1 both increased fluorescence that was not reduced by addition of Ro 31-8220.
The major difference between these studies and those carried out in the absence of
serum, however, was observed with DEA/NO. Although this compound produced a
small inhibition of ROS generation in medium alone, a significant increase in
fluorescence above control levels was obtained in the presence of serum, which was
reduced back to control levels by Ro 31-8220. This suggests either that DEA/NO is
able to stimulate oxidative burst in the presence of serum or that it is able to release
the natural brake on ROS generation exerted by serum. A number of factors make
the latter possibility more likely; given the protective effect of serum against other
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stimuli such as PMA, the lack of oxidative burst-stimulating effects of DEA/NO in
medium alone and the anti-neutrophil effects of NO that have been widely reported
(Granger and Kubes, 1996), it is unlikely that a pure NO donor would be able to
promote ROS generation from neutrophils in the presence, but not in the absence, of
serum. Furthermore, the good correlation between the level of fluorescence
generated by DEA/NO in the presence of serum and that seen in control cells in
medium alone suggests that reversal of the inhibition of the oxidative burst by serum
is a more plausible explanation. Enhanced fluorescence observed with DEA/NO is
not due to DEA/NO generating an oxidant species itself in the presence of serum, as
Ro 31-8220 was able to reverse this effect, demonstrating a role for neutrophil-
derived oxygen radicals in oxidation of DHR 123. Previous studies have suggested
that albumin, a highly-abundant protein present in serum, is able to inhibit the
oxidative burst in neutrophils (Nathan et al., 1993). Furthermore, it is known that S-
nitrosoalbumin is formed in plasma from S-nitrosation of albumin by derivatives of
NO (Stamler et al., 1992;Crane et al., 2002). It is therefore possible that albumin in
serum is responsible for the inhibition of DHR 123 oxidation and that modification
of albumin by NO, through formation of S-nitrosoalbumin is sufficient to reverse this
inhibition.
In order to test the hypothesis that DEA/NO may reverse the brake on
endogenous ROS generation exerted by serum through modification of serum
proteins such as albumin, experiments were carried out to compare DHR 123
oxidation under various conditions. Neutrophils were incubated with DHR 123 for 2
h in medium alone, in medium supplemented with 10% autologous serum or in
medium supplemented with human serum albumin (HSA; 0.4% w/v), to which PBS,
PMA (10 nM) or DEA/NO (1 mM) were added. This percentage of HSA was
chosen because albumin is present in serum at levels of approximately 4% (Rutstein
et al., 1954), and 10% serum is added to neutrophils in serum-replete studies.
Therefore, 0.4% HSA represents the approximate levels of albumin observed in the
whole serum studies. If the hypothesis is valid, the inhibition of oxidative burst
observed with serum should be mimicked by the presence of HSA in the culture
medium. However, DEA/NO should reverse this inhibition and return the
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fluorescence level to that of control. These studies showed that the presence of HSA
reduced fluorescence in a manner similar to that observed with whole serum. This
concurs with previous findings by Valerius et al, who found that O2" release from
neutrophils was inversely proportional to levels of albumin, and suggested that this
effect was due to inhibition of neutrophil adhesion (Valerius, 1983). In the presence
of HSA, both DEA/NO and PMA increased fluorescence to levels above control.
This suggests that the inhibition of ROS generation by serum is multifactorial, and
not due solely to albumin, as this inhibition is more easily overcome by DEA/NO
than is seen with whole serum. Therefore the hypothesis is valid and DEA/NO does
reverse the albumin-mediated inhibition of the oxidative burst in neutrophils. It is
likely that this effect is mediated by modification of albumin by NO from DEA/NO,
in particular S-nitrosation of the serum protein seems a potential candidate to explain
the abolition of the inhibitory effect of serum. The implications of these results are
that in serum-replete apoptosis studies (Chapter 4), pro-apoptotic effects of DEA/NO
may be mediated by ONOO", as this compound promotes the oxidative burst from
neutrophils and NO from DEA/NO may react with O2 from the neutrophils to
generate ONOO".
In summary, therefore, two independent indicators of NO or oxidant species
generation both demonstrate that diazeniumdiolate compounds such as DEA/NO and
SPER/NO release free NO alone, and can therefore be considered to be 'pure' NO
donors. On the other hand, both SIN-1 and GEA 3162 release NO and O2"
concomitantly, and should therefore be considered to be ONOO" generators. In
future chapters, therefore, the diazeniumdiolates, DEA/NO and SPER/NO, will be
referred to as NO donors and SIN-1 and GEA 3162 as ONOO" donors. Biological
effects of DEA/NO are unlikely to be mediated by ONOO" in the absence of serum,
despite ROS generation by neutrophils. However, in the presence of serum, this
possibility cannot be excluded, as increased ROS production is observed in the
presence of both DEA/NO and serum. This observation may be due to reversal of
protective effects of serum on neutrophils by DEA/NO. Having carefully
characterised the above compounds in terms of their NO or ONOO" generation, they
were then used to investigate the regulation of apoptosis in neutrophils by NO and
Chapter 3: Characterisation ofNO Release 96
Regulation ofNeutrophil Apoptosis by NO and ONOO"
ONOO", with comparisons being made between NO donors of differing rates of
decomposition and compounds that liberate ONOO".
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Chapter 4: Effects of NO/ONOO" Donors on the Rate of
Neutrophil Apoptosis
4.1 Introduction
NO has been shown to be a critical regulator of apoptotic cell death in many
cell types, and can be either pro- or anti-apoptotic. Low concentrations ofNO tend
to be protective and these effects are frequently attributed to increased cGMP and/or
S-nitrosation of caspase proteases (Liu and Stamler, 1999). Inhibition or delay of
apoptosis has been observed in trophoblasts (Dash et al., 2003), neurones
(Thippeswamy et al., 2001; Ha et al., 2003), endothelial cells (Suschek et al., 1999)
cardiomyocytes (Andreka et al., 2001; Zingarelli et al., 2002), hepatocytes (Kim et
al., 1997), keratinocytes (Weller et al., 2003), B lymphocytes (Genaro et al., 1995),
chondrocytes (Oh and Chun, 2003) and eosinophils (Beauvais et al., 1995).
NO has also been shown to promote apoptotic cell death, either directly
through exogenously-supplied NO or as an essential mediator of apoptosis triggered
by other stimuli. In contrast to inhibition of apoptosis, NO-mediated induction of
apoptosis is usually reported to be independent of cGMP and is often attributed to the
initiation of the stress pathway and the associated mitochondrial changes
characteristic of this pathway, frequently through formation of ONOO". Direct
induction of apoptosis has been demonstrated in eosinophils (Zhang et al., 2003b), T
lymphocytes (Valenti et al., 2003), various colon cancer cell lines (Liu et al., 2003),
chondrocytes (Blanco et al., 1995), cardiomyocytes (Taimor et al., 2001; Chae et al.,
2001), neuroblastoma cells (Oh-Hashi et al., 1999), insulin-secreting (3 islet cell-like
cell lines (Bernabe et al., 2001) and neurones (Ghatan et al., 2000; Wang et al.,
2003; Zhang et al., 2002). NO has been reported to mediate apoptosis induced by
farnesyltransferase inhibitors in chronic myeloid leukaemia cells (Selleri et al.,
2003), that promoted by morphine in T lymphocytes (Wang et al., 2001) and also
mediates cytokine (LPS/IFN-y)-induced death in macrophages (Scivittaro et al.,
1997).
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Neutrophil apoptosis has been shown to be enhanced by exogenously-
supplied NO by a number of groups (Fortenberry et al., 1998; Blaylock et al., 1998;
Singhal et al., 1999; Fortenberry et al., 1999; Ward et al., 2000). In order to
understand the mechanism of action of the effects ofNO or ONOO" donor drugs on
neutrophil apoptosis, a selection of agents with specific properties were used. The
aims of the experiments described in this chapter were to characterise the effects of
two diazeniumdiolate NO donors with different rates of NO release, DEA/NO and
SPER/NO, the oxatriazole 5-imine derivative compound, GEA 3162, and the ONOO"
donor, SIN-1, on neutrophil apoptosis, using a number of different events to measure
apoptotic cell death. Both concentration-response and time-course studies were used
to examine the relative potencies and temporal effects of these compounds.
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4.2 Results
4.2.1 Assessment of constitutive neutrophil apoptosis
Four independent events of neutrophil apoptosis were measured in these
studies: the characteristic morphological changes of cell shrinkage and nuclear
condensation, exposure of phosphatidylserine (PS) on the outer surface of apoptotic
neutrophils, shedding of CD 16 from the cell surface and intemucleosomal DNA
fragmentation. When these techniques were applied to constitutive neutrophil
apoptosis, all four correlated well, and by 20 h the levels of apoptosis detected were
53.1 ± 2.8, 67.9 ± 2.7, 61.2 ± 5.9 and 61.5 ± 9.8 % apoptosis respectively (p > 0.05,
one-way ANOVA; Figure 4.1). All four events occurred virtually simultaneously in
spontaneous apoptosis. Levels of apoptosis remained low (approximately 1 %) in
cells undergoing constitutive apoptosis until the 8 h time point, at which time 9.8 ±
6.4 % of cells exhibited morphological signs of apoptosis. Apoptosis then increased
rapidly at later time points, producing a sigmoidal curve when apoptosis was plotted
vs. time.
4.2.2 Concentration-response studies using NO/ONOO' donors
In order to determine appropriate concentrations of NO/ONOO" donors to
use, concentration-response studies were carried out. Neutrophils were incubated in
the absence or presence ofNO (DEA/NO or SPER/NO; 0.1 pM - 1 mM) or ONOO"
(GEA 3162; 0.1 pM - 100 pM) donors for 20 h, then apoptosis was assessed by
morphology and Annexin V binding. These studies showed that low concentrations
of the NO donors delayed neutrophil apoptosis compared to control. The inhibition
obtained was small (< 10 %), but the results achieved statistical significance (p <
0.05, one-way ANOVA with Student-Newman-Keuls post-hoc test) at concentrations
of 0.1 - 30 pM for DEA/NO by morphology and 0.1 - 300 pM by Annexin V
binding. At the lowest concentration (0.1 pM), morphological apoptosis was 54.0 ±
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Figure 4.1 Correlation of 4 different techniques in the measurement of
constitutive neutrophil apoptosis. Neutrophils (4.5 x 10s cells/ml) were incubated
in Iscove's MDM supplemented with 10 % autologous serum for 1, 2, 4, 8, 16 or 20
hours, then apoptosis was assessed by morphology, Annexin V binding, PI
intercalation and CD16 shedding. Results represent mean ± S.E.M. from n = 3-6
experiments.
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4.9 % vs. 59.9 ± 4.4 % control, and PS exposure was 64.1 ± 3.2 % vs. 72.3 ± 2.6 %
(Figure 4.2). Using SPER/NO, a significant inhibition (p < 0.05, one-way ANOVA
with Student-Newman-Keuls post-hoc test) was seen at concentrations of 0.1 - 3 pM
by morphology and 0.1 pM by Annexin V binding. Morphological apoptosis
measured with 0.1 pM SPER/NO was 42.9 ± 2.7 % vs. 53.1 ± 2.8 % control, and PS
exposure was 60.1 ± 1.9 % vs. 67.9 ± 2.7 % (Figure 4.3).
In contrast, higher concentrations of these compounds showed an acceleration
of neutrophil apoptosis. Concentrations of 1 mM DEA/NO produced a significant (p
< 0.05, one-way ANOVA with Student-Newman-Keuls post-hoc test) induction of
apoptosis by morphology and by Annexin V binding. Neutrophils treated with 1 mM
DEA/NO showed 100 % morphological apoptosis, compared to 59.9 ± 4.4 %
apoptosis in PBS-treated cells, and 81.1 +5.7 % PS exposure compared to 72.3 ± 2.6
% control (Figure 4.2). A significant induction of neutrophil apoptosis was observed
with concentrations of 300 pM - 1 mM SPER/NO when apoptosis was assessed by
morphology and with 1 mM as determined by Annexin V binding (p < 0.05, one-way
ANOVA with Student-Newman-Keuls post-hoc test). Neutrophils exposed to 1 mM
SPER/NO for 20 h showed 89.5 ±5.1 % morphological apoptosis vs. 53.1 ± 2.8 %
control, and PS exposure in these cells was 82.0 ± 2.7 % compared to 67.9 ± 2.7 % in
untreated cells (Figure 4.3).
When neutrophils were exposed to the ONOO" donor, GEA 3162, no
significant reduction of the rate of apoptosis was seen at concentrations equivalent to
that observed with the diazeniumdiolates; at the lowest concentration (0.1 pM),
morphological apoptosis was measured as 49.3 ± 3.6 % compared to 53.1 ± 2.8 %
control, and levels of PS exposure were 66.6 ± 2.2 % vs. 67.9 ± 2.7 % in control cells
(p > 0.05, one-way ANOVA with Student-Newman-Keuls post-hoc test). However,
a significant (p < 0.05, one-way ANOVA with Student-Newman-Keuls post-hoc test)
acceleration of morphological neutrophil apoptosis was achieved with 30 and 100
pM of this compound. Using 100 pM GEA 3162, virtually all cells underwent
apoptosis over 20 h, with death measured as 93.6 ± 3.0 % compared to 53.1 ± 2.8 %
control (Figure 4.4A). However, no significant increase in apoptosis was detectable
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Figure 4.2 Concentration-response graphs for DEA/NO on neutrophil apoptosis
assessed by morphology and Annexin V binding. Neutrophils (4.5 x 106 cells/ml)
were incubated in Iscove's MDM supplemented with 10 % autologous serum for
20 hours in the absence or presence of DEA/NO (0.1 pM - 1 mM), then apoptosis
was assessed by (A) morphology and (B) Annexin V binding. Results represent
mean ± S.E.M. from n = 6 experiments. Asterisks represent significant (p < 0.05)
difference from control (dashed line) by one-way ANOVA with Student-Neuman-
Keuls post-hoc test.
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Figure 4.3 Concentration-response graphs for SPER/NO on neutrophil apoptosis
assessed by morphology and Annexin V binding. Neutrophils (4.5 x 106 cells/ml)
were incubated in Iscove's MDM supplemented with 10 % autologous serum for 20
hours in the absence or presence of SPER/NO (0.1 pM - 1 mM), then apoptosis
was assessed by (A) morphology and (B) Annexin V binding. Results represent
mean ± S.E.M. from n = 6 experiments. Asterisks represent significant (p < 0.05)
difference from control (dashed line) by one-way ANOVA with Student-Neuman-
Keuls post-hoc test.
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Figure 4.4 Concentration-response graphs for GEA 3162 on neutrophil apoptosis
assessed by morphology and Annexin V binding. Neutrophils (4.5 x 106 cells/ml)
were incubated in Iscove's MDM supplemented with 10 % autologous serum for
20 hours in the absence or presence of GEA 3162 (0.1 pM - 100 pM), then
apoptosis was assessed by (A) morphology and (B) Annexin V binding. Results
represent mean ± S.E.M. from n = 6 experiments. Asterisks represent significant
(p < 0.05) difference from control (dashed line) by one-way ANOVA with Student-
Neuman-Keuls post-hoc test.
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when Annexin V binding was used as the measure of apoptosis (p > 0.05, one-way
ANOVA with Student-Newman-Keuls post-hoc test); 100 pM GEA 3162 gave 65.5
±5.3 % PS exposure vs. control levels of 67.9 ± 2.7 % as assessed by this technique
(Figure 4.4B).
4.2.3 Time-course studies using NO/ON00' donors
Time-course studies were then performed to look at the changes characteristic
of neutrophil apoptosis over time in the absence and presence of these compounds.
Neutrophils were exposed to NO donors (DEA/NO and SPER/NO; 0.1 pM or 1 mM)
or the ONOO" donor, GEA 3162 (30 or 100 pM) for 1, 2, 4, 8, 16 or 20 h and
apoptosis measured by four different techniques; morphology, Annexin V binding,
CD16 shedding and PI intercalation.
Studies using DEA/NO at concentrations of 0.1 pM and 1 mM demonstrated
the biphasic effect of this compound on neutrophil apoptosis. Throughout the 20-h
incubation period, the inhibition of morphological apoptosis evoked by the lower
concentration of DEA/NO was minimal, with a difference from control only
observed at time points of 16 h and later, and only representing a difference of a few
percent. At 16 h, apoptosis was 42.5 ± 7.2 % compared to 54.0 ± 8.3 % control
(Figure 4.5). Although the overall time course line for 0.1 pM DEA/NO did not vary
significantly from control (p > 0.05, 2-way ANOVA), the inhibition observed at 20 h
was significantly different from control (p < 0.05, two-tailed paired t test).
This was also the case for apoptosis measured by Annexin V binding, with
PS exposure at 16 h being measured as 45.3 ± 6.1 % vs. 54.1 ± 4.3 % in untreated
cells (Figure 4.6B), although the time course line failed to reach statistical
significance (p > 0.05, 2-way ANOVA). However, data obtained at 20 h showed
significant differences from control (p < 0.05, two-tailed paired t test). Typical flow
cytometry traces (Figure 4.6A) show only a slight leftward shift of fluorescence from
control at 8 and 20 h, representing inhibition of PS exposure. These traces
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demonstrate the trends observed in each replication of this experiment, although the
precise levels of apoptosis varied from experiment to experiment due to biological
variation between donors.
However, assessment of apoptosis by CD 16 shedding showed virtually
identical levels of apoptosis to control throughout the 20-h period and no significant
difference from control was detectable between the lines (p > 0.05, two-way
ANOVA); at 20 h, control apoptosis was 61.2 ± 5.9 % and in the presence of
DEA/NO, it was 58.2 ± 2.4 (p > 0.05, two-tailed paired t test; Figure 4.7B). This is
clearly shown in virtually identical flow cytometry profiles for untreated and 0.1 pM
DEA/NO-treated cells at both 8 and 20 h (Figure 4.7A).
The inhibition of neutrophil apoptosis by 0.1 pM DEA/NO was seen using PI
intercalation as a measure of internucleosomal DNA fragmentation. Such inhibition
was apparent at 16 h, and by 20 h apoptosis was 47.1 ± 10.7 % compared to control
levels of 61.5 ± 9.8 % (Figure 4.8B). However, the time course lines did not quite
reach statistical significance (p > 0.05, two-way ANOVA). Again, examples of
histograms obtained by flow cytometry are shown in Figure 4.8A.
Acceleration of neutrophil apoptosis by 1 mM DEA/NO occurred much more
quickly than the inhibition by 0.1 pM DEA/NO. Morphologically, large differences
from control were seen by 4 h (34.9 ± 8.5 % vs. 1.0 ± 0.1 % apoptosis in control
cells, and increased levels of apoptosis were maintained through the remainder of the
culture period (p < 0.0001, two-way ANOVA; Figure 4.5).
Annexin V binding gave less conclusive results than morphology, with a
clear difference not being seen until 8 h, and this difference was smaller than that
seen by morphology; 29.4 ± 14.2 % compared to 8.9 ± 3.5 % control (Figure 4.6B),
although a significant (p < 0.0001) difference from the control time course was
detectable by 2-way ANOVA. Flow cytometry profiles show a distinct increase in
highly-fluorescent neutrophils exposed to 1 mM DEA/NO compared to control at
both 8 and 20 h (Figure 4.6A).
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Figure 4.5 Time course studies for effects of DEA/NO on neutrophil apoptosis
assessed by morphology. Neutrophils (4.5 x 10® cells/ml) were incubated in
Iscove's MDM supplemented with 10 % autologous serum for 1 - 20 hours in the
absence or presence of DEA/NO (0.1 pM or 1 mM), then apoptosis was assessed
by morphology. Results represent mean ± SEM from n = 3 - 6 experiments.
Asterisks represent significant (p < 0.0001) difference from control (open symbols)
time-course by two-way ANOVA.
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Figure 4.6 Time course studies for effects of DEA/NO on neutrophil apoptosis
assessed by Annexin V binding. Neutrophils (4.5 x 106 cells/ml) were incubated in
Iscove's MDM supplemented with 10 % autologous serum for 1 - 20 hours in the
absence or presence of DEA/NO (0.1 pM or 1 mM), then apoptosis was assessed
by Annexin V binding (A) Typical flow cytometry traces showing percentage Annexin
V binding in neutrophils after 8 and 20 hours (B) Graph showing changes in PS
exposure over time in control cells or neutrophils treated with DEA/NO. Results
represent mean ± SEM from n = 3-6 experiments. Asterisks represent significant (p
< 0.0001) difference from control (open symbols) time-course by two-way ANOVA.
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Figure 4.7 Time course studies for effects of DEA/NO on neutrophil apoptosis
assessed by CD16 shedding. Neutrophils (4.5 x 106 cells/ml) were incubated in
Iscove's MDM supplemented with 10 % autologous serum for 1 - 20 hours in the
absence or presence of DEA/NO (0.1 pM or 1 mM), then apoptosis was assessed by
CD16 shedding (A) Typical flow cytometry traces showing percentage CD 16
shedding in neutrophils after 8 and 20 hours (B) Graph showing changes in CD16
shedding over time in control cells or neutrophils treated with DEA/NO. Results
represent mean ± SEM from n = 3-6 experiments. Asterisks represent significant (p
< 0.0001) difference from control (open symbols) time-course by two-way ANOVA.
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Figure 4.8 Time course studies for effects of DEA/NO on neutrophil apoptosis
assessed by PI intercalation. Neutrophils (4.5 x 106 cells/ml) were incubated in
Iscove's MDM supplemented with 10 % autologous serum for 1 - 20 hours in the
absence or presence of DEA/NO (0.1 pM or 1 mM), then apoptosis was assessed by
PI intercalation (A) Typical flow cytometry traces showing percentage hypodiploid cells
in neutrophils after 8 and 20 hours (B) Graph showing changes in PI intercalation over
time in control cells or neutrophils treated with DEA/NO. Results represent mean ±
SEM from n = 3-6 experiments. Asterisks represent significant (p < 0.01) difference
from control (open symbols) time course by two-way ANOVA.
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Assessment of apoptosis by CD 16 shedding correlated much more closely
with morphological observations, with induction of apoptosis becoming apparent by
just 2 h, with 14.0 ± 3.4 % of cells having shed surface CD16 compared to 3.5 ± 0.9
% control, and after 20 h, apoptosis was 92.2 ± 3.2 % vs. 61.2 ± 5.9 % control
measured by this method (Figure 4.7B). The time course for 1 mM DEA/NO was
significantly different from control (p < 0.0001, 2-way ANOVA). Examples of
histograms achieved when apoptosis was assessed by this method are shown in
Figure 4.7A, although a clear leftward shift in fluorescence is only evident at 20 h.
By propidium iodide intercalation, a clear difference between treated and
untreated cells was again apparent by 4 h, with 25.6 ± 4.5 % of cells having
hypodiploid DNA content, representing internucleosomal DNA fragmentation,
compared to 7.7 ± 2.5 % in untreated cells. The acceleration of the rate of apoptosis
by 1 mM DEA/NO was evident throughout the remainder of the culture period (p <
0.01, 2-way ANOVA), although the extent of this induction reduced towards 20 h, as
apoptosis measured by this technique slowed down and was 'caught up' by control
cells, so that by 20 h, 67.7 ± 17.6 % of DEA/NO-treated cells were measured as
apoptotic compared to 61.2 ± 5.9 % in control cells (Figure 4.8B). The increase in
internucleosomal DNA fragmentation is plainly evident in the flow cytometry
histograms at both 8 and 20 h (Figure 4.8A).
Similar to the anti-apoptotic effects of low concentrations of
DEA/NO, 0.1 pM SPER/NO inhibited neutrophil apoptosis over a comparable time
course. As for DEA/NO, the inhibition of morphological apoptosis did not become
apparent until 16 h of culture and beyond, and the time course was not significantly
different from control (p > 0.05, two-way ANOVA) over the 20 h. After 16 h, 45.8 ±
7.3 % of SPER/NO-treated cells showed the characteristic morphology of apoptosis
compared to 54.0 ± 8.3 % control (Figure 4.9), and at 20 h, a significant difference
from control apoptosis was seen (p < 0.05, two-tailed paired t test).
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Figure 4.9 Time course studies for effects of SPER/NO on neutrophil apoptosis
assessed by morphology. Neutrophils (4.5 x 106 cells/ml) were incubated in
Iscove's MDM supplemented with 10 % autologous serum for 1 - 20 hours in the
absence or presence of SPER/NO (0.1 pM or 1 mM), then apoptosis was
assessed by morphology. Results represent mean ± SEM from n = 3-6
experiments. Asterisks represent significant (p < 0.01) difference from control
(open symbols) time course by two-way ANOVA.
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Figure 4.10 Time course studies for effects of SPER/NO on neutrophil apoptosis
assessed by Annexin V binding. Neutrophils (4.5 x 10® cells/ml) were incubated in
Iscove's MDM supplemented with 10 % autologous serum for 1 - 20 hours in the
absence or presence of SPER/NO (0.1 |A/I or 1 mM), then apoptosis was
assessed by Annexin V binding (A) Typical flow cytometry traces showing
percentage PS exposure in neutrophils after 8 and 20 hours (B) Graph showing
changes in PS exposure over time in control cells or neutrophils treated with
SPER/NO. Results represent mean ± SEM from n = 3-6 experiments. Data did
not reach statistical significance.
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Figure 4.11 Time course studies for effects of SPER/NO on neutrophil apoptosis
assessed by CD16 shedding. Neutrophils (4.5 x 106 cells/ml) were incubated in Iscove's
MDM supplemented with 10 % autologous serum for 1 - 20 hours in the absence or
presence of SPER/NO (0.1 pM or 1 mM), then apoptosis was assessed by CD16
shedding (A) Typical flow cytometry traces showing percentage CD16 shedding in
neutrophils after 8 and 20 hours (B) Graph showing changes in CD16 shedding over
time in control cells or neutrophils treated with SPER/NO. Results represent mean ±
SEM from n = 3-6 experiments. Asterisks represent significant (p < 0.05) difference
from control (open symbols) time course by two-way ANOVA.
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Figure 4.11 Time course studies for effects of SPER/NO on neutrophil apoptosis
assessed by CD16 shedding. Neutrophils (4.5 x 106 cells/ml) were incubated in Iscove's
MDM supplemented with 10 % autologous serum for 1-20 hours in the absence or
presence of SPER/NO (0.1 pM or 1 mM), then apoptosis was assessed by CD16
shedding (A) Typical flow cytometry traces showing percentage CD16 shedding in
neutrophils after 8 and 20 hours (B) Graph showing changes in CD16 shedding over
time in control cells or neutrophils treated with SPER/NO. Results represent mean ±
SEM from n = 3-6 experiments. Asterisks represent significant (p < 0.05) difference
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Annexin V binding studies showed a small inhibition of apoptosis by 0.1 pM
SPER/NO by 16 h (48.1 ± 4.5% vs. 54.1 ± 4.3 % control), which was not much more
apparent, but was significant, by 20 h (60.1 ± 1.9 % vs. 67.9 ± 2.7 %; Figure 4.1 OB).
Overall, the time course in 0.1 pM SPER/NO-treated neutrophils was not
significantly different from that seen in control cells ( p > 0.05, 2-way ANOVA), but
at the 20-h time point a significant difference was seen (p < 0.05, two-tailed paired t
test). Flow cytometry histograms show virtually no difference in PS exposure at 8 h,
but an apparent inhibition by 20 h (Figure 4.1OA).
No significant inhibition was observed using CD16 shedding as a measure of
apoptosis (p > 0.05, two-way ANOVA), although a general inhibitory tend was
visible, with SPER/NO-treated neutrophils showing 59.1 ± 5.2 % apoptosis after 20 h
and control cells 61.2 ± 5.9 % (Figure 4.1 IB). The examples of flow cytometry
histograms show no inhibition at 8 h but some inhibition at 20 h by this technique
(Figure 4.11A).
Inhibition measured by PI intercalation showed the clearest evidence of
inhibition, becoming apparent after 16 h (43.5 ± 7.5 % vs. 49.0 ± 7.0 % control) and
reaching levels of 50.5 ± 10.2 % by 20 h, compared to 61.5 ± 9.8 % in control cells,
although this data did not reach significance (p > 0.05, two-way ANOVA; Figure
4.12B). However, assessment of the 20-h time point vs. control by two-tailed paired
t test showed a significant difference (p < 0.05). Flow cytometry histograms shown
in Figure 4.12A demonstrate no difference in DNA fragmentation from control in 0.1
pM SPER/NO-treated cells at 8 h but a marked inhibition at 20 h.
The induction of neutrophil apoptosis initiated by 1 mM SPER/NO occurred
at a slower rate than with an equivalent concentration ofDEA/NO. Morphologically,
increased apoptosis was observed after 16 h, with 66.4 ±3.9 % of cells having
undergone apoptosis compared to 54.0 ± 8.3 % apoptosis detectable in control cells.
This effect was more pronounced by 20 h, at which time 89.5 ±5.1 % of SPER/NO-
treated cells were apoptotic vs. 53.1 ± 2.8 % control (Figure 4.9). The overall time
course was found to be significantly different from control (p < 0.01, two-way
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ANOVA).
PS exposure was again the least obvious event of apoptosis in NO-treated
cells, with an increase in apoptosis only seen at 20 h (82.0 ± 2.7 % vs. 67.9 ± 2.7 %
control; Figure 4.1 OB). The time course was found not to be significantly different
from control over the 20 h (p > 0.05, 2-way ANOVA), but results obtained at the 20-
h time point were significantly different from control (p < 0.05, two-tailed paired t
test). This phenomenon is clearly shown in the examples of flow cytometry
histograms, in which no difference from control is visible at 8 h, but a marked
increase is evident at 20 h (Figure 4.1 OA).
A general pro-apoptotic trend for 1 mM SPER/NO was achieved when
apoptosis was measured by CD16 shedding, reaching levels of 76.6 ± 3.8 % CD16
shedding compared to control levels of 61.2 ± 5.9 % at 20 h (p < 0.05, two-way
ANOVA; Figure 4.1 IB). The leftward shift in fluorescence in cells exposed to 1
mM SPER/NO compared to control can be seen at both 8 and 20 h in the examples of
flow cytometry histograms shown in Figure 4.11A.
However, unexpected results were obtained with 1 mM SPER/NO when
apoptosis was assessed by PI intercalation. Figure 4.12B shows that
internucleosomal DNA fragmentation was decreased compared to control throughout
the 20-h time course, with levels of hypodiploid cells measured being remarkably
similar to those observed with 0.1 pM SPER/NO. At the 20-h time point, control
levels of apoptosis were 61.5 ± 9.8 %, whereas the percentage of cells with
hypodiploid DNA content in SPER/NO-treated cells was 48.5 ± 13.5 % (Figure
4.12B). However, although this inhibition was clearly visible, it was not statistically
significant (p > 0.05, two-way ANOVA). Flow cytometry histograms shown in
Figure 4.12A illustrate the inhibition of DNA fragmentation by ImM SPER/NO,
which is particularly prominent at 8 h, although this effect was not seen on every
replication of the experiment.
Concentrations of 30 and 100 pM were used to study the time-course of
induction of neutrophil apoptosis by the ONOO" donor, GEA 3162, as these
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concentration were shown to be effective at inducing apoptosis in the concentration-
response studies. Morphological studies of apoptosis showed a concentration-
dependent increase in the percentage of cells displaying the characteristic changes of
apoptosis compared to control cells. With the lower concentration of GEA 3162,
increased apoptosis from control was apparent at 8 h culture and beyond, with levels
of apoptosis measured as 27.5 ± 12.5 % vs. 9.8 ± 6.4 % control at 8 h, rising to 67.5
± 6.2 % vs. 53.1 ± 2.8 % control by 20 h (p < 0.05, two-way ANOVA). However,
acceleration of apoptosis was visible by 4 h with 100 pM GEA 3162 (20.6 ± 11.9 %
compared to 1.0 ± 0.1 % control). This effect reached a maximum of 93.6 ± 3.0 %
vs. 53.1 ± 2.8 % control by the end of the culture period (p < 0.0001, two-way
ANOVA; Figure 4.13).
As observed in the concentration-response studies, assessment of apoptosis
by Annexin V binding showed no significant difference of GEA 3162-treated
neutrophils from control cells at 20 h (p > 0.05, two-way ANOVA), for both
concentrations of GEA 3162. However, increased PS exposure was observed at
earlier time points with 100 pM GEA 3162, although this was a small effect
compared to that observed by morphology; the pro-apoptotic effect was most clearly
visible at 4 h, when 12.8 ± 9.7 % of cells had exposed PS, compared to 1.9 ± 0.5 %
in control cells (Figure 4.14B). The enhancement of PS exposure at early time points
followed by lack of effects at later time points is clearly shown in the flow cytometry
histograms shown in Figure 4.14A, in which increased fluorescence is seen in cells
treated with both 30 and 100 pM GEA 3162 at 8 h, but virtually identical histograms
to control are seen after 20 h culture.
Once again, studies investigating the extent ofCD16 shedding showed a good
correlation with morphological observations of apoptosis. The increase in CD16
shedding compared to control was evident after 4 h culture, was maintained
throughout the culture period, and was clearly concentration-dependent (p < 0.05,
two-way ANOVA, for 30 mM GEA 3162; p < 0.0001, two-way ANOVA, for 100
pM GEA 3162). At the 4-h time point, control apoptosis was 4.1 + 0.9 %, but
apoptosis measured in neutrophils exposed to 30 pM GEA 3162 was 10.8 + 6.0
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Figure 4.13 Time course studies for effects of GEA 3162 on neutrophil apoptosis
assessed by morphology. Neutrophils (4.5 x 106 cells/ml) were incubated in
Iscove's MDM supplemented with 10 % autologous serum for 1-20 hours in the
absence or presence of GEA 3162 (30 or 100 pM), then apoptosis was assessed
by morphology. Results represent mean ± SEM from n = 3-6 experiments.
Asterisks represent significant (* p < 0.05; *** p < 0.0001) difference from control
(open symbols) time course by two-way ANOVA.
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Figure 4.14 Time course studies for effects of GEA 3162 on neutrophil apoptosis
assessed by Annexin V binding. Neutrophils (4.5 x 106 cells/ml) were incubated in
Iscove's MDM supplemented with 10 % autologous serum for 1 - 20 hours in the
absence or presence of GEA 3162 (30 or 100 pM), then apoptosis was assessed
by Annexin V binding (A) Typical flow cytometry traces showing percentage
Annexin V binding in neutrophils after 8 and 20 hours (B) Graph showing changes
in PS exposure over time in control cells or neutrophils treated with GEA 3162.
Results represent mean ± SEM from n = 3-6 experiments. Data did not reach
statistical significance.
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Figure 4.15 Time course studies for effects of GEA 3162 on neutrophil apoptosis
assessed by CD16 shedding. Neutrophils (4.5 x 10® cells/ml) were incubated in Iscove's
MDM supplemented with 10 % autologous serum for 1-20 hours in the absence or
presence of GEA 3162 (30 or 100 pM), then apoptosis was assessed by CD16 shedding
(A) Typical flow cytometry traces showing percentage CD16 shedding in neutrophils after
8 and 20 hours (B) Graph showing changes in CD16 shedding over time in control cells
or neutrophils treated with GEA 3162. Results represent mean ± SEM from n = 3 - 6
experiments. Asterisks represent significant (* p < 0.05; *** p < 0.0001) difference from
control (open symbols) by two-way ANOVA.
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Figure 4.16 Time course studies for effects of GEA 3162 on neutrophil apoptosis
assessed by PI intercalation. Neutrophils (4.5 x 106 cells/ml) were incubated in
Iscove's MDM supplemented with 10 % autologous serum for 1 - 20 hours in the
absence or presence of GEA 3162 (30 or 100 pM), then apoptosis was assessed by
PI intercalation (A) Typical flow cytometry traces showing percentage hypodiploid cells
in neutrophils after 8 and 20 hours (B) Graph showing changes in PI intercalation over
time in control cells or neutrophils treated with GEA 3162. Results represent mean ±
SEM from n = 3-6 experiments. Asterisks represent significant (p < 0.0001) difference
from control (open symbols) time course by two-way ANOVA.
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%, and that in cells treated with 100 pM of this compound was 31.5 ± 10.8 %.
Differences from control levels of apoptosis were highest at the 8 h time point, when
30 pM GEA 3162 produced 35.6 ± 14.4 and 100 pM produced 72.0 ± 15.1 %
apoptosis, whereas control apoptosis was just 13.6 ± 6.4 %. By 20 h, the induction of
apoptosis was less marked; 73.2 ± 4.9 % and 89.5 + 3.7 % apoptosis was achieved by
30 and 100 pM GEA 3162 respectively and untreated cells showed 61.2 ± 5.9 %
CD16 shedding (Figure 4.15B). These effects are demonstrated in the typical flow
cytometry histograms, in which GEA 3162 produces a concentration-dependent
leftward shift in fluorescence, representing the shedding of CD16 from the cell
surface, and this effect is more pronounced at 8 h than at 20 h (Figure 4.15A).
Interestingly, a paradoxical concentration-dependent inhibition of
internucleosomal DNA fragmentation by GEA 3162 was observed by PI
intercalation, which was more pronounced than that seen with SPER/NO. With 30
pM GEA 3162, the percentage of hypodiploid cells followed that seen in control
cells closely until the 16 h time point when inhibition became apparent (40.1 ± 9.5 %
vs. 49.0 ± 7.0 % control) and reached a maximum after 20 h (43.6 ± 12.9; Figure
4.16B). Although this time course failed to reach significance from control (p >
0.05, two-way ANOVA), the extent of DNA fragmentation in response to 30 mM
GEA 3162 was significantly different from control (p < 0.05, two-tailed paired t
test).
The inhibition seen with 100 pM GEA 3162 became evident after 8 h (6.5 ±
2.2 % compared to 15.7 ± 7.0 % in control cells), and by 20 h was 27.1 ± 8.5 %,
whereas DNA fragmentation in control cells was 61.5 ± 9.8 %. The overall time
course in response to 100 mM GEA 3162 was significantly different from control (p
< 0.0001, two-way ANOVA; Figure 4.16B). The examples of flow cytometry
histograms in Figure 4.16A show inhibition of internucleosomal DNA fragmentation
by 100 pM GEA 3162 only at 8 h and both 30 and 100 pM GEA 3162 at 20 h.
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4.2.4 Effects of the ONOO' donor, SIN-1, on neutrophil apoptosis
In order to test whether the effect seen with GEA 3162 is a general ONOO"
effect or is specific to GEA 3162 itself, the known ONOO" donor, SIN-1 (1-3 mM)
was used at a 20-h time point. A concentration-dependent enhancement of
neutrophil apoptosis was seen in the presence of SIN-1; at 20 h, 1 mM of this
compound caused 64.5 ± 7.4 % morphological apoptosis and 3 mM caused 74.9 ±
8.3 %, compared to control levels of 33.7 ± 4.3 % (p < 0.05, two-way ANOVA with
Bonferroni post-hoc test). Addition of SOD (50 U/ml) reversed this effect, taking the
level of apoptosis observed with 1 mM SIN-1 back down to 47.7 ± 4.1 % and that
seen with 3 mM to 45.0 ± 2.9 % (p > 0.05, two-way ANOVA with Bonferroni post-
hoc test; Figure 4.17).
Measurement of apoptosis by Annexin V binding produced the same results
as seen by morphology; 1 mM SIN-1 produced 58.9 ± 5.9 % PS exposure and 3 mM
produced 62.9 ± 1.8 %, compared to 30.2 ± 4.2 % control (p < 0.05, two-way
ANOVA with Bonferroni post-hoc test). Again, this induction of apoptosis was
reversible by 50 U/ml SOD, bringing apoptosis induced by 1 mM and 3 mM SIN-1
down to 38.6 ± 3.1 % and 44.9 ± 5.8 % respectively (p > 0.05 vs. untreated cells,
two-way ANOVA with Bonferroni post-hoc test; Figure 4.18B). Typical flow
cytometry histograms for assessment of apoptosis by Annexin V binding are shown
in Figure 4.18A.
Similarly, assessment of apoptosis by CD16 shedding showed the same
effects of SIN-1 on neutrophil apoptosis. Exposure of neutrophils to 1 mM SIN-1
gave 63.8 ±5.3 % apoptosis and to 3 mM SIN-1 gave 74.5 ± 7.8 %, whereas control
apoptosis as measured by this technique was 35.2 ± 3.2 % (p < 0.05, two-way
ANOVA with Bonferroni post-hoc test). Once again, the presence of 50 U/ml SOD
reversed the increased apoptosis observed with SIN-1; apoptosis with 1 mM and 3
mM SIN-1 in the presence of SOD was 44.4 ± 4.2 % and 41.8 ± 3.4 % respectively
(p > 0.05 vs. control, two-way ANOVA with Bonferroni post-hoc test; Figure
4.19B). Flow cytometry histograms shown in Figure 4.19A demonstrate this effect.
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Figure 4.17 Effect of SIN-1 on morphological apoptosis in human neutrophils.
Neutrophils (4.5 x 106 cells/ml) were incubated in Iscove's MDM supplemented
with 10 % autologous serum for 20 hours in the absence or presence of SIN-1 (1
or 3 mM) and the absence or presence of SOD (50 U/ml), then apoptosis was
assessed by morphology. Results represent mean ± SEM from n = 5
experiments. Two-way ANOVA revealed significant (p < 0.05) differences
between treatment groups, and asterisks represent significant (p < 0.05) difference
from control (without SOD) by Bonferroni post-hoc test.
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Figure 4.18 Effect of SIN-1 on Annexin V binding in human neutrophils.
Neutrophils (4.5 x 10® cells/ml) were incubated in Iscove's MDM supplemented
with 10 % autologous serum for 20 hours in the absence or presence of SIN-1 (1
or 3 mM) and the absence or presence of SOD (50 U/ml), then apoptosis was
assessed by Annexin V binding (A) Typical flow cytometry traces showing
percentage PS exposure in neutrophils after 20 hours (B) Graph showing changes
in PS exposure in control cells or neutrophils treated with SIN-1 ± SOD. Results
represent mean ± SEM from n = 5 experiments. Two-way ANOVA revealed
significant (p < 0.05) differences between treatment groups, and asterisks
represent significant (p < 0.05) difference from control (without SOD) by
Bonferroni post-hoc test.
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Figure 4.19 Effect of SIN-1 on CD16 shedding in human neutrophils. Neutrophils
(4.5 x 106 cells/ml) were incubated in Iscove's MDM supplemented with 10 %
autologous serum for 20 hours in the absence or presence of SIN-1 (1 or 3 mM)
and the absence or presence of SOD (50 U/ml), then apoptosis was assessed by
CD16 shedding (A) Typical flow cytometry traces showing percentage CD16
shedding in neutrophils after 20 hours (B) Graph showing changes in CD16
shedding in control cells or neutrophils treated with SIN-1 ± SOD. Results
represent mean ± SEM from n = 5 experiments. Two-way ANOVA revealed
significant (p < 0.05) differences between treatment groups, and asterisks
represent significant (p < 0.05) difference from control (without SOD) by
Bonferroni post-hoc test.
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Figure 4.20 Effect of SIN-1 on PI intercalation in human neutrophils. Neutrophils
(4.5 x 106 cells/ml) were incubated in Iscove's MDM supplemented with 10 %
autologous serum for 20 hours in the absence or presence of SIN-1 (1 or 3 mM)
and the absence or presence of SOD (50 U/ml), then apoptosis was assessed by
PI intercalation (A) Typical flow cytometry traces showing percentage hypodiploid
neutrophils after 20 hours (B) Graph showing changes in PI intercalation in control
cells or neutrophils treated with SIN-1 ± SOD. Results represent mean ± SEM
from n = 5 experiments. Two-way ANOVA revealed significant (p < 0.05)
differences between treatment groups, and asterisks represent significant (p <
0.05) difference from control (without SOD) by Bonferroni post-hoc test.
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Results obtained using PI intercalation as a measure of apoptosis provided the
most interesting observations; SIN-1 had the same inhibitory effect as GEA 3162 on
internucleosomal DNA fragmentation. A concentration-dependent decrease in the
percentage of hypodiploid cells was seen with SIN-1; 24.4 ± 2.4 % and 13.8 ± 2.3 %
apoptosis was seen with 1 mM and 3 mM of this compound respectively, compared
to 38.5 ±6.1 % in untreated cells (p < 0.05 two-way ANOVA with Bonferroni post-
hoc test). However, unlike other indices of apoptosis, the presence of SOD failed to
fully reverse the effects of SIN-1. In the presence of SOD (50 U/ml), apoptosis
levels were 31.3 ± 3.7 % and 15.8 ± 4.2 % with 1 mM and 3 mM SIN-1 respectively
(Figure 4.20), and the inhibition of DNA fragmentation remained significantly
different from control (p < 0.05, two-way ANOVA with Bonferroni post-hoc test).
4.3 Discussion
These experiments were carried out in order to compare the effects of pure
NO donors and ONOO" donors on neutrophil apoptosis and to examine the rates at
which these effects occur. Firstly, concentration-response studies were conducted to
examine how effective these compounds were at modifying the rate of neutrophil
apoptosis. Time course studies were then carried out to compare the rate at which
these compounds exerted their effects, and to determine whether NO and ONOO"
have different mechanisms of action. These studies were carried out using
morphology, Annexin V binding, CD16 shedding and propidium iodide (PI)
intercalation, as measures of apoptosis in order to determine whether events
associated with apoptosis proceed at different rates or simultaneously.
The dichotomous effects of NO on apoptosis are demonstrated in these
studies through the use of the diazeniumdiolate compounds, DEA/NO and
SPER/NO. Low concentrations of these compounds inhibited the rate of neutrophil
apoptosis (0.1 - 30 pM for DEA/NO and 0.1-3 pM for SPER/NO), as assessed by
morphology. Although several previous studies have demonstrated pro-apoptotic
effects of NO on neutrophils, this is the first time that an inhibitory effect has been
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shown. However, although significant, the inhibitory effect of these compounds
(particularly DEA/NO) is minimal, both in terms of the extent of inhibition (< 10%)
and the rate at which these effects are observed (16 h and later). This is especially
true when compared to the extent of inhibition observed with other inhibitors of
neutrophil apoptosis such as db-cAMP, LPS and GM-CSF. Overall, DEA/NO is
relatively inactive as an inhibitor of neutrophil apoptosis, and SPER/NO only slightly
more active. Both compounds produce a much more profound accelerating effect on
neutrophil apoptosis and are therefore more active in inducing apoptosis at higher
concentrations than they are at inhibiting this process.
Time-course studies failed to demonstrate a significant difference from
control by two-way ANOVA for either of these compounds by any of the techniques
used. However, this may be due to the delayed effects of these compounds, with
inhibition not being observed until 16 h or later. Indeed, statistical analysis of the
20-h time points (two-tailed paired t test) demonstrated a significant (p < 0.05)
difference between drug-treated and control cells at this time point for the majority of
techniques.
In contrast, neutrophil apoptosis was promoted by high concentrations of
these compounds (1 mM for DEA/NO and 300 pM - 1 mM for SPER/NO, as
assessed by morphology). This concurs with previous reports of biphasic actions of
NO. It has previously been proposed that low NO concentrations are likely to protect
cells from apoptosis, whereas higher concentrations are pro-apoptotic (Dimmeler and
Zeiher, 1997; Kim et al., 1999). The induction of apoptosis by high concentrations
of DEA/NO occurs much more rapidly than the inhibition seen with low
concentrations, suggesting that the differential effects of this compound do not
represent opposing effects on the same pathway. This is in agreement with the
published literature; protection from apoptosis by NO has been reported to be
mediated by cGMP in eosinophils (Beauvais et al., 1995), B lymphocytes (Genaro et
al., 1995), hepatocytes (Kim et al., 1997), neural cells (Fiscus, 2002), astrocytes
(Takuma et al., 2002), monocytic cells (Barsacchi et al., 2002), lymphoblastoid cells
(Gomes et al., 2002), keratinocytes (Weller et al., 2003) and trophoblast cells (Dash
et al., 2003), whereas promotion of apoptosis has been shown to be cGMP-
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independent in smooth muscle cells (Nishio et al., 1996), endothelial cells (Shen et
al., 1998), neutrophils (Ward et al., 2000) and eosinophils (Zhang et al., 2003b). It is
possible that low concentrations stimulate the formation of cGMP, which mediates
anti-apoptotic actions of NO, but that higher concentrations initiate alternative pro-
apoptotic pathways that override the cGMP effect and drive the cells into
programmed cell death.
This hypothesis is supported by observations in astrocytes, in which a
biphasic effect of the NO donor, [N-ethyl-2-(l-ethyl-hydroxy-2-nitrosohydrazino)-
ethanamine] (NOC12), on apoptosis was seen. Although inhibition of cGMP
abolished the protective effects of low concentrations in this cell type, it exacerbated
the toxic effects of higher concentrations, suggesting that cGMP activation partially
abrogates the pro-apoptotic effects of NO (Takuma et al., 2002). Additionally,
cGMP-mediated activation of JNK by NO has been implicated as having a role in
delaying and reducing the extent of NO-induced apoptosis in cardiac myocytes
(Andreka et al., 2001), and sGC activation by NO has also been implicated in
limiting NO-induced damage in neural cells (Fiscus, 2002). On the other hand, both
inhibition and induction of neutrophil apoptosis achieved using 0.1 pM and 1 mM
SPER/NO respectively were only visible at time points of 16 h and beyond by most
techniques. Therefore, the pro- and anti-apoptotic effects of SPER/NO may reflect
contrasting actions on the same pathway.
The slower effects of the diazeniumdiolates do not become apparent until 16
h of culture, therefore it is possible that these effects are mediated through regulation
of gene expression, as the NO released from these compounds would not persist until
these times in culture, particularly in the case of the fast-releasing diazeniumdiolate,
DEA/NO. This is also true of the pro-apoptotic actions of 1 mM SPER/NO.
However, the fast effects of 1 mM DEA/NO are seen by 4 h, making it possible that
the induction of apoptosis by this compound is independent of gene transcription.
The rate at which NO is released from the diazeniumdiolates affects the pro-
apoptotic actions of these compounds; fast release of NO from DEA/NO (from
which NO generation is likely to be complete in under 1 h) causes a rapid induction
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of apoptosis, whereas the more sustained release of lower concentrations ofNO from
the same concentration of SPER/NO (approximately a 12-h duration ofNO release)
promotes apoptosis at a much slower rate.
In contrast, the rate of NO release does not influence the rate at which the
inhibition of neutrophil apoptosis occurs, with 0.1 p.M of both DEA/NO and
SPER/NO producing inhibition of apoptosis at 16 h and later. However, the slower
NO release from 0.1 pM SPER/NO is more effective at inhibiting neutrophil
apoptosis than the rapid burst of NO from 0.1 pM DEA/NO. The inhibition of
apoptosis at 20 h is more pronounced with SPER/NO than with DEA/NO; a
difference of only 5.9 % from control morphological apoptosis is achieved with 0.1
pM DEA/NO, whereas a difference of 10.2 % apoptosis is seen with the same
concentration of SPER/NO, showing that SPER/NO is a slightly more effective
inhibitor of neutrophil apoptosis. On the other hand, an inhibitory effect of DEA/NO
is observed with higher concentrations of DEA/NO; with this compound, inhibition
ofmorphological apoptosis is seen with concentrations of 30 pM and below, whereas
with SPER/NO, the concentration has to go down to 3 pM before a statistically
significant difference from control is seen.
The induction of apoptosis by the diazeniumdiolates occurs at lower
concentrations of SPER/NO than DEA/NO; a significant difference was seen with
300 pM of this compound compared to 1 mM with DEA/NO. However, 1 mM
DEA/NO produced 100 % apoptosis of neutrophils by 20 h, whereas the same
concentration of SPER/NO only gave 89.5 % apoptosis. The time course of the
induction of apoptosis by 1 mM DEA/NO is more highly significant than that seen
with 1 mM SPER/NO for apoptosis measured by morphology (p < 0.0001 vs. p <
0.01) and CD 16 shedding (p < 0.0001 vs. p < 0.05). Therefore, very high
concentrations of DEA/NO have a more effective pro-apoptotic effect than seen with
SPER/NO and a large burst of NO is marginally more effective than chronic
exposure to NO.
In contrast to the 'pure' NO donors, ONOO" released from GEA 3162 did not
inhibit neutrophil apoptosis, even at low concentrations, suggesting that this effect of
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NO is not shared by ONOO". However, GEA 3162 induced apoptosis at
concentrations lower than with the diazeniumdiolates (30 pM and above), and this
effect was concentration-dependent, as results obtained with 100 pM GEA 3162
were more highly significant than with 30 pM GEA 3162 when induction of
apoptosis was assessed by morphology (p < 0.0001 vs. p < 0.05) or CD16 shedding
(p < 0.0001 vs. p < 0.05). This is consistent with previous findings for this
compound on neutrophil apoptosis (Ward et al., 2000). The rate of induction of
apoptosis followed similar kinetics to 1 mM DEA/NO, with a difference from control
being seen by 4 h when apoptosis was measured by most methods. Indeed, the levels
of morphological apoptosis detected at all time points were remarkably similar for
100 pM GEA 3162 and 1 mM DEA/NO, with the diazeniumdiolate producing
marginally higher levels of apoptosis.
For diazeniumdiolate compounds, the four independent events of neutrophil
apoptosis (morphological changes, PS exposure, CD16 shedding and DNA
fragmentation) occurred virtually simultaneously, with no single event occurring
noticeably before the others. This is in agreement with observations using cultured
cardiomyocytes treated with agonistic anti-Fas antibody, in which nuclear
condensation and DNA fragmentation occurred simultaneously (Takemura et al.,
2001). However, it is at odds with observations in rat ventricular myocytes, in which
PS exposure preceded DNA fragmentation in response to staurosporine (Rucker-
Martin et al., 1999) and in a number of cell types, including neutrophils, in which PS
exposure was found to trail other apoptotic events, such as CD16 shedding (Frey,
1997). Staurosporine treatment of eosinophils led to apoptotic morphological
changes which were visible before evidence of PS exposure (Walsh et al., 1998) and
studies in HL-60 cells showed that PS exposure was followed by morphological
observations of apoptosis and DNA fragmentation sequentially in response to
etoposide or cisplatin (Kravtsov et al., 1999). The temporal regulation of apoptotic
events therefore appears to be dependent upon both the cell type and the initiating
stimulus.
The inhibition of DNA fragmentation produced by GEA 3162 occurred at
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later time points than the induction of the other apoptotic events. By Annexin V
binding, increased apoptosis was only observed at early time points and was not
different from control at later time points. The reason for this discrepancy is unclear,
but it is consistent with results obtained by Frey, in which aged neutrophils showed
complete CD 16 shedding, whilst PS exposure only occurred in a subset of
neutrophils (Frey, 1997). It is notable that in some conditions, Annexin V binding
gave the least apparent indication of modification of apoptosis by NO or ONOO"
donors, in that differences were smaller or did not appear until later time points than
with other methods. This suggests that a proportion of neutrophils are relatively
resistant to the exposure of PS on the outer cell surface, and that this technique is not
ideal for the assessment of neutrophil apoptosis. For GEA 3162 and 1 mM
DEA/NO, CD 16 shedding correlated most closely with morphological observations,
and for 1 mM SPER/NO, Annexin V binding gave levels of apoptosis closest to
morphology. Inhibition of apoptosis by 0.1 pM DEA/NO was most profoundly
apparent using PI intercalation to assess apoptosis, whereas with SPER/NO,
morphological assessment of apoptosis gave the clearest indication of inhibition.
A paradoxical inhibition of DNA fragmentation was observed using
SPER/NO and GEA 3162. However, the shorter-lasting NO donor, DEA/NO, failed
to inhibit this process. The differential effects of the two diazeniumdiolates is likely
to be related to the half-lives of these two compounds. It is possible that NO from
diazeniumdiolates has to combine with neutrophil-derived O2" to form peroxynitrite
in order to exert an inhibitory effect. It is unlikely that O2" levels would be very high
in cultured neutrophils during the time that it takes DEA/NO to completely release
all its bound NO (less than 1 h), therefore there is little potential for ONOO"
generation as the presence of these two molecules is unlikely to coincide temporally.
In contrast, NO from SPER/NO is generated over a 12-h period, during which time
the levels of spontaneously-generated O2" in neutrophils could become sufficiently
high to allow significant ONOO" formation, as free NO and O2" could potentially be
present simultaneously within the neutrophils. Alternatively, ONOO" formation
could occur with both DEA/NO and SPER/NO, but the inhibitory effect may occur at
the level of a relatively late event of the DNA fragmentation pathway, such as
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inhibition of active caspase 3, and therefore be dependent upon the availability of
ONOO" at the time of activation of this enzyme, which is feasible with SPER/NO but
less so with DEA/NO.
The inhibitory effect on DNA fragmentation was more profound with the
ONOO" donor, GEA 3162 than with SPER/NO. This observation is consistent with
the above hypothesis, as GEA 3162 is a generator of ONOO" through simultaneous
release ofNO and O2", therefore NO levels are matched by levels of O2" and ONOO"
formation will be maximal. On the other hand, NO from SPER/NO would have to
combine with O2" from neutrophils to form ONOO". Thus, the formation of ONOO"
using SPER/NO is likely to be limited by the relative concentrations of the two
species; it is highly unlikely that a large proportion of the free NO from SPER/NO
would be converted to ONOO", therefore ONOO" levels would be lower than with
GEA 3162, and inhibition would be less pronounced.
The known ONOO" donor, SIN-l, was used to examine whether this effect is
exclusive to GEA 3162, or is a common phenomenon of neutrophil exposure to
ONOO". These studies confirmed the inhibition of DNA fragmentation by ONOO"
donors, despite enhancement of various other characteristic events of neutrophil
apoptosis. As for GEA 3162, the inhibitory effect of SIN-l on internucleosomal
DNA fragmentation was concentration-dependent. This inhibition was not fully
reversible by SOD, which converts O2" to H2O2, thus reducing the availability of O2"
for combination with NO to form ONOO". This likely suggests that only a small
amount of ONOO" is required to be formed in order to inhibit DNA fragmentation.
As previously mentioned, the reaction kinetics for the formation of ONOO" from NO
and O2" are 3 times faster than those for the dismutation of O2" by SOD. Therefore,
even in the presence of SOD, some ONOO" is still likely to be formed, and this may
be sufficient to influence the DNA fragmentation pathway. These surprising
findings demonstrate that different events of neutrophil apoptosis may be dissociated
from each other and, therefore, may be differentially regulated. Inhibition of DNA
fragmentation has previously been reported by one group, who noted that low
concentrations of ONOO" promote DNA fragmentation through inhibition of poly
(ADP-ribose) synthetase (PARS) in HL60 cells, via a caspase 3 dependent
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mechanism, but that concentrations of 60 pM ONOO" actually inhibit this process
(Virag et al., 1998).
Internucleosomal DNA fragmentation has been reported to be a definitive
event of apoptotic cell death, and several studies have used this event as the sole
determinant of the level of apoptosis. However, the present studies show that several
different apoptotic events should routinely be measured, as assessment of the extent
ofDNA fragmentation may not accurately reflect the level of this form of cell death.
The dissociation of DNA fragmentation from other events of apoptosis has
previously been reported in other cell types, under various experimental conditions.
Xu et al demonstrated the dissociation of apoptotic events from DNA fragmentation
in a hepatoma cell line. DNA fragmentation induced by c-myc was dependent upon
zinc and was only observed in serum-free conditions (Xu et al., 1996). In contrast,
zinc has been shown to inhibit endonuclease activity in peripheral blood
lymphocytes, in which treatment with H2O2 induced apoptotic cell death without
DNA fragmentation (Marini and Musiani, 1998). It has also been shown that nuclear
condensation characteristic of apoptosis does not require DNA fragmentation in
order to occur. Transformed Jurkat T cells or TF-1 cells overexpressing caspase-
resistant ICAD exhibited nuclear condensation in the absence ofDNA fragmentation
in response to staurosporine, etoposide, UV or gamma radiation (Jurkats) or GM-
CSF withdrawal in TF-1 cells (Sakahira et al., 1999; Mcllroy et al., 1999). Neuronal
PC 12 cells treated with activated microglia undergo apoptosis, and overexpression of
Bcl-2 in these cells caused morphological changes of cell death without DNA
fragmentation, which was ascribed to a non-apoptotic form of cell death (Tanabe et
al., 1999). DNA laddering was absent in three strains of MCF-7 breast cancer cells
treated with doxorubicin, despite increased apoptosis (Gooch and Yee, 1999).
Oligonucleosomal DNA fragmentation can also be inhibited in hematopoietic cells
exposed to hyperosmotic shock by inhibition of CI" efflux (Rasola et al., 1999).
PC 12 neurons with caspase 3 knocked out were induced to undergo apoptosis by K+
deprivation, although in contrast to wild type cells, DNA fragmentation and
chromatin condensation were absent from apoptosis in these cells, suggesting that
caspase 3 is required for these apoptotic events in this cell type, but not for apoptotic
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cell death per se (D'Mello et al., 2000). Furthermore, caspase 3 was shown to be
critical for DNA fragmentation and nuclear condensation in MCF-7 breast carcinoma
cells in response to H2O2, although caspase 3 null cells still exposed PS exposure and
underwent apoptotic death, providing further evidence for the dissociation of DNA
fragmentation from other apoptotic events (Kim et al., 2000). Upregulation of
catalase led to inhibition of caspase 3 activation and DNA fragmentation in PC 12
cells in response to H2O2 but was not sufficient to inhibit death (Jiang et al., 2001).
Apoptosis in the absence of DNA fragmentation was also observed in cultured
• • • • 2"b r\ 2"b
cardiomyocytes in response to an agonistic anti-Fas antibody when Ca /Mg
dependent endonuclease was blocked using excess zinc (Takemura et al., 2001). The
neuroblastoma cell line, IMR-5, also underwent apoptosis without DNA
fragmentation on exposure to staurosporine, and this was attributed to loss of CAD
protein during apoptosis, as DNA fragmentation was observed on overexpression of
human recombinant CAD (Yuste et al., 2001). Therefore, several authors have
advised against single parameter detection of apoptotic cell death (Frey, 1997;
Gooch and Yee, 1999; Kravtsov et al., 1999). However this is the first time that
such a phenomenon has been shown and studied in detail in neutrophils.
To summarise, 'pure' NO donors exert differential effects upon neutrophil
apoptosis, in which low concentrations delay but high concentrations enhance this
form of cell death, although the inhibitory effect is modest (< 10%). The rate of NO
release has an impact on the biological effects of the diazeniumdiolates; the fast-
releasing drug, DEA/NO, inhibits apoptosis to a lesser extent than seen with the
slower release from SPER/NO, but a significant effect is seen with higher
concentrations. In contrast, the induction of apoptosis requires a higher
concentration of DEA/NO than SPER/NO, but accelerates apoptosis to a greater
extent. Only the pro-apoptotic effect is observed with the ONOO" donor, GEA 3162.
Unexpectedly, both GEA 3162 and the longer-lasting pure NO donor, SPER/NO
produce an inhibition of DNA fragmentation compared to control cells, a
phenomenon previously reported in a number of different cell types, but not
previously in neutrophils.
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Chapter 5: Mechanisms of Action of NO /ONOO" donors
5.1 Introduction
This thesis has demonstrated both pro- and anti-apoptotic effects of NO
donors, and pro-apoptotic effects of ONOO" donors in neutrophils, however the
mechanisms through which these compounds act remain to be elucidated. A number
of mechanisms have been proposed to account for the regulatory effects of NO and
ONOO" in vitro, as discussed in previous chapters.
The DNA fragmentation pathway proceeds downstream of caspase 3
activation through the stress or death receptor-mediated pathways, but the sole role
for caspase 3 in this pathway is in the activation of a 40 kDa endonuclease, known as
caspase-activated DNase (CAD), or DNA fragmentation factor 40 (DFF40) (Liu et
al., 1997). CAD/DFF40 exists as a cytoplasmic complex with the inhibitor of
caspase-activated DNase (ICAD), which is known as DNA fragmentation factor 45
(DFF45) in humans. It is now known that ICAD/DFF45 acts as a chaperone
molecule as well as an endogenous inhibitor of CAD/DFF40 (Enari et al., 1998), and
its presence is essential during translation to ensure the correct folding and effective
DNase activity of CAD/DFF40 (Uegaki et al., 2000).
CAD/DFF40 is a protein of 342 amino acids and contains a nuclear
localisation signal (NLS), whereas ICAD exists as long and short forms, which differ
by the presence or absence of a NLS due to alternative splicing (Liu et al.,
1997;Samejima and Earnshaw, 2000). These two molecules interact via their CAD
domains, which are homologous regions of approximately 80 amino acids at the N-
termini of these two molecules via oppositely-charged amino acids within the beta
sheets of their respective CAD domains (Uegaki et al., 2000; Otomo et al., 2000).
Active caspase 3 is able to proteolytically cleave ICAD/DFF45 at two sites
(Liu et al., 1997; Sakahira et al., 1998). This releases the endonuclease,
CAD/DFF40, from inhibition and this molecule translocates to the nucleus, where it
degrades DNA into the internucleosomal fragments that produce a characteristic
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laddering pattern by gel electrophoresis. However, it has been suggested that
CAD/DFF40 may instead induce activity of a Ca2+/Mg2+-dependent endonuclease
and have no DNase activity of its own (Liu et al., 1997).
It has been shown that caspase 7 is also able to cleave ICAD/DFF45,
although the physiological significance of this is questionable (Wolf et al., 1999).
Others have demonstrated that ICAD/DFF45 can be cleaved by two caspases,
including caspase 3, but that cleavage by caspases other than caspase 3 fails to
activate CAD/DFF40 (Tang and Kidd, 1998). Once ICAD/DFF45 has been cleaved
by capsases, however, caspase activity is no longer required for the execution of
DNA fragmentation (Samejima et al., 1998). A 40 kDa human endonuclease, named
CPAN, that is inhibited by ICAD/DFF45 has been described, with the authors
suggesting that this may represent the human homologue of CAD/DFF40 (Halenbeck
et al., 1998).
Both caspases and CAD/DFF40 contain reduced cysteines that may be
essential for the correct functioning of these proteins (Mohr et al., 1997;Sakahira et
al., 2000), and NO and NO-related species have been shown to inhibit caspase
activity through thiol modification (Mohr et al., 1997). Dithiothreitol (DTT) is a
reducing agent that is able to maintain protein thiols in their reduced state.
Therefore, if GEA 3162 acts through oxidative modification of reduced cysteines
contained within essential proteins of the DNA fragmentation pathway, the effect
would be inhibited in the presence ofDTT.
The induction of apoptosis by NO has been proposed to be mediated by
ONOO" (Liaudet et al., 2000). This could be possible in neutrophils due to release of
O2" from these cells that could combine with NO from NO donors to generate
ONOO". Scavenging of O2" would therefore prevent DEA/NO-mediated neutrophil
apoptosis if ONOO" generation is necessary. Cu/Zn SOD dismutates extracellular
O2" to H2O2, therefore addition of SOD alongside DEA/NO would inhibit the
induction of neutrophil apoptosis ifONOO" generation occurs outside the cell.
The principal aim of these experiments was to make some progress towards
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the elucidation of the mechanism by which ONOO" from GEA 3162 is able to inhibit
DNA fragmentation in neutrophils undergoing apoptosis. This was done using the PI
intercalation method of assessing apoptosis, and Western blotting. Further
experiments were carried out to investigate the possibility that DEA/NO-induced
apoptosis is mediated by ONOO", using the multiple techniques for assessing
apoptosis described in Chapter 4.
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5.2 Results
5.2.1 Verification of the effects of NO/ONOO' donors on DNA fragmentation
in human neutrophils
The inhibitory effects ofGEA 3162 and SPER/NO, but not of DEA/NO were
verified using gel electrophoresis to detect the characteristic 'laddering' pattern of
fragmented DNA in apoptotic cells. DNA was isolated from neutrophils treated with
PBS (control); the fungal metabolite and known inducer of neutrophil apoptosis,
gliotoxin (positive control; 0.1 pg/ml); the cell permeable analogue of cAMP and
known inhibitor of neutrophil apoptosis, db-cAMP (negative control; 0.2 mM) or
NO/ONOO" donors at concentrations known to inhibit or induce apoptosis for 8 or 20
h. Morphological apoptosis was measured alongside the gel electrophoresis ofDNA,
in order to verify that the compounds were having the expected effects on neutrophil
apoptosis. In all cases, DNA fragmentation was visibly increased in gliotoxin-treated
cells and reduced in cells exposed to db-cAMP, and these results were borne out by
morphological observations of apoptosis; gliotoxin always increased apoptosis, while
db-cAMP always inhibited apoptosis compared to control.
The extent ofDNA laddering was very similar to control in cells treated with
0.1 pM DEA/NO but increased compared to control (PBS-treated) cells in
neutrophils exposed to 1 mM DEA/NO at both 8 (Figure 5.1A) and 20 (Figure 5.IB)
h. Apoptosis measured morphologically was 18.0 % with 0.1 pM and 91.4 % with 1
mM DEA/NO at 8 h compared to 16.3 % control, and at 20 h control apoptosis was
45.2 % compared to 25.9 % and 100 % apoptosis with 0.1 pM and 1 mM DEA/NO
respectively.
In cells treated with SPER/NO, an inhibition ofDNA laddering was seen with
both 0.1 pM and 1 mM of this compound at 8 h, with no fragmentation at all being
visible with 1 mM, although morphological apoptosis was 21.8 % with 0.1 pM and
22.4 % with 1 mM SPER/NO, compared to 17.4 % control (Figure 5.2A). At 20 h,
differences in the extent of laddering were not clearly visible with either
concentration of SPER/NO, in contrast to morphological apoptosis, which was 54.8
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M C G D0.1 ImM
8 HR
% Morphological Apoptosis
Control Gliotoxin db-cAMP 0.1 pM 1 mM
DEA/NO DEA/NO
16.3 84.8 0.8 18.0 91.4
Control Gliotoxin db-cAMP 0.1 pM 1 mM
DEA/NO DEA/NO
% Morphological Apoptosis 45.2 100 2.8 25.9 100
Figure 5.1 Effects of DEA/NO on DNA fragmentation. Neutrophils (4x10® cells) were
incubated for (A) 8 or (B) 20 hours with PBS (control; C), gliotoxin (0.1 pg/ml; G), db-
cAMP (0.2 mM; D) or 0.1 pM or 1 mM DEA/NO. DNA was then extracted and run on a
2% agarose gel containing ethidium bromide and visualised under u.v. light, along with
molecular weight markers (M). Morphological apoptosis of the neutrophil population
was assessed by cytospin alongside DNA fragmentation.
Chapter 5: Mechanisms ofAction 143
Regulation ofNeutrophil Apoptosis by NO and ONOO
8 HR
% Morphological Apoptosis 17.4
Control Gliotoxin db-cAMP 0.1 |iM 1 mM
SPER/NO SPER/NO
79.2 1.1 21.8 22.4
Control Gliotoxin db-cAMP 0.1 rrM 1 mM
SPER/NO SPER/NO
% Morphological Apoptosis 54.8 100 29.9 54.8 75.8
M C G D 0.1 ImM
20 HR
M C G D 0.1 ImM
Figure 5.2 Effects of SPER/NO on DNA fragmentation. Neutrophils (4 x 106 cells)
were incubated for (A) 8 or (B) 20 hours with PBS (control; C), gliotoxin (01 jxg/ml; G),
db-cAMP (0.2 mM; D) or 0.1 pM or 1 mM SPER/NO. DNA was then extracted and run
on a 2% agarose gel containing ethidium bromide and visualised under u.v. light, along
with molecular weight markers (M). Morphological apoptosis of the neutrophil
population was assessed by cytospin alongside DNA fragmentation.
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A M C G D 30 100
Control Gliotoxin db-cAMP 30 pM 100 pM
GEA 3162 GEA 3162
% Morphological Apoptosis 13.6 100 2.4 55.3 90.0
B
M C G D 30 100
20 HR
% Morphological Apoptosis
Control Gliotoxin db-cAMP 30 pM 100 pM
GEA 3162 GEA 3162
48.6 100 2.8 50.2 100
Figure 5.3 Effects of GEA 3162 on DNA fragmentation. Neutrophils (4 x 106 cells)
were incubated for (A) 8 or (B) 20 hours with PBS (control; C), gliotoxin (0.1 pg/ml; G),
db-cAMP (0.2 mM; D) or 30 or 100 pM GEA 3162. DNA was then extracted and run on
a 2% agarose gel containing ethidium bromide and visualised under u.v. light, along
with molecular weight markers (M). Morphological apoptosis of the neutrophil
population was assessed by cytospin alongside DNA fragmentation.
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% with 0.1 pM and 75.8 % with 1 mM SPER/NO, and 54.8 % in control cells
(Figure 5.2B).
No DNA fragmentation was detectable in neutrophils treated with either 30 or
100 pM GEA 3162 at 8 h, despite morphological observations of 55.3 % and 90.0 %
apoptosis respectively vs. 13.6 % control in these cells (Figure 5.3A). At 20 h, a
small amount of laddering was visible with 30 pM GEA 3162, although this was
clearly less evident than that seen in control cells. However, a total lack of DNA
fragmentation was still observed with 100 pM GEA 3162 at this time point.
Morphologically, 50.2 % apoptosis was seen with 30 pM of this compound, and 100
% with 100 pM, compared to 48.6 % control at 20 h (Figure 5.3B).
5.2.2 Effects ofDTT on inhibition of DNA fragmentation by GEA 3162
In order to test the hypothesis that the inhibition of DNA fragmentation in
cells treated with GEA 3162 occurs through the oxidative modification of critical
proteins in the DNA fragmentation pathway, neutrophils were pre-incubated with the
reducing agent, dithiothreitol (DTT) before being exposed to GEA 3162 for 20 h.
Apoptosis was then assessed by PI intercalation and again, morphological changes of
apoptosis were measured to verify the pro-apoptotic effects of GEA 3162 on
apoptosis. Figure 5.4A shows that treatment with GEA 3162 alone caused a
concentration-dependent inhibition of DNA fragmentation as measured by PI
intercalation. DNA fragmentation was seen in 61.6 ± 4.5 % of cells treated with
30pM GEA 3162 and in 49.5 ± 4.2 % of cells exposed to 100 pM (p < 0.05, one-way
ANOVA with Student-Newman-Keuls post-hoc test) compared to 69.0 ±4.1 %
control. However, the presence ofDTT (100 or 300 pM) reversed this inhibition in a
concentration-dependent manner back to control levels. Neutrophils pre-treated with
100 pM DTT showed 66.4 ± 3.9 % DNA fragmentation in response to 30 pM GEA
3162 and 55.9 ± 6.3 % with 100 pM of this compound, and treatment with 300 pM
DTT led to 68.4 ±5.1 % and 71.7 ± 3.8 % DNA fragmentation in response to 30 and
100 pM GEA 3162 respectively (p > 0.05 from control, one-way ANOVA with
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Figure 5.4 Effects of DTT on GEA 3162-induced inhibition of DNA fragmentation.
Neutrophils (4.5 x 106 cells/ml) were incubated for 20 hours with PBS (control) or 30
or 100 pM GEA 3162 in the absence or presence of dithiothreitol (DTT; 100 - 300
pM). Apoptosis was then assessed by (A) propidium iodide intercalation and (B)
morphology. Results represent mean ± S.E.M. from n = 7 experiments. Asterisks
represent significant (p < 0.05) difference from control by one-way ANOVA with
Student-Newman-Keuls post-hoc test.
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Student-Newman-Keuls post-hoc test). DTT had no effect on the levels of DNA
fragmentation in untreated cells (65.7 ± 4.8 % and 63.8 ± 5.5 % with 100 and 300
pM DTT respectively, compared to 69.0 ±4.1 % in cells not exposed to DTT; p >
0.05, one-way ANOVA with Student-Newman-Keuls post-hoc test).
In order to ensure that DTT itself does not affect the rate of apoptosis in
neutrophils, morphological assessment of apoptosis was carried out alongside PI
intercalation. These studies showed that the concentration-dependent induction of
neutrophil apoptosis by GEA 3162 was unaffected by the presence of DTT (Figure
5.4B). Morphological apoptosis induced by 30 and 100 pM GEA 3162 was 75.2 ±
3.4 % and 95.2 ± 3.1 % respectively compared to 68.9 ± 5.2 % control (p < 0.05
from control with 100 mM GEA 3162, one-way ANOVA with Student-Newman-
Keuls post-hoc test). In the presence of DTT (100 or 300 pM), levels of apoptosis
were 64.7 ± 4.6 % and 73.9 ± 5.9 % respectively in cells exposed to 30 pM GEA
3162, and 89.4 ± 4.1 % and 88.9 ± 3.3 % respectively in response to 100 pM GEA
3162. Apoptosis in cells exposed to DTT remained significantly different from
control apoptosis (p < 0.05, one-way ANOVA with Student-Newman-Keuls post-hoc
test) in the 100 pM GEA 3162-treated cells.
5.2.3 Effects ofDTT on gliotoxin-induced neutrophil apoptosis
These experiments were also carried out to determine the effects of DTT on
apoptosis in neutrophils induced to undergo apoptosis by gliotoxin. Following 20 h
exposure to gliotoxin, PI intercalation showed that 88.5 ± 5.0 % of cells had
hypodiploid DNA content compared to 62.5 ± 8.3 % control (p < 0.05, one-way
ANOVA with Dunnett's post-hoc test; Figure 5.5A). Morphologically, gliotoxin
induced 97.4 ± 1.5 % of cells to undergo apoptosis by 20 h compared to 61.6 ± 5.7
control (p < 0.05, one-way ANOVA with Dunnett's post-hoc test; Figure 5.5B). In
contrast to the effects seen with GEA 3162, however, the presence of DTT (100 or
300 pM) slightly inhibited DNA fragmentation in response to this compound in a
concentration-dependent manner; with 100 pM DTT, 83.9 ± 6.5 % of gliotoxin-
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Figure 5.5 Effects of DTT on gliotoxin-induced neutrophil apoptosis. Neutrophils
(4.5 x 106 cells/ml) were incubated for 20 hours with PBS (control) or gliotoxin (0.1
pg/ml) in the absence or presence of dithiothreitol (DTT; 100 - 300 pM). Apoptosis
was then assessed by (A) propidium iodide intercalation and (B) morphology.
Results represent mean ± S.E.M. from n = 6 experiments. Asterisks represent
significant (p < 0.05) difference from control by one-way ANOVA with Dunnett's post-
hoc test.
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Figure 5.6 Effects of DTT on gliotoxin-induced neutrophil apoptosis. Neutrophils
(4.5 x 106 cells/ml) were incubated for 4 hours with PBS (control) or gliotoxin (0.1
pg/ml) in the absence or presence of dithiothreitol (DTT; 100 - 300 pM). Apoptosis
was then assessed by (A) propidium iodide intercalation and (B) morphology.
Results represent mean ± S.E.M. from n = 4 experiments. Asterisks represent
significant (p < 0.05) difference from control by one-way ANOVA with Dunnett's
post-hoc test.
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treated cells had hypodiploid DNA content, and with 300 pM DTT, the level was
78.4 ± 7.8 %, but these levels remained significantly different from control levels (p
< 0.05, one-way ANOVA with Dunnetf s post-hoc test).
This inhibitory effect of DTT was not confined to DNA fragmentation; in
contrast to the lack of effect of DTT on morphological apoptosis induced by GEA
3162, this reducing agent slightly decreased the extent of morphological apoptosis in
cells exposed to gliotoxin. In the presence of 100 pM DTT, apoptosis was 94.2 ±5.3
%, and with 300 pM DTT, it was 88.5 ± 6.6 % (p < 0.05 from control, one-way
ANOVA with Dunnett's post-hoc test), whereas in gliotoxin-treated cells in the
absence of DTT, apoptosis was 97.4 ± 1.5 % and that in untreated cells was 61.6 ±
5.7 %.
The effects of DTT on gliotoxin-induced neutrophil apoptosis were also
examined at 4 h, when gliotoxin induces less than 100 % apoptosis, so that any
increase in DNA fragmentation in the presence of DTT, as seen with GEA 3162,
would be detectable. At this time point, gliotoxin produced 29.9 ± 9.0 % DNA
fragmentation compared to 8.3 ±3.1 % in control cells (p < 0.05, one-way ANOVA
with Dunnetf s post-hoc test; Figure 5.6A). As seen with the later time point, DTT
reduced the levels of DNA fragmentation in gliotoxin-treated cells, in contrast to the
effects observed with GEA 3162, and this effect was more pronounced than that
observed at 20 h. In the presence of 100 pM DTT, 12.1 ± 4.6 % of neutrophils had
hypodiploid DNA content, and with 300 pM DTT, this figure was as low as 6.9 ± 2.2
%, i.e. DNA fragmentation was reduced to control levels (p > 0.05 from control, one¬
way ANOVA with Dunnett's post-hoc test).
Consistent with the results achieved at 20 h, the presence of DTT also
inhibited morphological induction of apoptosis by gliotoxin at 4 h (Figure 5.6B).
Cells exposed to gliotoxin showed 44.6 ± 5.9 % apoptosis by morphology, compared
to 1.8 ± 0.3 % control (p < 0.05, one-way ANOVA with Dunnett's post-hoc test), but
levels of apoptosis were reduced to 11.1 ± 3.8 % and 3.9 ± 1.1 % with 100 and 300
pM DTT respectively (p > 0.05, one-way ANOVA with Dunnett's post-hoc test).
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5.2.4 Effects ofNO/ONOO' donors on breakdown of ICAD/DFF45
Breakdown of the inhibitor and chaperone molecule of CAD/DFF40,
ICAD/DFF45, was assessed by Western blotting. Whole cell neutrophil lysates were
made from freshly-isolated neutrophils and following 8 h culture in the presence of
gliotoxin (positive control), PBS (control), or NO/ONOO" donors at concentrations
known to induce neutrophil apoptosis. Lysates were assessed for ICAD/DFF45
levels using a mouse anti-human ICAD/DFF45 monoclonal antibody followed by a
goat anti-mouse IgG antibody conjugated to HRP, and developed using ECL fluid.
Figure 5.7 shows the resulting Western blot, in which levels of ICAD/DFF45 were
shown to be reduced in neutrophils treated with gliotoxin (Lane 2), 30 or 100 pM
GEA 3162 (Lanes 4 & 5) and with 1 mM DEA/NO (Lane 6). In contrast, levels were
unchanged from control, or possibly slightly higher than control, in cells exposed to
1 mM SPER/NO (Lane 7).
5.2.5 Effect of SOD on DEA/NO-mediated Neutrophil Apoptosis
In order to investigate the possibility that neutrophil apoptosis induced by
DEA/NO is mediated by the formation of ONOO", cells were coincubated with SOD
(50 U/ml) to scavenge any O2" released from neutrophils during incubation.
Measurement of apoptosis by all four techniques (morphology, Annexin V binding,
CD 16 shedding and PI intercalation) showed no effect of SOD (50 U/ml) on control
levels of apoptosis (p > 0.05, one-way ANOVA with Dunnett's post-hoc test).
DEA/NO (1 mM) induced apoptosis as measured by morphology (98.7 ±1.3 % vs
51.8 ± 10.2 % control, p < 0.05, one-way ANOVA with Dunnett's post-hoc test;
Figure 5.8). However, the presence of 50 U/ml SOD failed to affect the rate of
apoptosis in cells exposed to DEA/NO, with apoptosis in the presence of SOD
measured as 98.8 ± 1.2 % compared to 98.7 ± 1.3 % in the absence of SOD, and
remained significantly different from control (p < 0.05, one-way ANOVA with
Dunnett's post-hoc test).
Chapter 5: Mechanisms of Action 152
Regulation ofNeutrophil Apoptosis by NO and ONOO
Figure 5.7 Western blotting for ICAD/DFF45. Whole cell lysates were made
from freshly isolated neutrophils (Lane 1) or those treated for 8 hours with 0.1
pg/ml gliotoxin (Lane 2), PBS control (Lane 3), 30 pM GEA 3162 (Lane 4), 100
pM GEA 3162 (Lane 5), 1 mM DEA/NO (Lane 6) or 1 mM SPER/NO (Lane 7).
Blots were probed with antibody against ICAD/DFF45 (1:500 dilution) followed by
goat anti-mouse IgG-HRP secondary antibody (1:1250 dilution) and developed
onto photographic film using electrochemiluminescence (ECL) fluid.
Representative blot of two blots performed from one set of whole cell lysates.
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Similarly, apoptosis measured by Annexin V binding showed a lack of effect
of SOD (Figure 5.9). Annexin V binding in neutrophils exposed to 1 mM DEA/NO
was 92.4 ±3.2 %, whereas in control cells it was 63.0 ± 2.5 % (p < 0.05, one-way
ANOVA with Dunnett's post-hoc test). In the presence of SOD (50 U/ml), apoptosis
in response to DEA/NO was 94.8 ± 2.2 % and this was still significantly different
from control, despite the presence of SOD (p > 0.05, one-way ANOVA with
Dunnett's post-hoc test).
CD16 shedding in DEA/NO-treated cells was measured as 99.3 ± 0.3 %, but
was only 55.4 ± 5.9 % in untreated cells (p < 0.05, one-way ANOVA with Dunnett's
post-hoc test; Figure 5.10). Once again, the addition of SOD (50 U/ml) failed to
significantly inhibit the acceleration of apoptosis by DEA/NO; in the presence of
SOD, apoptosis was 98.6 ± 0.5 % (p < 0.05 from control, one-way ANOVA with
Dunnett's post-hoc test).
Measurement of apoptosis by PI intercalation again showed enhanced
apoptosis in response to 1 mM DEA/NO, with 80.3 ± 6.6 % of cells having
hypodiploid DNA content compared to 54.5 ± 7.9 % control, although this just failed
to reach significance (p > 0.05, one-way ANOVA with Dunnett's post-hoc test).
Coincubation with 50 U/ml SOD once again failed to inhibit the pro-apoptotic effect
of DEA/NO, with apoptosis measured as 78.9 ± 5.2 % (p > 0.05 from control, one¬
way ANOVA with Dunnett's post-hoc test; Figure 5.11).
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control DEA/NO
Figure 5.8 Effects of SOD on DEA/NO-induced neutrophil apoptosis as assessed
by morphology. Neutrophils (4.5 x 106 cells/ml) were incubated for 20 hours with
PBS (control) or DEA/NO (1 mM) in the absence or presence of SOD (50 U/ml).
Apoptosis was then assessed by morphology. Results represent mean ± S.E.M.
from n = 3 experiments. Asterisks represent significant (p < 0.05) difference from
control by one-way ANOVA with Dunnett's post-hoc test.
Chapter 5: Mechanisms ofAction 155
Regulation ofNeutrophil Apoptosis by NO and ONOO
□ control
control DEA/NO
Figure 5.9 Effects of SOD on DEA/NO-induced neutrophil apoptosis as assessed
by Annexin V binding. Neutrophils (4.5 x 106 cells/ml) were incubated for 20 hours
with PBS (control) or DEA/NO (1 mM) in the absence or presence of SOD (50 U/ml).
Apoptosis was then assessed by Annexin V binding. Results represent mean ±
S.E.M. from n - 3 experiments. Asterisks represent significant (p < 0.05) difference
from control by one-way ANOVA with Dunnetfs post-hoc test.
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Figure 5.10 Effects of SOD on DEA/NO-induced neutrophil apoptosis as assessed
by CD16 shedding. Neutrophils (4.5 x 106 cells/ml) were incubated for 20 hours with
PBS (control) or DEA/NO (1 mM) in the absence or presence of SOD (50 U/ml).
Apoptosis was then assessed by CD16 shedding. Results represent mean ± S.E.M.
from n = 3 experiments. Asterisks represent significant (p < 0.05) difference from
control by one-way ANOVA with Dunnett's post-hoc test.
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Figure 5.11 Effects of SOD on DEA/NO-induced neutrophil apoptosis as assessed
by PI intercalation. Neutrophils (4.5 x 10® cells/ml) were incubated for 20 hours with
PBS (control) or DEA/NO (1 mM) in the absence or presence of SOD (50 U/ml).
Apoptosis was then assessed by PI intercalation. Results represent mean ± S.E.M.
from n = 3 experiments.
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5.3 Discussion
Experiments using gel electrophoresis as an alternative measure of DNA
fragmentation confirmed the results previously obtained using propidium iodide
intercalation. DNA gels run following 8 h neutrophil incubation with NO/ONOO"
donors showed no difference from control or a small reduction in laddering with low
(0.1 pM) concentrations of the diazeniumdiolates and with a high (1 mM)
concentration of SPER/NO. In contrast, cells treated with a high (1 mM)
concentration of DEA/NO exhibited increased DNA laddering compared to control,
whereas those exposed to GEA 3162 (30 or 100 pM) showed no evidence of DNA
laddering.
Following 20 h incubation, no difference from control laddering was
observed in neutrophils exposed to 0.1 pM DEA/NO or SPER/NO (0.1 pM or 1
mM), and DNA fragmentation was increased in cells treated with 1 mM DEA/NO.
Cells treated with 30 pM GEA 3162 exhibited some DNA laddering, although this
was clearly less marked than in control cells. In the presence of 100 pM GEA 3162,
no DNA laddering was seen, even at 20 h.
These results were consistent with observations made using propidium
iodide, in which low concentrations of the diazeniumdiolates showed a small
decrease in DNA fragmentation, and high concentrations of DEA/NO increased
DNA fragmentation, which were consistent with morphological observations of
apoptosis, but high concentrations of SPER/NO and GEA 3162 showed a
paradoxical inhibition of DNA fragmentation despite an increase in morphological
apoptosis. This shows that the unexpected results obtained with PI intercalation were
real effects of the NO/ONOO" donors, rather than peculiarities of this assay. It also
confirms the concentration-dependent nature of the inhibition of fragmentation by
GEA 3162; at 20 h, a small amount of laddering was seen with 30 pM GEA 3162,
although this was clearly less than control, but no laddering whatsoever was seen
with 100 pM GEA 3162. This suggests that a concentration of 30 pM GEA 3162 is
sufficient to delay the onset of DNA fragmentation, but not to completely block this
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process, but that 100 pM is able to block the DNA fragmentation pathway almost
completely.
Having confirmed the ability ofGEA 3162 to inhibit DNA fragmentation in
neutrophils, the mechanism by which this occurs was investigated. The DNA
fragmentation pathway contains several proteins containing reduced cysteines within
their active sites. It has previously been shown that NO can S-nitrosate caspases to
inactivate them (Mohr et al., 1997;Li et al., 1997), however it is unlikely that
caspases such as caspase 3 are the target for the inhibitory effect of GEA 3162, as
inactivation of this enzyme would affect multiple events of apoptosis, such as
chromatin condensation and cell shrinkage, rather than just DNA fragmentation.
However, the mouse homologue of the downstream protein of the DNA
fragmentation pathway, CAD/DFF40, contains several reduced cysteines within its
structure (Mukae et al., 1998;Enari et al., 1998). The amino acid sequence and 3D
structure of CAD/DFF40 are shown in Figure 5.12, with cysteine residues coloured
yellow. These cysteines could be potential targets for oxidative modification by NO
or NO-related species, thus inactivating the enzyme and preventing DNA
fragmentation. Alternatively, inactivation of the protein could occur via
nitrotyrosine formation within the protein by ONOO".
As ONOO" is a powerful oxidant species, which is highly reactive and highly
unstable, with a half-life of 1.9 seconds (Muscara and Wallace, 1999), neutrophils
were pre-treated with the reducing agent, dithiotreitol (DTT; 100-300 pM) to
determine whether this agent could block the inhibitory effect of GEA 3162 on DNA
fragmentation over a 20-h culture period. DTT has been used in many studies, in
particular as a strategy to maintain protein cysteine residues in their reduced state,
and to prevent or reverse S-nitrosation of proteins (Mohr et al., 1997;Arstall et al.,
1998).
Assessment of DNA fragmentation by PI intercalation showed that the
inhibition of DNA fragmentation by GEA 3162 was concentration-dependent,
although the effect was less pronounced than observed in the time-course studies,
with only the inhibition produced by 100 mM GEA 3162 reaching statistical
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Figure 5.12 Amino acid sequence and 3D structure of Caspase Activated DNase
(CAD/DFF40). (A) Amino acid sequence of human CAD/DFF40 [Adapted from Mukae et
at, Proc. Nat. Acad. Sci., 95, 9123-9128 (1998)]. (B) 3D structure of CAD/DFF40, with
regions coloured yellow representing cysteine residues. [From Protein Data Bank]
Chapter 5: Mechanisms ofAction 161
Regulation ofNeutrophil Apoptosis by NO and ONOO"
significance (p < 0.05, one-way ANOVA with Student-Newman-Keuls post-hoc
test). This appeared to be an effect of the pre-incubation period (15 min), as parallel
experiments conducted on the same set of neutrophils without the pre-incubation
period showed profound inhibition of DNA fragmentation in response to GEA 3162
(data not shown). This suggests that leaving the neutrophils for a period of time
following isolation conferred a degree of resistance to the inhibitory effects of GEA
3162. It was also observed that constitutive apoptosis was lower in pre-incubated
cells than in those incubated immediately following isolation.
Despite the reduced inhibitory effect of GEA 3162, the presence of DTT was
shown to be effective in overcoming the blockade ofDNA fragmentation in response
to this compound. Inhibition mediated by both 30 and 100 pM GEA 3162 was
reversed to control levels in a concentration-dependent manner by DTT. This
confirms that the inhibitory effect of GEA 3162 is mediated by an oxidative
mechanism, and supports the hypothesis of oxidative modification of critical proteins
of the DNA fragmentation pathway by ONOO" liberated from GEA 3162.
In order to determine whether DTT affects the apoptotic process itself, thus
accounting for the increased DNA fragmentation observed in cells exposed to DTT,
cells treated with GEA 3162 in the absence or presence of the reducing agent were
also subjected to morphological assessment of apoptosis. These studies confirmed
that the presence of DTT had no effect on the levels of either constitutive or GEA
3162-mediated apoptosis, with no significant difference being observed between
levels of apoptosis in the absence or presence of DTT in any of the experimental
conditions (p > 0.05, one-way ANOVA with Student-Newman-Keuls post-hoc test).
This indicates that constitutive apoptosis itself is not dependent upon the generation
of reactive oxygen species, as has been suggested (Watson et al., 1996), and that the
initiation of apoptosis by GEA 3162 is also independent of oxidative modifications
of proteins. However, it also suggests that the mechanism by which GEA 3162
inhibits the DNA fragmentation pathway does rely on an oxidative process, possibly
S-nitrosation of protein, which remains to be elucidated.
In order to demonstrate that the effects of DTT observed with GEA 3162 are
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specific to apoptosis induced by this compound and not common to all apoptotic
stimuli, the experiment was repeated in neutrophils exposed to the fungal metabolite,
gliotoxin, for 20 h. These studies demonstrated the acceleration of neutrophil
apoptosis by gliotoxin compared to control, with most of the cells being apoptotic by
20 h. However, in contrast to cells exposed to GEA 3162, DTT did not increase the
levels of DNA fragmentation as assessed by PI intercalation. Indeed, a small
reduction in DNA fragmentation was observed. Morphological assessment of
apoptosis in these cells also demonstrated a possible inhibitory effect of DTT on
gliotoxin-induced apoptosis.
A 4 h time point with gliotoxin was also investigated because any increase in
DNA fragmentation levels in the presence ofDTT would not be detectable at 20 h, as
the majority of gliotoxin-treated cells showed evidence of hypodiploid DNA content
at this time point. At 4 h of incubation, a significant (p < 0.05, one-way ANOVA
with Dunnett's post-hoc test) increase in DNA fragmentation was observed in
gliotoxin-treated cells compared to control, but this was substantially less than 100 %
of cells, allowing any DTT-mediated increase in DNA fragmentation to be observed.
However, at this time point, the inhibition of the pro-apoptotic effects of gliotoxin by
DTT were more marked, reducing the percentage of cells with hypodiploid DNA
content back to control levels. Similar findings were made with morphological
studies of apoptosis, demonstrating that DTT has a protective effect against
gliotoxin-mediated neutrophil apoptosis, but does not appear to have any pro-
apoptotic effects on apoptosis, or even DNA fragmentation, by itself.
Such data imply that gliotoxin induces neutrophil apoptosis via an oxidative
mechanism, as the reducing agent was able to inhibit both morphological and DNA
fragmentation events of apoptosis induced by this compound. This is consistent with
previous findings using gliotoxin as a pro-apoptotic stimulus; an oxidative
mechanism has been shown to be involved in gliotoxin-induced apoptosis in
thymocytes (Beaver and Waring, 1995) and macrophages (Suen et al., 2001).
It has been reported that the mechanism of activation of CAD/DFF40 bears a
remarkable similarity to the mechanism of activation of the transcription factor, NF-
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kB (Enari et al., 1998), and NO has been shown to inhibit NF-kB activation though
induction and stabilisation of the inhibitor molecule, IkB, that is the equivalent of
ICAD/DF45 in the DNA fragmentation pathway (Peng et al., 1995). Therefore,
Western blotting studies were carried out to determine whether NO/ONOO" donors
are able to inhibit the proteolytic cleavage of ICAD/DFF45 in neutrophils.
Cells were exposed to NO/ONOO" donors, gliotoxin (positive control) or PBS
(control) for 8 h, as this is the time when the most marked differences in DNA
fragmentation are observed with some compounds, such as DEA/NO. Whole cell
lysates were made from freshly-isolated neutrophils and those incubated for 8 h, and
analysed by Western blot for levels of ICAD/DFF45. Both long (45 kDa) and short
(40 kDa) splice variants of ICAD/DFF45 were detectable in neutrophils.
Reduced levels of ICAD/DFF45 compared to control were detected in
gliotoxin-treated neutrophils as expected, as this compound induces neutrophil
apoptosis alongside enhanced DNA fragmentation, as described in the previous
section. Neutrophils exposed to GEA 3162 (30 or 100 pM) showed a concentration-
dependent breakdown of ICAD/DFF45, and DEA/NO-treated cells showed clearly
visible ICAD/DFF45 breakdown. Flowever, SPER/NO-treated cells showed no
breakdown of ICAD/DFF45, and the band was possibly larger than that seen in
control cells.
Although it was to be expected that any ICAD/DFF45 breakdown in
SPER/NO-treated cells would be minimal, as accelerated apoptosis is not seen until
16 h with this compound, the large band suggests that the inhibition of DNA
fragmentation by SPER/NO may be mediated through inhibition of ICAD/DFF45
breakdown, and therefore stabilisation of the ICAD/CAD complex. This would
represent a similar mechanism of inhibition of CAD/DFF40 activation as has been
previously reported for NF-kB (Peng et al., 1995). Levels of ICAD/DFF45 would
also have to be tested at 16 or 20 h to establish whether this hypothesis holds true.
An apparent decrease in ICAD/DFF45 levels was observed in neutrophils
treated with DEA/NO, which is the expected result as this compound enhances DNA
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fragmentation, which is particularly obvious at the 8 h time point. Therefore,
acceleration of neutrophil apoptosis by DEA/NO proceeds through the established
DNA fragmentation pathway
In contrast, ICAD/DFF45 levels decreased with increasing concentrations of
GEA 3162, demonstrating that the inhibition of DNA fragmentation evoked by this
compound does not involve inhibition of the cleavage of ICAD/DF45. As expected,
therefore, GEA 3162-derived ONOO" does not inhibit the apoptotic pathway at the
level of caspase 3, or other caspases able to activate CAD/DFF40, as this would have
resulted in an inhibition of ICAD/DFF45 breakdown. The inhibition therefore must
occur downstream of ICAD/DFF45 cleavage, for example through inhibition of the
activity of CAD/DFF40 through oxidative modification of its reduced cysteines after
its release from inhibition by ICAD/DFF45 cleavage. Alternatively, GEA 3162-
derived ONOO" may alter DNA itself, leaving it more resistant to internucleosomal
cleavage by CAD/DFF40, or it may modify chromatin-associated proteins such as
histone HI, high mobility group proteins or topoisomerase II, that have been reported
to be associated with the ICAD/CAD complex and to potentiate CAD/DFF40 activity
(Zhang and Xu, 2002). In particular, histone HI associates with active CAD/DFF40
and confers DNA binding and endonuclease activity on CAD/DFF40 (Liu et al.,
1999), therefore histone HI modification could prevent its interaction with
CAD/DFF40 and therefore inhibit DNA fragmentation. Furthermore, CAD/DFF40
oligomerises to form a complex before binding to DNA (Liu et al., 1999), therefore
oxidative modification of active CAD/DFF40 via its reduced cysteines could
potentially inhibit complex formation and hence DNA binding and cleavage.
The lack of internucleosomal DNA fragmentation in neutrophils exposed to
NO/ONOO" donors such as GEA 3162 and SPER/NO may have implications for
their potential therapeutic use. It has been suggested that the absence of DNA
fragmentation could lead to large amounts ofDNA escaping from apoptotic cells and
either provoking an autoimmune response or being taken up by neighbouring cells
and potentially leading to the development of cancer (Zhang and Xu, 2002).
The cytotoxic effects of NO are often attributed to the formation of ONOO"
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(Liaudet et al., 2000), although this is not always necessarily the case, as others have
shown a direct cytotoxic effect of NO without the need for ONOO" formation
(Fricker et al., 1999). Apoptosis experiments were carried out using SOD to
determine whether DEA/NO-induced apoptosis is mediated by ONOO" generated by
NO liberated from DEA/NO combining with O2" released from neutrophils during
incubation. However, these experiments showed no effect of SOD on DEA/NO-
mediated neutrophil apoptosis, suggesting that there is no role for ONOO" in this
process. This is in contrast to observations with the ONOO" donor, GEA 3162, in
which SOD has been shown to inhibit the induction of neutrophil apoptosis by this
compound (Ward et al., 2000).
However, SOD is not cell permeable, therefore would only be effective if the
combination ofNO and O2" occurred outside the cells. Intracellular SOD mimetics
are available, and could be used to scavenge intracellular neutrophil-generated O2" in
order to inhibit ONOO" formation within the cells. It is possible that NO is able to
pass into the neutrophils before generating ONOO" by interacting with O2" contained
within the neutrophils. However, this is unlikely to occur, because the NO from
DEA/NO would all be released very early during the incubation period, probably
before the neutrophils generate any significant levels of ROS. Furthermore, were
DEA/NO to act via ONOO" formation, it would be expected that this compound
would have the same inhibitory effects on DNA fragmentation as ONOO" generators,
rather than enhancing DNA fragmentation.
To summarise, therefore, the inhibition of internucleosomal DNA
fragmentation by GEA 3162 occurs via an as yet uncharacterised oxidative
mechanism. However, the induction of morphological neutrophil apoptosis by this
compound is not redox-sensitive. The inhibition of internucleosomal DNA
fragmentation does not occur at the level or upstream of ICAD/DFF45 breakdown, as
a concentration-dependent increase in this process is seen on exposure to GEA 3162
(30 - 100 pM). However, the lesser degree of inhibition observed with SPER/NO
(0.1 pM - 1 mM) may occur through inhibition of ICAD/DFF45 cleavage, as a large
band corresponding to ICAD/DFF45 was observed by Western blotting, although
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this remains to be confirmed. There is no evidence in these studies to suggest that
DEA/NO-induced neutrophil apoptosis is mediated by ONOO" generation. However,
this hypothesis could still possibly hold true, as SOD only scavenges extracellular
O2", and this would require further investigation using intracellular SOD mimetics or
a O2" specific spin trapping agent.
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Chapter 6: Summary and future directions
6.1 Summary and Conclusions
Many factors are able to positively or negatively influence the rate of
neutrophil apoptosis in vitro, which may have implications in vivo by determining
the duration of an inflammatory response. Apoptosis is a physiological, active
process which serves to eliminate unwanted or damaged cells without eliciting an
inflammatory reaction. Apoptosis also facilitates non-inflammatry phagocytic cell
clearance by macrophages. Thus, neutrophil apoptosis is an important process in the
resolution of inflammation, as the alternative form of cell death, necrosis, provokes
profound inflammation. Furthermore, phagocytic clearance of necrotic cells leads to
release of pro-inflammatory factors from macrophages, therefore leading to
exacerbated inflammation and tissue damage, and contributing to the pathogenesis of
chronic inflammation. NO is an important molecule in inflammation, contributing to
the bactericidal actions of inflammatory cells as well as possessing powerful
vasodilator properties. Additionally, NO can regulate the lifespan of neutrophils, by
affecting the rate at which these cells undergo apoptotic cell death. The aim of this
thesis was to characterise the regulation of neutrophil apoptosis by NO and NO-
related species in vitro.
These studies have demonstrated that diazeniumdiolate compounds, DEA/NO
and SPER/NO, spontaneously generate free NO in aqueous solution; release of NO
from DEA/NO occurs much more rapidly than from SPER/NO, although equivalent
concentrations of these two compounds generate the same amount of NO overall.
Consequently, DEA/NO generates a brief spike of high concentrations of NO,
whereas SPER/NO produces a prolonged flux of lower concentrations of NO. NO
from these compounds was unable to oxidise DHR 123 to rhodamine 123, a process
used to distinguish between compounds that release free NO vs. those that release
oxidative species such as peroxynitrite (ONOO"). In contrast, the sydnonimine, SIN-
1, and the oxatriazole-5-imine derivative, GEA 3162, failed to liberate free NO,
except in the presence of SOD, which dismutates superoxide anion (O2") to hydrogen
peroxide, and were both able to oxidise DE1R 123. Thus, these two compounds both
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simultaneously generate NO and O2", which rapidly react to form the powerful
oxidant species, peroxynitrite ONOO". These results were confirmed by the
demonstration of oxidation of DHR 123, in contrast to pure NO. Therefore, SIN-1
and GEA 3162 are ONOO" generators, rather than pure NO donors.
Neutrophil apoptosis studies showed that both diazeniumdiolate compounds
have a biphasic effect on apoptosis. Whereas low concentrations of these
compounds delay the rate of apoptosis, high concentrations promote this form of cell
death. A more sustained release of NO from SPER/NO gives a more profound
inhibitory effect than the rapid spike of the same total amount ofNO from DEA/NO,
and enhances apoptosis at lower concentrations than DEA/NO. Elowever, the pro-
apoptotic effects of DEA/NO occur much more rapidly than that evoked by
SPER/NO and the highest concentration of DEA/NO tested induces a higher level of
apoptosis than the equivalent concentration of SPER/NO. In contrast, the ONOO"
donor, GEA 3162, shows no anti-apoptotic effects at equivalent concentrations to
those that give an inhibitory effect with the diazeniumdiolates. However, pro-
apoptotic effects are observed at lower concentrations of GEA 3162 than observed
with the diazeniumdiolates.
An unexpected inhibition of DNA fragmentation alongside enhancement of
other apoptotic events is observed with the pure NO donor, SPER/NO and more
markedly with the ONOO" donor, GEA 3162. The established ONOO" donor, SIN-1,
also gives this paradoxical dissociation of DNA fragmentation from other apoptotic
events, showing that the inhibition evoked by GEA 3162 is a general ONOO"-
mediated effect, rather than an effect that is peculiar to GEA 3162. Further studies
showed that the inhibition ofDNA fragmentation is an oxidative effect as it could be
abolished by addition of a reducing agent. However, Western blotting studies
showed that the breakdown of ICAD/DFF45 is not affected by GEA 3162.
The promotion of neutrophil apoptosis is important for the resolution of acute
inflammation and prevention of chronic inflammatory conditions. Limiting the
lifespan of this cell type would consequently limit the amount of histotoxic and pro¬
inflammatory substances released into the local environment. This thesis has shown
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that NO and related species, such as ONOO", are able to push neutrophils into
apoptotic cell death, and may therefore be useful therapeutically. It is important to
consider, however, that an upregulation of neutrophil apoptosis must not overwhelm
the phagocytic capacity of the tissue, or apoptotic neutrophils would undergo
secondary necrosis, thus exacerbating inflammation and tissue damage. Any
profound induction of neutrophil apoptosis, therefore, would have to be accompanied
by a similar upregulation of phagocytosis by macrophages. Further work is required
to investigate the effects ofNO and ONOO" donors on neutrophil apoptosis, and their
subsequent clearance by macrophages, in order to determine which class of
compound offers the most promising therapeutic potential, as described below.
6.2 Future Directions
6.2.1 Mechanisms of NO and ONOO'-mediated inhibition or induction of
neutrophil apoptosis
The effects of various NO and ONOO"-releasing compounds have been
thoroughly characterised in this thesis, but mechanisms of action have not been
elucidated. Future studies would therefore focus on the mechanisms through which
NO and ONOO" regulate neutrophil apoptosis.
A cutting edge proteomics approach could be taken to determine the up- or
down-regulation of critical apoptotic proteins in response to exposure to these
compounds. This technology involves alkylation of cysteine-containing proteins
with isotope-coded affinity tags (ICAT) containing either a light or a heavy isotope
of deuterium and a biotin affinity tag. One sample is labelled with the isotopically
light reagent and the other with the heavy reagent, then samples are mixed and
treated with trypsin to form peptides that are easily analysed by mass spectrometry
(MS). Following cation exchange chromatography, mixtures are passed over a
monomeric avidin-agarose column, which binds ICAT-labelled peptides through
their biotin tag. Eluted peptides are then isolated by microcapillary liquid
chromatography electrospray ionisation tandem mass spectrometry (LC/MS/MS).
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The mass spectrometer can distinguish light and heavy isotope-labelled peptides due
to their mass difference and the relative amounts in each sample can be measured. It
is able to analyse a specific peptide of interest, even if many other peptides are
present in the sample.
The advantage of this method over classical proteomics approaches is that it
allows both determination of the identity of the peptides of interest and quantitative
analysis of their relative abundance between samples in a single step. In particular,
the gene products whose expression is induced by the transcription factors, NF-kB
and API could be investigated.
Furthermore, as the MAP kinase pathways are believed to have a role in
apoptotic signalling in many cell types, it would be interesting to conduct studies to
analyse activation levels of the 3 principal MAP kinase pathways; the ERK, JNK and
p38 MAP kinase pathways. Kinase assays could be used to determine the activities
of various kinase enzymes within these pathways, and Western blotting techniques
could be used to measure the presence of kinases in their unphosphorylated (inactive)
or phosphorylated (active) forms. Results obtained using this technique could then
be verified through the use of pharmacological inhibitors of relevant signalling
pathways.
This approach may allow identification of signalling pathways involved in
promotion or inhibition of neutrophil apoptosis in response to NO or ONOO".
Additionally, the levels of pro- and anti-apoptotic Bcl-2 family proteins that are
known to be expressed in neutrophils, levels of active caspases and NF-kB activation
could also be assessed using Western blotting techniques. Where appropriate
antibodies are available, activation ofMAP kinases and caspases, and localisation of
Bcl-2 family proteins, could be visualised by immunofluorescence. Our group has
successfully used the HIV-TAT system to introduce dominant negative signalling
proteins into neutrophils (HIV-TAT-I-kB) and macrophages (HIV-TAT-cas). This
system could potentially be exploited to definitively prove the involvement of
particular signalling molecules in neutrophil apoptosis. These studies taken together
would allow a picture to be built up of the mechanisms through which neutrophil
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apoptosis is regulated by NO and ONOO", and time course studies would give an
indication of the temporal regulation and integration of these pathways to produce
models for the induction or inhibition of neutrophil apoptosis.
6.2.2 Apoptosis studies in cytokine- or adhesion-activated neutrophils
Studies on the regulation of neutrophil apoptosis have so far been carried out
on non-activated cells. However, it is well established that, in vivo, adhesion of
neutrophils to the endothelium and to extracellular matrix leads to neutrophil
activation and a delay in the rate at which these cells undergo apoptosis. This may
be a factor in the persistence of extravasated neutrophils within inflammatory sites,
which prolongs the inflammatory response and may contribute to the pathogenesis of
chronic inflammatory conditions. Therefore, it is important to examine the effects of
the NO/ONOO" releasing compounds on adhesion-activated neutrophils. This could
be done by repeating the experiments already carried out following culture of
neutrophils on a monolayer of endothelial cells, which should reduce the rate of
constitutive apoptosis. The hypothesis is that NO/ONOO" donors are able to override
the survival signals promoted by adhesion of neutrophils to the endothelial cells.
Similar to the experiments in non-activated cells, the signalling pathways involved
could be determined using the proteomics, Western blotting and pharmacological
approaches described above.
Furthermore, in order to examine the potential effects of these compounds
within inflammatory sites, it would be useful to undertake studies to examine
whether the NO/ONOO" donors are able to override survival signals evoked by pro¬
inflammatory mediators that are likely to be present at inflammatory sites, such as
GM-CSF and LPS. Neutrophils could be exposed to such mediators before,
simultaneously and after addition of the NO/ONOO" donors in order to determine
whether the timing of exposure to these compounds is critical in determining the
extent to which they are able to overcome the survival pathways induced by
inflammatory mediators.
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Figure 6.1 Effects of GEA 3162 on the dexamethasone-mediated delay of
neutrophil apoptosis. Neutrophils (5 x 10® cells/ml) were exposed to 1, 30 or
1000 nM dexamethasone in the absence and presence of GEA 3162 (1-10 pM)
for 20 hours, then apoptosis was assessed by (A) Morphology and (B) Annexin V
binding. Results represent mean ± S.E.M. from n = 4 experiments. Baseline
(control) levels of apoptosis were 72.5 ± 4.2 % by morphology and 56.5 ±2.5 %
by Annexin V binding.
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Other agents that are able to delay neutrophil apoptosis, such as synthetic
glucocorticoids, could also be assessed. Preliminary studies have demonstrated the
ability of low concentrations of GEA 3162 (that do not in themselves induce
apoptosis) to reduce the inhibition of neutrophil apoptosis seen with exposure to low
concentrations of the synthetic glucocorticoid, dexamethasone, although it has no
effect with higher concentrations of dexamethasone (Figure 6.1). These studies
could be extended to determine the mechanism of this reversal; the hypothesis is that
this compound S-nitrosates the glucocorticoid receptor, thereby preventing binding
of dexamethasone. It has previously been shown that NO can S-nitrosate critical
cysteine residues in the glucocorticoid receptor to inhibit glucocorticoid binding
(Galigniana et al., 1999).
6.2.3 Mechanisms of inhibition ofDNA fragmentation
The inhibition of internucleosomal DNA fragmentation by ONOO" and
longer-lasting NO donors should be further investigated, using the hypothesis that
oxidative modifications of important proteins in the DNA fragmentation pathway are
responsible for the inhibition. Western blotting could be carried out using a
'NitroGlo' kit to examine the level of S-nitrosation in treated neutrophils compared
to untreated cells. Potential target proteins of the DNA fragmentation pathway may
then be purified and evaluated on an individual basis. Furthermore, to determine
whether GEA 3162 can directly inhibit the activity of Caspase-Activated DNase
(CAD/DFF40), a plasmid vector for the expression of CAD/DFF40 and
ICAD/DFF45 developed in the laboratory of Bill Earnshaw at the University of
Edinburgh could be transfected into E. coli, and the CAD-ICAD complex would be
purified. The complex could then be treated with active caspase 3 in order to
degrade the ICAD, leaving the active CAD, which would then be exposed to PBS
(control) or GEA 3162 for varying periods of time before being applied to isolated
DNA from neutrophils and left for a period of several hours. The DNA would then
be run by gel electrophoresis to look for the characteristic laddering pattern
generated by CAD, as an indication of the activity ofCAD.
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In order to test the hypothesis that pure NO donors with a slower rate of NO
release are able to inhibit DNA fragmentation via ONOO" formation, but that faster-
releasing compounds are unable to do so, it would be interesting to test a range of
diazeniumdiolate compounds with varying rates of release. If the hypothesis holds
true, the extent of inhibition of DNA fragmentation seen with these compounds
should correlate with the half-life of decomposition. Furthermore, in order to
investigate whether inhibition of DNA fragmentation is not observed with faster-
releasing diazeniumdiolates because NO and O2" are not present simultaneously
within cells, neutrophils could be stimulated with an activating agent such as PMA to
provoke early generation of O2" which should coincide with the timescale of NO
release, thus promoting ONOO" generation. DNA fragmentation could then be
assessed by propidium iodide intercalation to determine whether diazeniumdiolates,
such as DEA/NO, that do not inhibit DNA fragmentation in their own right are able
to do so following stimulation with PMA.
6.2.4 Effects of NO/ONOO' donors on neutrophil apoptosis in PBS or culture
medium without serum
Recent studies have suggested that in the presence of HEPES (which is
present at a concentration of 25 mM in Iscove's MDM culture medium), NO from
diazeniumdiolates is undetectable as ONOO" is preferentially formed through
oxidation of HEPES (Keynes et al., 2003). Therefore it is possible that the pro-
apoptotic effects of SPER/NO and DEA/NO seen in Iscove's MDM plus 10 %
autologous serum are mediated by ONOO" formation, rather than by NO.
Furthermore, it has been shown that buffer components such as HEPES have the
ability to convert ONOO" to NO-donating compounds, but that this effect is not
observed in phosphate buffer (Schmidt et al., 1998), suggesting that apoptosis
induced by ONOO" donors may be due, at least in part, to generation of free NO.
others have reported that SIN-1-mediated cytotoxicity is due to H2O2 formation in
the presence of HEPES, but is due to ONOO" in its absence (Lomonosova et al.,
1998). The studies described in this thesis have all been carried out in Iscove's
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MDM, but have not been carried out in HEPES-free medium. In order to elucidate
any potential influence of serum proteins or buffer components such as E1EPES on
neutrophil apoptosis induced in vitro by NO/ONOO" donors, apoptosis studies could
be carried out in Iscove's MDM without serum, in PBS and in PBS supplemented
with 10 % autologous serum.
6.2.5 Effects of NO/ONOO' donors on apoptosis in other cell types
The apoptosis studies could be extended into other cell types that are relevant
to inflammatory disease processes within the cardiovascular system, such as
endothelial cells and macrophages. Ideally, a NO/ONOO* donor would be found that
is able to induce apoptosis in neutrophils but does not affect endothelial cell
apoptosis at the same concentration. These studies may have implications for
protection against or regression of inflammatory conditions such as post-angioplasty
restenosis or myocardial ischaemia-reperfusion injury. Potential beneficial effects of
these compounds could be tested using animal models of inflammation.
6.2.6 Clearance of apoptotic neutrophils following treatment with NO/ONOO'
donors
Phagocytosis studies could be carried out to examine whether neutrophils that
have been induced to undergo apoptosis by NO/ONOO" donors are still effectively
cleared by macrophages. For example, these studies have shown that PS exposure on
the outer surface ofGEA 3162-treated cells is not different from control cells at a 20-
h time point. This lack of enhancement of PS exposure may have adverse effects in
vivo if the clearance of these cells is not similarly upregulated, as cells may undergo
pro-inflammatory secondary necrosis. A flow cytometric assay could be used to
examine the uptake of these cells by human macrophages differentiated in culture
from isolated monocytes, to determine whether this is increased from control in GEA
3162-treated cells.
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These studies should provide further insights into the differences that exist
between distinct classes of NO and ONOO" donors, in particular differences in
mechanisms of action. Elucidation of the apoptotic pathways induced by these
compounds could allow particular pathways to be harnessed therapeutically. These
studies should also provide information as to which type of NO or ONOO" donor is
most likely to prove effective in an inflammatory situation, for example, which
compound proves most effective at over-riding survival signals initiated by pro¬
inflammatory mediators or neutrophil adhesion, and with which compounds are
apoptotic neutrophils most effectively phagocytosed following apoptosis. These
studies could therefore determine which NO or ONOO" donors should be most
rigorously pursued in terms of further research or future development of potential
therapeutic compounds.
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